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Abstract 
 
Background:  Vascular calcification is a common complication of advanced 
chronic kidney disease, contributing to increased cardiovascular mortality.  
Hypercalcaemia is a recognised risk factor for calcification, and calcimimetics 
show protective actions in vivo.  In addition to its central role in Ca2+ 
homeostasis, the calcium sensing receptor (CaSR) has been identified in 
smooth muscle cells, suggesting extracellular Ca2+ and calcimimetics may 
have a more direct role in the modulation of mineralisation. 
 
Methods and results:  The presence of CaSR in bovine aortic smooth muscle 
cells (BAoSMC) is confirmed using immunofluorescence and western blot.  In 
an in vitro model of calcification (i.e. β-glycerophosphate induction) Ca2+ 
dose-dependently increases SMC mineralisation and induces alkaline 
phosphatase activity.  Transfecting cells with a dominant negative CaSR does 
not attenuate Ca2+-induced SMC mineralisation.  Confirming previous reports, 
calcimimetics R-568 (1 nM) and AMG641 (10 pM, 100 pM and 1nM) delay the 
process of calcification.  However S-568 (1 nM), an isomer of R-568 that 
shows little/no activity at the CaSR, fails to elicit any protective effects.  The 
signalling pathways activated by R-568 (1nM), in the presence of 2.5 mM 
Ca2+ are investigated in human aortic smooth muscle cells (HAoSMC) using a 
multibead phosphoprotein detection array.  R-568 (1 nM) produces significant 
elevations in MEK and p90RSK phosphorylation.  The relevance of these 
molecules in the mineralisation process is not investigated, although it is 
interesting to note that, elevations in MEK and p90RSK phosphorylation are 
not observed in HAoSMC incubated with Ca2+ alone (i.e. 5 mM Ca2+ vs. 0.5 
mM Ca2+).   
 
Conclusions:  These results suggest that the delay in mineralisation afforded 
by calcimimetics are mediated via the CaSR, whilst the increased 
mineralisation observed when cells are exposed to 1.8 mM Ca2+ are, at least 
in part, independent of the CaSR.  
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Chapter 1: Introduction 
 
1.1 Vascular calcification in chronic kidney disease (CKD) 
Calcification of the cardiovascular system is associated with a number of 
diseases including metabolic syndrome, diabetes, hypertension and 
atherosclerosis.  However, its most devastating manifestation is in patients 
with chronic kidney disease (CKD), the focus of this work.  Patients with CKD, 
particularly end stage renal disease (ESRD), show a disproportionate burden 
of vascular calcification1-4 which contributes to the markedly increased 
cardiovascular risk and mortality in these patients (Figure 1.1).   
 
 
 
 
 
 
 
Figure 1.1  Cardiovascular mortality rates (per 1000 person-years) in dialysis patients 
vs. the general population (GP) (adapted from de Jager et al. (2009)
5
). 
de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne 
P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW. Cardiovascular and 
noncardiovascular mortality among patients starting dialysis. Jama. 2009;302:1782-1789 
 
 
In general, the prevalence and intensity of vascular calcification increases as 
kidney function declines.  Although calcification can be present at early stages 
of CKD6, 7, increased calcification is observed prominently once a patient 
enters ESRD and requires dialysis treatment1, 6, 8.  It has been suggested that 
dialysis may prime arteries to develop vascular calcification9 as more rapid 
progression of vascular calcification is detected in dialysis patients compared 
to the general population1, 10.    
 
The majority of CKD patients who require dialysis die as a result of 
cardiovascular events, and the presence and extent of vascular calcification 
are independent predictors of cardiovascular disease and mortality11.  Arterial 
This image has been 
removed by the author for 
copyright reasons. 
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calcification leads to a number of adverse clinical outcomes i.e. myocardial 
infarction, congestive heart failure, valvular heart disease3, 11, 12 that can 
cause cardiovascular disease or aggravate its severity.   
 
Calcification can occur at two distinct sites in the vessel wall: the intima and 
the media and both types of arterial calcification can occur in CKD.  Intimal 
calcification involves localised calcification in the vicinity of lipid or cholesterol 
deposits within an atherosclerotic plaque.  Calcification can be detected on 
the shoulders and at the base of the plaque13.  Intimal calcification is thought 
to be triggered by inflammatory processes14.  In an in vivo model of 
atherosclerosis, accumulation of infiltrating macrophages was shown to be 
one of the earliest steps in the calcification processes, potentially acting as a 
trigger for further pro-calcifying actions15.   
 
Medial calcification (also known as Mönckeberg’s sclerosis) is typically 
observed as a pipeline-like distribution and can occur all around the vessel16.  
In contrast to intimal calcification, it occurs in the absence of lipid or 
cholesterol deposits17 and without macrophage infiltration suggesting that 
distinct mechanisms may underlie the development of these two types of 
calcification.   
 
Intimal and medial calcification also differ in their clinical consequences.  
Medial calcification results in stiffening of the vasculature and reduced 
vascular compliance which is associated with increased pulse pressure18, 19 
and left ventricular hypertrophy20.  Whereas, intimal Ca2+ deposition may 
contribute to atherosclerotic plaque instability21 which can cause myocardial 
infarction and thrombotic events.   
 
 
 
 
 
 
 
  3 
 
 
 
 
 
Figure 1.2  Coronary artery calcification of a CKD patient (adapted from Amann K.  
(2008)
17
).  Both intimal (*) and medial calcification (arrow) are observed in hematoxylin and 
eosin (H&E) stain (A) and Kossa stain (B).  
Amann K. Media calcification and intima calcification are distinct entities in chronic kidney 
disease. Clinical journal of the American Society of Nephrology : CJASN. 2008;3:1599-1605 
 
 
In CKD patients, one or both of intimal and medial calcification can be 
observed4, 22 (Figure 1.2).  Looking at a select subgroup of individuals with 
coronary artery disease and varying kidney function, Nakamuru et al. (2009) 
found that intimal calcification is observed in most cases of vascular 
calcification with CKD, across stages 1-5, whereas medial calcification is 
typically only present when more severe CKD ensues i.e. CKD stage 4/5 and 
haemodialysis patients6.  Despite the delay in presentation, the development 
of medial calcification does not appear to be dependent on intimal calcification 
as medial calcification can be identified in segments that show no signs of 
intimal calcification17.   
 
Amongst haemodialysis patients the presence of predominantly intimal 
calcification has been shown to be associated with a relative higher risk in 
mortality compared to predominantly medial calcification16.  Additionally within 
the dialysis population, patient characteristics influence the likelihood of 
developing intimal or medial calcification: intimal calcification is typically 
observed in older patients with a conventional atherosclerotic risk factors 
whereas medial calcification is observed in younger patients and is related to 
the time on dialysis and the Ca x P balance16.   
 
 
This image has been 
removed by the author for 
copyright reasons. 
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1.2  Mechanisms of vascular calcification in CKD 
Knowledge of the mechanisms underlying vascular calcification have greatly 
increased in recent years.  Thinking has evolved from the original hypothesis 
suggesting that vascular calcification is a passive degenerative process, to 
understanding vascular calcification to be a highly regulated, active, cell–
mediated process that involves phenotypic change23, 24. The process shows 
many similarities to bone formation and cells with osteoblastic and 
chondrogenic potential have been identified in vascular tissue25-28.   
 
There is growing acceptance that smooth muscle cells (SMCs) undergo a 
phenotypic transition and act as the source of the osteochondrogenic 
precursors.  SMCs are the predominant cell type found in the artery wall and 
unlike most cell types, retain phenotypic plasticity in response to injurious 
stimuli.  With treatment of pro-calcifying stimuli, SMC cultures can be induced 
to express osteoblastic and chondrogenic transcription factors whilst in 
parallel showing reduced expression of SMC marker proteins (i.e. expression 
of α-smooth muscle actin and SM22α)29, 30.  Evidence in favour of SMCs as 
the source of the osteochondrogenic precursors came with the findings by 
Speer et al. (2009) who, using genetic fate mapping of matrix Gla protein 
mutant mice (MGP -/-), identified that the chondrocytic cells identified in areas 
of calcification had differentiated from SMCs29.   
 
The onset of expression of bone marker proteins, and reduced expression of 
SMC markers, appears to be a trigger for mineralisation rather than a 
consequence, as these events precede calcification29.  Moreover, a recent 
report by Speer et al. (2010) suggests that it is primarily the induction of the 
osteogenic transcription factors and not the loss of the SMC markers which 
promote mineralisation30.  Loss of myocardin alone does not appear to drive 
an osteochondrogenic phenotype change or an increased propensity to 
mineralise30.  Similarly, forced expression of SMC markers does not affect the 
calcification ability of SMCs when treated with the pro-calcifying factor, 
inorganic phosphate30.  However, that is not to say that the reduced 
expression of SMC markers is just a consequence of SMC transdifferentiation 
as in cases of arterial injury, expression of SMC markers appears to be 
  5 
protective.  A recent study demonstrated that mice deficient in SM22α exhibit 
enhanced medial chondrogenesis in response to arterial injury compared to 
their wild type counterparts31. 
 
Of particular interest within these recent studies is data suggesting that SMC 
transdifferentiation may be reversible and cells can regain SMC properties30.  
When cultured in medium that favours SMC differentiation (i.e. supplemented 
with 20% FBS) vascular cells with an osteochondrogenic phenotype regained 
SMC properties showing increased expression of SMC marker proteins (i.e. 
SM22α and α-sma), in parallel to reduced expression of osteochondrogenic 
gene expression30.  Additional support for the reversibility of vascular SMCs in 
the osteochondrogenic state is provided by data reporting that sevelamer (a 
phosphate binder) reduces established calcification in a mouse model of 
atherosclerosis and CKD32.  Together these findings suggest that vascular 
calcification may be therapeutically treated and potentially reversed.   
 
 
 
Figure 1.3  Mechanisms contributing to the initiation and promotion of vascular 
calcification.  Loss of mineralisation inhibitors (for example, matrix Gla protein (MGP), fetuin-
A and pyrophosphate (PPi)), cellular apoptosis and the production of calcifying matrix vesicles, 
and transdifferentiation of SMCs all contribute to process of mineralisation.  
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The complete mechanism underlying transdifferentiation and mineralisation is 
still under investigation.  A number of key events contribute to vascular 
calcification initiation and progression (Figure 1.3), including dysregulated 
mineral metabolism, loss of local and systemic inhibitors of calcification, 
induction of apoptosis and matrix vesicle (MV) release, and development of a 
calcifiable extracellular matrix26, 33.   
 
 
1.2.1  Dysregulated mineral metabolism as a trigger for calcification in 
CKD 
Abnormal regulation of mineral ion homeostasis is one of the major problems 
in patients with CKD and is strongly linked to the development of calcification.  
There is increasing evidence that hyperphosphatemia, hypercalcaemia, an 
increased Ca × P product and hyperparathyroidism may increase 
susceptibility to develop vascular calcification34.  Direct actions of elevated 
levels of phosphate and Ca2+ on SMCs have been shown and their 
contribution to calcification beginning to be unravelled, discussed in sections 
1.2.1.2 and 1.2.1.3 respectively.    
 
 
1.2.1.1  Dysregulated mineral homeostasis in CKD 
In normal physiology Ca2+ and phosphate levels are under tight control via a 
number of hormonal regulators which work through concerted actions on the 
intestine, kidney and bone.  Hormonal regulators of phosphate metabolism 
include parathyroid hormone (PTH), 1,25(OH)2D3, FGF-23 and klotho.  PTH, 
1,25(OH)2D3 and klotho are also regulators of Ca
2+ metabolism.  The actions 
of these hormonal regulators are illustrated in Figure 1.4.  The physiological 
role of calcitonin in humans remains unclear, although inhibition of bone 
resorption is detected at pharmacological doses underlying its use for Paget's 
disease, osteoporosis and hypercalcaemia of malignancy35.  For detailed 
reviews on Ca2+ and phosphate homeostasis see Bergwitz and Juppner 
(2010)36, Renkema et al. (2008)37. 
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Figure 1.4  Ca
2+
 and phosphate homeostasis (adapted from Renekema et al. (2008)
37
).  
Mechanisms responsible for the control of Ca
2+
 and phosphate (Pi) homeostasis are 
interlinked.  The calcium sensing receptor (CaSR) in the parathyroid glands responds to free 
extracellular Ca
2+
 and modulates PTH secretion.  PTH acts directly, on renal Ca
2+
 
reabsorption, and indirectly, via stimulation of 1,25(OH)2D3 production, to increase serum 
Ca
2+
.  Hyperphosphatemia also stimulates secretion of PTH, which acts directly to increase 
urinary excretion of phosphate whilst indirectly increases intestinal absorption via 
1,25(OH)2D3.  Both PTH and 1,25(OH)2D3 stimulate the FGF-23-klotho axis, increasing Pi 
excretion.  To ensure tight regulation of Ca
2+
 and Pi homeostasis numerous feedback loops 
exist – 1,25(OH)2D3 inhibits PTH secretion, and FGF-23 inhibits the synthesis of 1,25(OH)2D3 
and PTH.    
Renkema KY, Alexander RT, Bindels RJ, Hoenderop JG. Calcium and phosphate 
homeostasis: Concerted interplay of new regulators. Annals of medicine. 2008;40:82-91 
 
 
In CKD, the mechanisms that normally ensure tight control of serum 
phosphate and Ca2+ levels are dysregulated and cannot sufficiently 
compensate for changes in serum phosphate and Ca2+.  With renal 
insufficiency the ability of the kidney to excrete phosphate and generate 
1,25(OH)2D3 is compromised.  Additionally, in CKD changes in the expression 
of the hormonal regulators, and the relationship between them, contribute to 
the mineral dysregulation observed and development of secondary 
hyperparathyroidism.  
 
In humans, FGF-23 levels rise in parallel to declining renal function38-40.  
Stimulation of FGF-23 is typically triggered by elevations in serum phosphate 
or increased 1,25(OH)2D3.  However the trigger in early CKD remains unclear 
as FGF-23 levels appear to increase before the development of 
hyperphosphatemia 41, 42.  Using a model of progressive CKD in rats, 
Hasegawa et al. (2010) assessed the development of mineral dysregulation 
by evaluating different biochemical parameters in the serum over an extended 
This image has been 
removed by the author for 
copyright reasons. 
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timeframe.  Interestingly, significant elevations in FGF-23 were detected on 
day 10, while increased phosphate was not detected until day 30 (Figure 1.5).  
Although Hasegawa et al. (2010) described FGF-23 as the first biochemical 
change, it has also been shown that PTH is necessary for the initial elevation 
in FGF-23 levels, as a parathyroidectomy prevented the increase in FGF-23 in 
kidney failure rats43.  Therefore the onset of events may be more complex 
than shown (Figure 1.5). 
 
FGF-23 inhibits 1α-hydroxylase, a key enzyme in the development of 
1,25(OH)2D3 
44-47
  and can also stimulate 24-hydroxylase, an enzyme involved 
in the inactivation of vitamin D metabolites46.  Therefore, increased levels of 
FGF-23 result in reductions in 1,25(OH)2D3, further confounded by the 
reduced capacity of the kidney to convert 25(OH)D3.  With reduced generation 
of 1,25(OH)2D3, and therefore reduced intestinal Ca
2+ absorption, 
hypocalcaemia ensues.  Hypocalcaemia acts as a stimulus for PTH secretion, 
which acts on the bone to increase serum Ca2+ and in doing so also increases 
serum phosphate.  As the glomerular filtration rate declines in advanced CKD, 
inefficient urinary phosphate excretion combined with disordered bone 
remodelling results in hyperphosphatemia. 
 
 
 
 
 
 
Figure 1.5  Time course of biochemical changes in rats with anti-GBM nephritis 
(adapted from Hasegawa et al. (2010)
42
).  Progressive nephritis was induced in Wistar-
Kyoto rats by injecting an anti-glomerular basement membrane antiserum.  On days 0, 10, 20, 
30 blood samples were collected and sera prepared.  The figure illustrates the sequential 
changes in serum parameters compared to control rats (i.e. those injected with an equivalent 
volume of normal rabbit serum), at their first presentation.  All changes shown are significantly 
different vs. control.   
Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto 
S, Shimada T. Direct evidence for a causative role of fgf23 in the abnormal renal phosphate 
handling and vitamin d metabolism in rats with early-stage chronic kidney disease. Kidney 
international. 2010;78:975-980 
This image has been 
removed by the author for 
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With persistent hyperphosphatemia, 1,25(OH)2D3 deficiency and 
hypocalcaemia, secondary hyperparathyroidism (SHPT) develops.  Whilst 
abnormal parathyroid function is detected in only some patients with stage 2 
CKD, it increases in prevalence with disease progression and most patients 
with stages 4 and 5 CKD show elevations in PTH48, 49.  PTH elevations are 
accompanied by parathyroid hyperplasia which increases the capacity of the 
parathyroid gland to synthesise and secrete PTH.  Additionally, expression of 
the “sensor” molecules on the parathyroid gland, the vitamin D receptor (VDR) 
and the calcium sensing receptor (CaSR), which normally act as part of a 
negative feedback loop, are decreased in renal failure50 and SHPT51, 52 
respectively.  It has also been suggested that in later stages of CKD the 
parathyroid gland may become resistant to the inhibitory signals produced by 
FGF-23, thus allowing high levels of FGF-23 and PTH to co-exist53.  It has 
been suggested that down regulation of klotho and FGF receptor 1 underlie 
this change, as parathyroid tissue of chronic haemodialysis patients showed 
reduced expression of these receptors54.  
 
In the absence of correctly functioning negative feedback loops, levels of PTH 
continue to rise and hypercalcaemia can be observed in later stages of CKD.  
Additionally, the management of SHPT of CKD and 1,25(OH)2D3 deficiency 
can involve calcium-based phosphate binders and vitamin D analogues55 both 
of which contribute to the generation of hypercalcaemia.  
 
 
1.2.1.2  Hyperphosphatemia as risk factor / contributor to vascular 
calcification  
Clear associations between serum phosphate and cardiovascular outcomes 
and mortality have been reported in haemodialysis patients1, 56-61 and in the 
general population62, 63.  The importance of phosphate regulation in the 
calcification process can also be observed in vivo by examining the 
phenotype of mice with a targeted deletion of either FGF-2364, 65 or klotho66 
both of which show hyperphosphatemia accompanied by enhanced vascular 
calcification.  Furthermore, in vitro it has been shown that culturing SMC in 
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conditions of elevated phosphate produces mineralisation71-78.  A number of 
potential mechanisms underlying phosphates pro-calcifying effect exist 
including, apoptosis and initiation / promotion of osteochondrogenic 
differentiation, discussed below. 
 
Phosphate has been shown to dose-dependently increase SMC apoptosis67, 
known to be important in the regulation of SMC calcification68.  
Downregulation of Gas6 (growth arrest-specific 6), a known apoptosis 
inhibitor in SMCs69, and its receptor Axl. is detected with exposure to 
increasing phosphate concentrations67.   
 
In response to increased phosphate, a number of authors have shown 
upregulation of osteochondrogenic gene expression (Runx2, osterix, alkaline 
phosphatase, osteopontin) accompanied by down regulation of SM lineage 
gene expression (including α-sma, SM22α) in SMC cultures30, 70-73.  
Phosphate-induced osteochondrogenic conversion has also been detected in 
vivo by El-Abbadi et al. (2009) showing upregulation of Runx2 and 
osteopontin with simultaneous down regulation of SM22ɑ in uremic mice fed 
with a high phosphate diet74.   
 
The mechanisms underlying phosphate-induced calcification have been 
shown to involve a number of different proteins / pathways.  Phosphate entry 
into SMCs, via Pit-1, has been shown to contribute to the process of 
phosphate-induced calcification75.  Loss of Pit-1, in vitro, and therefore 
inhibition of phosphate uptake reduces calcification and prevents 
Cbfa1/Runx2 and osteocalcin expression75.   
 
Also, recent reports highlight BGP as an inducer of H2O2, and more 
specifically mitochondrial superoxide76.  Blockade of mitochondrial ROS can 
abrogate β-glycerophosphate -induced calcification, and reduce expression of 
the osteogenic genes, Cbfa1 and Msx276.  Furthermore, in a rat model of 
dietary adenine-induced chronic renal failure, blockade of mitochondrial ROS 
by the use of MnTMPyP (Mn(III)tetrakis(1-methyl-4-pyridyl)porphyrin 
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pentachloride) reduces aortic ROS levels, p65 activation, and Ca2+ 
deposition76.   
 
Additionally the presence of BMP-2 is required for phosphate-induced 
mineralisation.  Addition of noggin, a BMP2 inhibitor, can block 
mineralisation77 (for a more comprehensive review of the effects of phosphate 
on SMC calcification see Shanahan et al. (2011)78). 
 
However, despite a seemingly key role for phosphate in vascular calcification, 
experiments performed using serum from uremic patients show that 
calcification occurs irrespectively of phosphate levels73, suggesting that other 
factors are required to induce mineralisation in the vasculature. 
 
 
1.2.1.3  Hypercalcaemia as risk factor / contributor to vascular 
calcification  
Hypercalcaemia has been shown to contribute to the increased morbidity in    
dialysis patients58, 61, 79.  Treatment with calcium-based phosphate binders vs. 
calcium free phosphate binders has been shown to accelerate arterial 
calcification in randomized control trials79, 80, however studies showing that 
calcium-based phosphate binders increase cardiovascular mortality are 
lacking in patients with ESRD81.    
 
The role of Ca2+ in calcification has received less attention than phosphate.  
On the basis of in vitro findings it is still unclear if Ca2+ can produce SMC 
mineralisation in the absence of phosphate, as contradictory reports exist82-84.  
Yang et al. (2004) reported Ca2+-induced mineralisation under normal 
phosphate conditions but observed that increased phosphate levels 
accelerated mineralisation, suggesting independent and synergistic 
mechanisms82, also observed by Reynolds et al. (2004)84.  However, Alam et 
al. (2009) failed to detect any mineralisation without an external phosphate 
source, suggesting phosphate plays a permissive role84.  Interestingly, when 
combined it appears that for a given Ca x P product elevated Ca2+ is more 
potent at inducing SMC calcification than elevated P85, 86. 
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Whether Ca2+-induced mineralisation is mediated by osteochrondogenic 
differentiation remains unclear.  Upregulation of alkaline phosphatase mRNA  
expression was detected in Ca2+ treated SMCs82, however a recent report 
shows that when Ca2+ is added to high phosphate media the level of alkaline 
phosphatase activity detected decreases86.   
 
To date, the role of Ca2+ as a promoter of calcification has largely focused on 
its effects on cell apoptosis and release of matrix vesicles.  Apoptosis has 
been demonstrated to precede calcification, and apoptotic bodies can initiate 
calcification in a similar way to matrix vesicles (MVs)68.  Matrix vesicles have 
been identified in mineralising tissues where they are believed to be released 
into the extracellular space and attach to matrix proteins initiating 
mineralisation87.  Exposing SMCs to elevated levels of Ca2+ promotes 
apoptosis and the release of matrix vesicles83.  In addition to promoting their 
formation, Ca2+ can also increase the mineralisation potential of MVs, 
increasing the level of Ca2+ incorporation83 and potentially the level of 
phosphate incorporation via upregulation of Pit-182.   
 
Under normal conditions, MV contain inhibitors of calcification, fetuin-A and 
MGP (discussed in sections 1.2.2.1 and 1.2.2.2 respectively), preventing 
mineralisation, however in CKD / ESRD lower levels of inhibitors are 
detected88.  Interestingly, Ca2+ has been shown to increase fetuin-A uptake 
into matrix vesicles83, 89, 90 and upregulate MGP production91, 92 potentially as 
an adaptive response.  However in the case of MGP it has been suggested 
that unprocessed MGP may be produced as a consequence of ER stress 
driven by prolonged exposure to elevated Ca2+, and that MGP levels 
eventually deplete from MV93. 
 
 
1.2.2  Inhibitors of vascular calcification  
The existence of inhibitors of calcification has long been suspected as serum, 
even of a healthy individual, is supersaturated with Ca2+ and phosphate and 
thus a mechanism(s) to prevent the development and progression of 
  13 
extraskeletal calcification must be in place.  Even in CKD patients, a small 
subset of patients do not develop calcification despite exposure to a similar 
uremic environment79.   
 
A number of calcification inhibitors have been identified including fetuin-A, 
matrix Gla protein (MGP), osteopontin (OPN), pyrophosphate (PPi) and 
osteoprotegerin (OPG).  Evidence suggests that these proteins may be 
deficient or non-functional in patients with CKD, and many have been 
correlated with calcification scores in CKD patients88, therefore increasing the 
likelihood of calcification (see Figure 1.6).  Our understanding of the role of 
these physiological inhibitors has been assisted by recent animal knockout 
models, discussed below.   
 
 
 
 
Figure 1.6  Schematic diagram illustrating the balance of inhibitors and inducers in 
normal physiology and CKD.  In normal physiology, calcification inhibitors protect from 
spontaneous calcification.  However, with reduced expression of inhibitors and additional 
drivers of calcification (hyperphosphatemia and hypercalcaemia) the balance shifts in CKD.  
MGP; matrix gla protein, OPN; osteopontin, PPi; pyrophosphate, OPG; osteoprotegerin, 
SHPT; secondary hyperparathyroidism. 
 
 
1.2.2.1  Fetuin-A  
Fetuin-A is a circulating serum protein that acts as a potent inhibitor of 
extraosseous calcification, accounting for ~50% of the calcification inhibitory 
capacity of serum94.  This inhibition is achieved by formation of colloidal 
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spheres with Ca2+ and PO4
3-, referred to as calciprotein particles95, 96 thereby 
preventing precipitation of basic calcium phosphate.  Fetuin-A can also 
modulate the calcification process locally.  Fetuin-A has been observed at 
sites of injury where it is internalised by SMCs, via an annexin-dependent 
mechanism97, inhibiting apoptosis of smooth muscle cells (SMCs) and 
preventing mineral nucleation from MVs89.  
 
The role of fetuin-A as an important mineralisation inhibitor was demonstrated 
when examining animals with targeted disruption of the fetuin gene.  Despite 
the mild calcification phenotype98, 99 of fetuin-A knock out mice (Ahsg -/-), 
extensive calcification was observed when mice were either a) on a high 
phosphate and vitamin D diet or b) normal diet and crossed onto a strain of 
calcification-prone mice (DBA/2)99.  Westenfield et al. (2004) produced an 
additional model, a double knock out of fetuin-A and apolipoprotein E (Ahsg -
/-, ApoE -/-) and, in support of existing findings, confirmed that fetuin-A 
deficiency enhances calcification100.  With induced CKD (i.e. a high phosphate 
diet and unilateral nephrectomy), these animals (Ashg -/- ApoE -/-) showed 
more extensive aortic calcification compared to their WT and ApoE-/- 
counterparts receiving the same treatment100.   
 
Clinically, the role of fetuin-A is more difficult to define as fetuin-A acts as an 
acute phase reactant and thus its production is down regulated with systemic 
inflammation.  However, significantly lower levels of fetuin-A have been 
observed in dialysis patients (vs. normal population)101, and associated with 
increased all-cause cardiovascular mortality101, 102.  A polymorphism in the 
fetuin-A gene (T256S) predisposes patients to low levels of serum fetuin-A 
and is associated with increased mortality versus those patients carrying the 
alternative polymorphism103, 104.  While none of these studies assessed the 
relationship between fetuin-A and the extent of vascular calcification, Moe et 
al. (2005) reported an inverse relationship between circulating levels of fetuin-
A and coronary calcification scores, in CKD stage 5 patients88.  Similar 
observations have also been noted in patients without CKD105, 106.  Moreover, 
serum from dialysis patients shows a reduced capacity to inhibit Ca x P 
product precipitation in vitro versus serum from normal controls, an effect that 
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can be reversed by addition of purified fetuin-A to physiological 
concentrations101.   
 
 
1.2.2.2  Matrix γ-Carboxyglutamic Acid Protein   
Matrix Gla (γ-carboxyglutamic acid) protein (MGP) was the first calcification 
inhibitor to be characterised in vivo107 and probably the most widely known.  
To produce its anti-calcification effects, MGP requires post translational 
gamma carboxylation107.  Out of 5 of the glut residues, 4 need to be converted 
to gla, for MGP’s inhibitory actions108, a process which is dependent on the 
availability of vitamin K.  Additionally, a second series of post translational 
modifications appear to be required to ensure successful secretion and 
functionality of MGP: phosphorylation of 3 serine residues109. 
 
MGP is expressed and secreted by SMCs 110, 111, and is found in high 
abundance in areas of calcification both in vitro111 and in vivo112, 113.  However 
it is the uncarboxylated form that is predominantly found in areas of 
calcification114.  MGP is believed to work via 1) direct inhibition of Ca2+ 
precipitation and crystalisation as a result of Ca2+-binding to Gla motif110, 115, 
and 2) antagonising bone morphogenetic protein 2 (BMP-2), which plays a 
role in osteoblast differentiation and thus bone formation116-118 and bone 
morphogenetic protein 4119.  Interestingly, the effect of MGP, in vitro, is 
dependent on the relative amounts of BMP-2 present and when BMP-2 is low 
MGP has been shown to promote calcification120.  MGP has also been 
identified as being associated with matrix vesicles83 however whether its 
mechanism of inhibition in matrix vesicles is the same as above, or MGP has 
other actions, is unknown.   
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Figure 1.7  Mineralised blood vessels in MGP deficient mice (taken from Luo et al. 
(1997)
107
). 
4 week old MGP -/- mice show prominent calcification of the arteries.  Calcified arteries 
resisted the alkaline digestion of soft tissues and show alizarin red staining, for mineral. 1 
carotid artery, 2 cervical trunk, 3 anxillary artery, 4 unnamed, 5 aortic arch, 6 aorta, 7 
intercostal artery, 8 coeliac artery, 9 renal artery, 10 iliac artery 
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous 
calcification of arteries and cartilage in mice lacking matrix gla protein. Nature. 1997;386:78-
81 
 
Deletion of the MGP gene in mice results in extensive arterial calcification 
within a few weeks (Figure 1.7) and aortic rupture causing premature death107.  
Restoration of MGP expression in SMC can rescue the calcification 
phenotype108.  Clinical data also suggest a role for MGP as a calcification 
inhibitor; an inverse association exists between serum MGP levels and 
calcification121, 122.  Additionally, mutations in the MGP gene resulting in 
truncated forms of MGP, i.e. Keutel syndrome123, produce widespread 
calcification in the tracheobronchial tree123, 124.  However, unlike in vivo 
models, patients survive until adulthood, suggesting that the truncated forms 
of MGP may retain some biological activity.  Additionally in CKD, an inverse 
relationship between total uncarboxylated MGP and vascular calcification is 
reported in haemodialysis patients125-127.  However, recently in a report 
examining all CKD patients and focusing only on dephosphorylated and 
uncarboxylated MGP (dp-ucMGP), it was reported that plasma dp-ucMGP 
increases progressively with CKD stage and is positively association with the 
severity of arterial calcification128 suggesting that the dephosphorylated and 
uncarboxylated form of MGP is regulated differently to the uncarboxylated 
form.     
 
 
 
This image has been 
removed by the author for 
copyright reasons. 
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1.2.2.3 Osteopontin 
Osteopontin (OPN) is a Ca2+-binding, phosphorylated glycoprotein normally 
found in mineralised tissues where it is involved in bone remodelling: 
promoting osteoclast function through αvβ3 integrin129 and inhibiting apatite 
crystal growth130.  Whilst OPN is not normally present in soft tissues it is 
secreted by macrophages, T cells, haematopoietic cells, SMCs, fibroblasts, 
and myocardial cells131. 
 
Whilst loss of OPN alone does not cause spontaneous calcification, in the 
presence of pro-calcifying stimuli, deficiency of OPN in vivo results in 
accelerated calcification132.  Similarly to MGP, the anti-calcification abilities of 
OPN are dependent on post translational modifications, its inhibitory effect 
being directly dependent on the number of phosphorylated sites133.    
 
In injured / atherosclerotic vessels, OPN is found in abundance134-140 and 
plasma OPN levels are significantly higher in patients with coronary 
calcification141.  OPN exists as a component of human atherosclerotic 
lesions137, 142 and is observed in the arteries of MGP null mice71.  In patients 
with coronary artery disease OPN correlates to disease severity, independent 
of conventional risk factors143.  Whilst a protective action for OPN is assumed, 
data supporting the suggestion of an atherogenic role for OPN rather than a 
protective one also exist144.   
 
 
1.2.2.4 Pyrophosphate 
Pyrophosphate (PPi) has demonstrated inhibition of mineralisation both in 
vivo145 and in vitro146, inhibiting hydroxyapatite formation via a direct 
physicochemical reaction147.  It has been suggested that PPi may also play a 
role in stabilising the SMC phenotype and preventing transdifferentiation148.   
 
To maintain PPi levels, its generation and release is modulated via 
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) and Ank 
respectively, and its breakdown via tissue nonspecific alkaline phosphatase 
(TNAP).  Studies in vivo and ex vivo report that deficiencies in ENPP1149 or 
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Ank, a pyrophosphate transporter150, or overexpression of TNAP149 results in 
extensive calcification.  Idiopathic infantile arterial calcification (IIAC) results 
from a genetic deficiency of pyrophosphate and in most cases this is related 
to deficiencies in ENPP1151.  These patients exhibit severe medial arterial 
calcification at an early age151, 152, and often die as a result of heart failure 
soon after birth highlighting the importance of pyrophosphate control.   
 
In vivo, upregulation of TNAP has been demonstrated in the aorta of uremic 
animals153 which may lead to vascular deficiency of PPi in CKD.  In fact, PPi 
levels are reported to be reduced in haemodialysis patients154, and a negative 
association with the severity of vascular calcification exists155.  Administration 
of exogenous PPi shows substantial inhibition of vascular calcification in 
uremic rats, without detrimental effects on bone156.  Despite the short half life 
of pyrophosphate, inhibition of calcification was achieved with small, transient 
elevations in plasma PPi and therefore PPi has been suggested as a therapy 
for uremic vascular calcification156. 
 
 
1.2.2.5 Osteoprotegerin   
Osteoprotegerin (OPG) is a member of the tumour necrosis factor (TNF)-
related family and is involved in bone metabolism.  In mice, the importance of 
OPG in vascular calcification is clear with OPG null mice (OPG -/-) showing 
both severe osteoperosis and spontaneous calcification157.  In vivo, loss of 
OPG results in markedly increased calcification when animals are subjected 
to pro-calcifying stimulus158 or pro-atherogenic conditions159.  Additionally, 
treatment with OPG can reduce the extent of calcification in animals prone to 
develop atherosclerosis159, 160 and calcification161.  
 
However the role of OPG in humans appears to be different.  Clinical studies 
have consistently reported that serum OPG levels are positively associated 
with the progression of coronary calcification88, 162-164.  Whilst it’s possible that 
OPG may be upregulated in response to vascular damage to exert its 
protective role, detrimental effects on the vasculature have also been 
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documented165, 166, however further work is required to complete our 
understanding. 
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1.3 Introduction to the calcium sensing receptor 
The calcium sensing receptor (CaSR) is central to the calcium homeostatic 
mechanism.  The CaSR senses free extracellular calcium ions and couples 
this information to intracellular signalling pathways enabling the cell to 
respond to increases in extracellular Ca2+ concentrations.  It is highly 
expressed in the parathyroid chief cells where it acts as the sensor 
modulating the synthesis and secretion of PTH.  High levels of extracellular 
Ca2+ activate the CaSR, which in turn inhibits the expression and secretion of 
PTH as well as inhibiting parathyroid cell proliferation167.  In contrast, when a 
fall in serum Ca2+ is sensed by the CaSR, increased release of preformed 
PTH is detected and, within hours, increased transcription of pre-pro-PTH 
mRNA168.  CaSR has also been shown to be highly abundant in the kidney169 
and thyroidal cells170 where it further contributes to Ca2+ homeostasis; 
controlling urinary Ca2+ excretion (reviewed by Riccardi and Brown (2010)171) 
and the release of calcitonin, respectively.   
 
The importance of CaSR in Ca2+ homeostasis is highlighted by the phenotype 
resulting from CaSR mutations in humans, including familial hypocalciuric 
hypercalcaemia (FHH; inactivating), neonatal severe primary 
hyperparathyroidism (NSHPT; inactivating), autosomal dominant 
hypocalcaemia (ADH: activating) and Bartter syndrome type V (activating).  
Heterozygous inactivating mutations of the CaSR gene typically cause FHH 
and homozygosity of the mutation manifests as NSHPT.  Patients present 
with hypercalcaemia and relative hypocalciuria.  The hypercalcaemia of FHH 
is mild to moderate, whereas children with NSHPT can develop severe 
hypercalcaemia and without quick intervention neurodevelopmental damage 
or fatality may result.  ADH is characterized by hypocalcaemia accompanied 
by hypercalciuria and an inappropriately low concentration of PTH.  Patients 
with activating CaSR mutations and features of Bartter syndrome additionally 
exhibit hypokalemia with renal potassium wasting, hyperreninemia, and 
hyperaldosteronemia.  CaSR autoantibodies have also been identified that 
can be activating or inactivating in nature, mimicking ADH172 and FHH172-174, 
respectively.   
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1.3.1 Structure and signalling of the CaSR  
The CaSR is a G-protein coupled cell surface receptor (GPCR), originally 
cloned from bovine parathyroid gland, and is well conserved showing a large 
degree of homology between different species.  The human CaSR gene is 
located on chromosome bands 3q13.3-21.  The cDNA has a coding region of 
3234 bp, producing a 1078aa protein.  Several splice variants have been 
reported175-177 however for many of these the functional significance is 
unknown.    
 
The CaSR belongs to family 3 (or C) G-protein coupled receptors.  Family 3 
represents a small subfamily of GPCRs including metabotropic glutamate 
receptors (mGluR1-8), GABAB receptors, GPRC6A responsible for sensing 
basic amino acids, sweet taste receptors (T1R1-3) and putative pheromone 
receptors (V2Rs).  Figure 1.8 shows the topology of the CaSR with its large 
extracellular domain (ECD) (612 residues), a transmembrane domain (TMD) 
of 250 amino acids containing the 7 membrane spanning helices, and an 
intracellular C-terminal domain (ICD) of 216 amino acids.   
 
Characteristic of family 3 GPCRS, the CaSR possesses an unusually large N-
terminal extracellular domain (ECD).  The ECD contains a bi-lobed venus fly 
trap domain, cysteine-rich domain and several N-linked glycosylation sites.  
The venus fly trap domain shows homology to the bacterial periplasmic 
binding protein178.  Based on the crystal structure of mGluR1 it has been 
suggested that the VFTD can exist in open and closed confirmations and 
agonist binding is thought to stabilise the closed confirmation179, 180.  The 
cysteine-rich domain is a second characteristic feature of family 3 GPCRs, 
present in all except orphan and GABAB receptors, and in the case of the 
CaSR has been shown to be critical for CaSR mediated signalling181.  Upon 
cloning of the CaSR, 11 putative N-linked glycosylation sites were identified 
and since, mutagenesis studies have highlighted the importance of 
glycosylation in cell surface expression of the CaSR182.   
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Figure 1.8 Schematic representation of the CaSR (adapted from Saidak et al. (2009)
183
).  
Predicted Ca
2+
 bindings sites are illustrated in purple, yellow, pink, green and blue
184
. 
Residues involved in both calcimimetic and calcilytic binding are shown in black, and those 
only involved in calcilytic binding in orange
185-187
.   
Saidak Z, Brazier M, Kamel S, Mentaverri R. Agonists and allosteric modulators of the 
calcium-sensing receptor and their therapeutic applications. Mol Pharmacol. 2009;76:1131-
1144 
 
Thirdly, all family 3 GPCRs function as dimers.  Dimerisation occurs in the 
endoplasmic reticulum through intermolecular disulfide bonds involving 
cysteines 129 and 131, and non-covalent interactions188-191.  The cell-surface 
CaSR is typically present in a homodimeric configuration, however instances 
of heterodimerisation of CaSR with other family 3 receptors has also been 
reported192-194. 
 
As a GPCR, the CaSR coordinates its signalling cascades via heterotrimeric 
G proteins.  The nature of the signalling pathways activated, i.e. the G 
proteins recruited, in response to CaSR activation varies depending on cell 
type and the CaSR has been labelled as a pleiotropic GPCR that can couple 
to more than one type of G-protein195.  A large amount of work has focused on 
the signalling in HEK cells transfected with the CaSR (CaSR-HEKs).  
Activation of the CaSR can stimulate phospholipase A2 (PL2A), C (PLC) and D 
(PLD)196.  Stimulation of PLC leads to the production of IP3 and activation of 
protein kinase C (PKC).  IP3 binds to IP3 receptors on the endoplasmic 
reticulum membrane, which causes Ca2+ mobilisation within the cell.  In 
parallel to activation of PLC, activation of the CaSR stimulates 
phosphatidylinositol 4-kinase (PIK4), involved in the first step in inositol lipid 
biosynthesis, via Gαq.  The CaSR not only interacts with Gαq, but can also 
This image has been 
removed by the author for 
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signal via Gαi, which results in the inhibition of adenylate cyclase and thus 
reduction of cyclic adenosine monophosphate (cAMP) levels197.  Finally, 
another important group of signalling molecules that can be activated by 
CaSR is the mitogen activated protein kinases (MAPK)198; which often result 
in changes in gene expression.  Whilst by no means an exhaustive list, genes 
known to be induced by MAPK signalling include COL1A1 (coding collagen 
1)199, 200, EGR1 (coding early growth response protein 1)201, 202, FOS203, 
HSPA5 (coding heat shock 70 kDa protein 5)204, HSPB1 (coding heat shock 
27 kDa protein)205, JUN206 and MYC207.   
 
Phosphorylation of the CaSR can alter the receptors signalling potential.  At 
least 5 PKC sites exist (T646, S794, T888, S895 and S915) )208 and 2 
predicted protein kinase A (PKA) sites (S899 and S900)209.  PKA 
phosphorylation is believed to contribute only a minor role in the regulation of 
CaSR209, however the effects of PKC phosphorylation on PTH secretion and 
Ca2+ mobilisation in the parathyroid were well known prior to the discovery of 
CaSR210, 211.  Mutation of each PKC site highlighted the importance of Thr888 
in the regulation of CaSR signalling; producing a substantial shift in EC50, 
whilst the other sites produces little (S895 and S915) or no change (T646 and 
S794)212.   PKC mediated inhibition of CaSR signalling can be stimulated by 
receptor activation, allowing for a negative feedback loop213.  
 
CaSR signalling has also been shown to be influenced by the presence of 
filamin A.  Filamin A is a cytoskeletal scaffold protein that has been shown to 
be important for CaSR mediated ERK activity214-216, Rho signalling217, 218 and 
JNK activation215.  In addition to its role in signalling, filamin A may also allow 
for greater stability of the CaSR at the plasma membrane219.  CaSR 
expression was shown to double in M2 cells when filamin A, not a natural 
expression, was transfected219.  Other binding partners of the CaSR include 
the inwardly rectifying K+ channels Kir4.1 and 4.2, dorfin, involved in the 
ubiquitination of the CaSR, the receptor activity-modifying proteins (RAMP) 
RAMP-1 and RAMP-3 involved in receptor trafficking and β-arrestins 
regulating internalisation and degradation (reviewed in detail by Huang and 
Miller (2007)220). 
  24 
 
 
1.3.2  Pharmacology of the CaSR 
A considerable number of ligands modulate CaSR activation and can be 
divided into 2 groups: orthosteric modulators which act on the CaSR directly 
or allosteric modulators, which modulate the effects of orthosteric modulators.  
Moreover the CaSR is responsive to changes in ionic strength221 and pH222.    
 
Whilst Ca2+ is the primary orthosteric agonist of the CaSR, many other 
orthosteric agonists exist.  A number of divalent and trivalent cations can 
activate the CaSR i.e. Gd3+, Al3+, Sr2+, Mn2+, Ni2+, Ba2+, and Mg2+ 223, however 
Ca2+ and Mg2+ are the only endogenous divalent agonists.  Other orthosteric 
agonists, which are all positively charged, include polyamines and 
aminoglycoside antibiotics223.   
 
The hill co-efficient for CaSR indicates that 3–5 Ca2+ ions bind 
cooperatively224 and initial work by Huang et al. (2007) identified 2 regions, 
amino acids 222–235 and 383–408, which when removed from the CaSR 
altered intracellular responses to Ca2+.  Additionally, insertion of these 
sequences into non-Ca2+ binding scaffold proteins gave the new protein the 
ability to bind Ca2+225.  More recent modelling work by the same group, 
utilised the crystal structure of mGluR1, and identified 5 potential Ca2+ binding 
sites in the ECD184.  Whilst binding of CaSR’s other cation agonists was not 
examined at each of the potential sites individually, Mg2+ and La3+ were 
shown to bind within select subdomains of the CaSR ECD containing 2-3 of 
the potential binding sites and competition between the agonists visible.  
Whilst, the ECD is believed to possess the primary extracellular ion binding 
site(s), it is not the only site for orthosteric binding.  Ray and Northup et al. 
(2002) report a response to Ca2+, Mg2+ and Gd3+ in a CaSR mutant lacking 
the ECD (T903-Rhoc), suggesting at least one other site within the TMD also 
participates in cation sensing226.   
 
Allosteric modulators independently have no effect on receptor activity (in the 
case of the physiological CaSR) but in the presence of an orthosteric agonist 
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can influence receptor activity i.e. shift the dose-response curve.  Both 
positive and negative allosteric modulators have been identified that can 
potentiate or attenuate the response to orthosteric agonists respectively.   
 
L-amino acids, in particular aromatic L-amino acids have been demonstrated 
to act as positive allosteric modulators of the CaSR227.  In addition to 
endogenous positive allosteric modulators, small molecule drugs (NPS R-568, 
AMG641, AMG073, Cinacalcet), also known as calcimimetics, have been 
developed.  Most calcimimetics are phenylalkylamines and are derived from 
Ca2+ channel blockers. Cinacalcet is approved for use in hyperparathyroid 
states (i.e. primary and secondary hyperpathyroidism and parathyroid 
carcinoma).  Interestingly, further potential for calcimimetics may exist as 
recent reports suggest the possibility of using calcimimetics to rescue CaSR 
mutants228. 
 
Despite their common actions, the binding sites for L-amino acids and 
calcimimetics appear to be distinct.   A chimeric receptor was developed in 
which the CaSR TMD was replaced with that of the rat mGluR1 receptor.  
While L-Phe enhanced the sensitivity of the chimeric receptor to Ca2+, R-467, 
a calcimimetic, produced no effect.  However, when assessed in an N-
terminally truncated CaSR R-467, but not L-Phe, increased receptor 
sensitivity229.   
 
Negative allosteric modulators of the CaSR, known as calcilytics, have also 
been developed (SB-751689, SB-423557).  As with the calcimimetics, the 
calcilytics are believed to bind in the 7TMD185, 187, and in some cases the 
binding site may overlap with the calcimimetics187.  No calcilytic is currently 
approved for use, however their potential as bone anabolic agents are being 
investigated for the treatment of osteoporosis.   
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1.4  Calcimimetics in vascular calcification 
The central role of CaSR in SHPT makes it an interesting target to attempt to 
restore mineral imbalance and potentially reduce risk factors for vascular 
calcification in CKD.  Currently calcimimetics represent the only available 
treatment of SHPT in CKD stage 5 patients which allows control of high PTH 
levels in the absence of a concomitant increase in serum Ca2+ and 
phosphate230, 231 and have been shown to be effective in this patient group.  
Therefore it was hypothesised that calcimimetics may also contribute to 
slowing the progression of vascular calcification in the setting of CKD.   
 
 
1.4.1 A systemic role for calcimimetics in the protection against vascular 
calcification  
Whilst clinical data are currently lacking to confirm or refute the ability of 
calcimimetics to attenuate vascular calcification in CKD patients, it is an area 
actively being researched and data from small scale studies emerging.  
Existing data report that cinacalcet treatment reduces cardiovascular-related 
hospitalization (39%) in haemodialysis patients with uncontrolled 
hyperparathyroidism232 and prospective studies investigating cardiovascular 
events in dialysis patients are ongoing (EVOLVE study; Evaluation of 
Cinacalcet HCl Therapy to Lower CV Events)233.  More specifically, attention 
is now also focused on vascular calcification as a primary endpoint.  A small 
scale, prospective, observational study has reported the ability of cinacalcet to 
reduce arterial stiffness of SHPT with CKD234 and the effect of cinacalcet plus 
low dose vitamin D on vascular calcification in CKD patients receiving dialysis 
is being addressed in the ADVANCE study235.  However, as we await robust 
clinical data, strong support for a protective role of calcimimetics comes from 
numerous in vivo studies.     
 
A number of uremic animal models exist including 5/6 nephrectomy and 
adenine-induced uremia.  Treatment of uremic animals with calcitrol and/or a 
high phosphate diet can be used to accelerate calcification in these models.  
The effect of calcimimetics in vivo have been investigated by a number of 
groups, and consistently show reduced vascular calcification and increased 
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survival236-239.  This benefit has been shown with different calcimimetic 
compounds including cinacalcet237, R-568238 and AMG641236, 239(Figure 1.9) 
eluding to a class effect.  As expected these actions are accompanied by 
alterations in serum biochemistry i.e. reductions in serum Ca2+ 92, 236, 237, 239, 
phosphate236, 239 and PTH236, 237 towards levels of non-uremic animals.  
Reduction in serum PTH is also accompanied by reductions in parathyroid 
gland volume in the order of around 50%236, 237.    
 
 
1.4.2 A protective role for calcimimetics on smooth muscle cells 
For the most part the beneficial actions of calcimimetics in vascular 
calcification have been attributed to reducing levels of the non-traditional risk 
factors (i.e. Ca2+, phosphate, PTH), supported by the observation that a 
parathyroidectomy can also suppress calcification237.  However, Ivanovski et 
al. (2009) surprisingly showed that R-568 not only to reduced intimal and 
medial calcification in uremic artherosclerotic mice, but also the progression of 
atherosclerosis240.  R-568 reduced the atherosclerotic plaque area fraction 
suggesting R-568 may have a more direct action on the vasculature 
responsible for eliciting this protection.  Moreover, with the identification of the 
CaSR in the vasculature, the possibility of a more direct effect of the 
calcimimetics also emerged.   
 
 
 
 
 
 
 
Figure 1.9  Protective effect of AMG641 in aortic mineralisation in adenine fed animals 
(taken from Henley et al. (2009)
236
).  Von Kossa-stained sections of aortas showing 
mineralisation from animals fed adenine (0.75%) for 4 weeks and treated for 4 weeks with 
either (A) AMG-641 (3 mg/kg, p.o.); (B) 10% captisol-vehicle for AMG 641 (1 ml/rat, p.o.)  
Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X, Martin D, Yao W, Lane N, Shalhoub V. 
The calcimimetic amg 641 abrogates parathyroid hyperplasia, bone and vascular calcification 
abnormalities in uremic rats. Eur J Pharmacol. 2009;616:306-313 
This image has been 
removed by the author for 
copyright reasons. 
  28 
1.4.2.1  CaSR expression in SMCs 
CaSR has been convincingly shown to be expressed in the vascular 
endothelium241, where upon activation it is responsible for an increase in 
intracellular Ca2+ and thus opening IKCa channels, suggestive of a role in 
controlling arterial blood pressure.  In addition in areas of calcification, 
phagocytic cells expressing the CaSR have been identified in uremic rats239.  
However it is the identification of the CaSR in SMC84, 92, 242-244 that has 
attracted the most attention.   
 
The presence of CaSR in SMCs was once a controversial topic.  Within the 
literature, some groups have failed to detect CaSR91, 245, 246.  However, CaSR, 
both in its protein and mRNA form, has been demonstrated in rat, bovine and 
human SMC84, 92, 242-244.  Interestingly, in 2 reports failing to detect CaSR, only 
the presence of CaSR mRNA was investigated91, 246, known to be in low 
abundance in SMC.  Additionally CaSR expression has been shown to be 
sensitive to culture conditions; Ca2+ concentrations of 1.8 mM present in 
normal DMEM (Dulbecco's Modified Eagle Medium) can result in reduced 
CaSR expression84.  Recently the use of knock down technologies has 
confirmed the presence of a functional CaSR in SMC84, 247. 
 
Limited information exists as to the function of CaSR in SMC.  So far, CaSR 
activation has been shown to increase proliferation via the MEK / ERK 
signalling pathways242-244 and protect against apoptosis242, however the 
relevance of CaSR in these processes in vivo have not yet been shown.   
 
 
1.4.2.2.  SMC CaSR and mineralisation  
Evidence exists supporting a role for the SMC CaSR in the process of 
vascular calcification.  Reduced expression of CaSR is observed in calcified 
human arteries versus non-calcified arteries and loss of the CaSR in vitro has 
been convincingly shown to be increase SMC mineralisation84.  Transfection 
of BAoSMCs with a dominant negative construct of CaSR resulted in 
accelerated mineralisation, data shown in Figure 1.1084.  In vitro findings show 
that constant exposure to high extracellular Ca2+, a promoter of calcification, 
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results in reduced expression of the CaSR84.  Similarly, arteries of ESRD 
patients, who are typically exposed to a high extracellular Ca2+ concentrations, 
also show reduced levels of CaSR expression vs. general population243.  
Decreased expression of the SMC CaSR may be one of the changes in 
ESRD patients that increase their susceptibility to the development of 
vascular calcification.     
 
 
 
 
 
 
 
 
Figure 1.10  Overexpression of the dominant negative calcium sensing receptor 
(dnCaSR) enhances mineralisation (taken from Alam et al. (2009)
84
).   
Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin 
D, Ward DT, Alexander MY, Riccardi D, Canfield AE. Calcification is associated with loss of 
functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res. 
2009;81:260-268 
 
In vitro, treatment of SMC with R-568 has been shown to delay the process of 
calcification84, 240.  These actions have been attributed to activation of the 
SMC CaSR as introduction of CaSR siRNA abolished this effect240.   Whilst 
the downstream mechanism contributing to the protective actions of 
calcimimetics on mineralisation is still under investigation, in vitro studies with 
a second calcimimetic, AMG641, show increased CaSR expression in 
BAoSMC92.  It is possible that by restoring CaSR expression, cells regain 
some protection against mineralisation.  Additionally, stimulation of CaSR with 
AMG641 in vitro has recently been shown to increase MGP expression by 
SMCs92, which may underlie their protective actions on mineralisation.   
This image has been 
removed by the author for 
copyright reasons. 
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1.5  Aims of this research  
Our understanding of the role of the CaSR in the modulation of calcification is 
by no means complete.  Whilst evidence points to a protective role for the 
CaSR, it is well   established that high concentrations of Ca2+, the major 
physiological agonist for the CaSR can trigger mineralisation of SMC, 
whereas positive allosteric modulation of the receptor appears to be protective.  
Distinct mechanisms of Ca2+ and calcimimetics must be at play, however the 
level of involvement of the CaSR in each of these processes is unknown.   
 
Whilst the activity of Ca2+ is certainly not limited to CaSR and calcification 
could be induced via a CaSR-independent mechanism, it is interesting that 
Gd3+ a second orthosteric agonist has also been shown to promote 
calcification in BAoSMC84.  Furthermore, common downstream actions are 
reported upon SMC treatment with Ca2+ or calcimimetics i.e. elevated MGP 
expression92, suggesting at least some shared mechanisms.   
 
Our understanding has, to some extent, increased recently as it has been 
shown that chronic stimulation with Ca2+ and Gd3+ result in down regulation of 
the SMC CaSR84 whereas AMG641 can increase SMC CaSR expression92, 
however the mechanisms involved in these differential process, and their 
relative contribution to SMC mineralisation, is unknown.   
 
Aims of research:  
1) To produce an explant culture of BAoSMC and in vitro model of 
calcification using methods described by Alam et al. (2009)   
2) Understand the relative involvement of CaSR in the effects of Ca2+ and 
calcimimetics on mineralisation:  
a. Test the differential effects of Ca2+ and calcimimetics on SMC 
mineralisation  
b. Test the hypothesis that the protective actions mediated by 
calcimimetics are related to their activity at the CaSR using 
pharmacological tools (research was performed prior to 
publication of data using siRNA to demonstrate CaSR mediated 
mechanisms) 
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3) Examine the signalling pathways activated by Ca2+ and calcimimetic 
treatment in attempt to  
a. Better understand the cellular consequences of CaSR activation 
in SMCs 
b. Evaluate the potential overlap between Ca2+- and calcimimetic-
induced activities 
c. Identify potentially protective signalling pathways mediated by 
the calcimimetics through CaSR activation  
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Chapter 2:  Methods 
 
2.1 Cell culture 
2.1.1  Isolation and culture of BAoSMC 
Bovine aorta was obtained from freshly slaughtered animals from a local 
abattoir.  The aorta was cut open longitudinally and a 2 cm2 section taken 
from the luminal face of the vessel wall, 20 cm below the left subclavian artery.  
The structure of the vessel wall is shown in Figure 2.1.  After thorough 
washing with sterile Hank’s balanced saline solution (HBSS; Invitrogen Ltd, 
Paisley, UK), the adventitia was removed by blunt dissection before removing 
the endothelial layer using a scalpel blade.  The aortic section was then 
further dissected, removing 2 mm2 sections of the medial layer and placing 
them luminal side down in a sterile 100 mm2 petri dish.    
 
 
 
 
 
 
 
Figure 2.1  Schematic diagram illustrating the structure of the aorta, showing the 
intima, smooth muscle cell containing media and adventita (taken from Ashley and 
Niebauer (2004)
248
).   
Ashley A.E. and Niebauer J (2004). Cardiology explained.  London, Remedica 
  
 
Aortic explants were cultured in Dulbeccos Modified Eagles Medium (DMEM) 
without CaCl2 (Invitrogen Ltd, Paisley, UK) containing 10% fetal calf serum 
(FCS), 100 U/mL penicillin, 100 g/mL streptomycin, 2 mM L- glutamine, 1 
mM sodium pyruvate and  1% non-essential amino acids.  To match 
physiological Ca2+ conditions, Ca2+ free medium was supplemented with 1 M 
CaCl2 to produce a final concentration of 1.2 mM CaCl2.  Amphotericin (1 
µg/ml; Invitrogen Ltd, Paisley, UK) was included in culture media for the first 2 
weeks to prevent fungal infections developing from the primary culture.  With 
This image has been 
removed by the author for 
copyright reasons. 
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the exception of those stated all cell culture reagents were purchased from 
Lonza (Lonza Biologics plc, Tewkesbury, UK).   
 
Nine 2 mm2 sections were arranged within one Petri dish and medium was 
initially added dropwise to the fresh explants.  The following day, 15 ml of 
medium was added to the culture. BAoSMCs were first seen to migrate from 
the tissue explant at 5–7 days, at which point explants were removed. Cells 
were maintained at 37 °C and 5% CO2 and medium renewed every 2–3 days.  
Cells were used between passages 3–10 with medium changed every second 
day. 
 
  
2.1.2  Culture of human SMC 
Proliferating human aortic SMC (HAoSMC), and all culture media for human 
cell culture, were purchased from Promocell (Heidelberg, Germany) and used 
for signalling experiments.  HAoSMC were cultured in smooth muscle cell 
growth media containing 5 % FCS, 5 µg/ml insulin, 0.5 ng/ml epidermal 
growth factor and 2.0 ng/ml basic fibroblast growth factor (basal Ca2+ 
concentration equals 1.6 mM).  Cells were maintained at 37 °C and 5 % CO2 
and medium renewed every 2–3 days.  Cells were used between passages 3–
8 and split with a ratio of 1:2.  Subcultivation was performed with DetachKit 
(Promocell) which utilises a trypsin/EDTA solution to promote detachment and 
a serum-free trypsin neutralisation solution to inactivate the trypsin. 
 
 
2.2  Immunofluorescence 
2.2.1  α-smooth muscle actin (-sma) staining 
BAoSMC at passage 3 were plated on 4-well chamber slides (Thermo 
Scientific Inc, Essex, UK) at a density of 1 x 104 cells/cm2.  The next day cells 
were fixed in 50% methanol (2.5 min), 100% methanol (2.5 min) and 50% 
methanol (2.5 min).  After washing, BAoSMCs were incubated with α-sma 
monoclonal antibody (Sigma-Aldrich Co, Dorset, UK) 1:400 in 1% rabbit 
serum (Dako, Glostrup, Denmark) for 1 hr at RT.  After washing three times 
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with phosphate buffered saline (PBS), cells were incubated with rabbit anti-
mouse fluorescein isothiocyanate (FITC) 1:100 (Dako, Glostrup, Denmark) for 
40 min at RT in the dark.  From this point onwards all experimental 
procedures were performed in the dark.  Cell nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI; final concentration 4 g/ml) for 30 sec, 
before washing and mounting with Vectashield (Vector Laboratories Ltd., 
Peterborough, UK).  Immunostained BAoSMCs were viewed with an upright 
microscope (Olympus BX51, Olympus, Essex, UK) and images captured 
using a high-resolution camera (Coolsnap ES camera (Photometrics, Arizona, 
US) with MetaVue Software (Molecular devices, California, USA)).  Specific 
band pass filter sets for DAPI and FITC were used to prevent bleed through 
from one channel to the next.  Control experiments were performed where the 
primary antibody was replaced with mouse immunoglobulin (IgG2a) (1:400) 
(DakoCytomation, Cambridgeshire, UK). 
 
 
2.2.2  CaSR staining 
BAoSMC (passage 4–6) and HAoSMC (human aortic smooth muscle cells; 
passage 4–5) were plated at 1 x 104 cells/cm2 on a 4-well chamber slide.   
Cells were fixed for 20 min with 4% formaldehyde in PBS.  Non-specific 
binding was prevented by blocking with 4% rabbit serum (Dako, Glostrup, 
Denmark) in 0.2% bovine serum albumin (BSA; Sigma-Aldrich Co, Dorset, 
UK) in PBS for 1 hr at RT.  SMCs were incubated with CaSR antibody (Affinity 
BioReagents MA1-934, Rockford, Illinois, USA), diluted in 4% rabbit serum in 
0.2% bovine serum albumin at 1:200, overnight at 4 °C.  After washing three 
times, cells were incubated for 1 hr at RT with rabbit anti-mouse FITC 
(BAoSMC and HAoSMC), goat anti-mouse Alexa Flour 488 and 568 
(Molecular Probes, Oregon USA) (HAoSMC) all diluted in 4% rabbit serum in 
0.2% bovine serum albumin at 1:40.  Coverslips were mounted using 
Vectashield (Vector Laboratories Ltd., Peterborough, UK) and sealed with nail 
varnish.  Alternatively, as control experiments, the CaSR primary antibody 
was replaced with a mouse IgG2a (DakoCytomation, Cambridgeshire, UK) or 
removed completely and cells incubated with the secondary antibody alone.  
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Immunostained SMCs were viewed and images captured as above but 
including a band pass filter set for texas red.  
 
 
2.3 Mineralisation assays  
2.3.1  Ca2+ experiments 
BAoSMC (passage 5–8) were plated in 6-well plates (Corning Inc., New York, 
USA) at 1 x 104 cells/cm2 in 10% FCS-DMEM.  The following day medium 
was changed to 5% FCS-DMEM.  Upon confluence (~day 5) the incubation 
medium was switched to calcification medium i.e. medium supplemented with 
5 mM -glycerophosphate (BGP) (Sigma-Aldrich Co, Dorset, UK).  The first 
day of culture in the calcification medium was defined as day 0.  For Ca2+ 
experiments, BAoSMCs were incubated with different Ca2+ concentrations 
(1.2, 1.8 and 2.2 mM).  Treatment medium was changed every 2–3 days.  
Time to onset of mineralisation was variable between preparations and 
individual experiments.  Mineralisation was visualised using alizarin red dye 
which stains Ca2+ deposits red (see section 2.3.3) and quantified by dye 
elution (see section 2.3.3).  
 
 
2.3.2  Calcimimetic experiments 
BAoSMC (passage 6–9) were plated and maintained as above.  Upon 
confluence, cells were treated with medium supplemented with 5 mM -
glycerophosphate (BGP) containing different Ca2+ concentrations (1.2 mM, 
1.8 mM, 2.2 mM), as indicated, with or without the calcimimetic R-568 (N-[3-
[2-chlorophenyl]propyl]-[R]-α-methyl-3-methoxybenzylamine; 1 nM) or its 
isomer S-568 (1 nM).  The first day of culture in the calcification medium was 
defined as day 0.  Functional responses to calcimimetics have been 
previously shown to be elicited in SMC within the range of baseline Ca2+ 
concentrations used in this study (1.8 mM or 2.2 mM Ca2+)84, 92.  The dose-
dependent effects of AMG641 (10 pM, 100 pM, 1 nM) were also investigated.  
All calcimimetic compounds were provided by Amgen, Thousand Oaks, 
California.  R-568 and S-568 were diluted in distilled water and AMG641 in 
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1:1000 DMSO for the most concentrated solution (1 nM).  Upon formation of 
nodules and deposition of mineral, calcification was visualized by alizarin red 
staining which stains Ca2+ deposits red (see section 2.3.3) and quantified by 
dye elution (see section 2.3.3). 
 
 
2.3.3  Alizarin red staining 
To visually detect mineralisation, alizarin red staining was used which 
identifies calcium-rich deposits in culture by staining them red.  To perform the 
staining, first, medium was aspirated, BAoSMCs washed with PBS and fixed 
with 2% formaldehyde and 1% sucrose in PBS for 20 min.  After washing 
BAoSMCs with PBS, 40 mM Alizarin Red (pH 4.1–4.2) was applied to cells for 
20 min.  Excess stain was removed using by washing the BAoSMCs with 
distilled H20 (pH 7.0) for 20 min.  After drying by evaporation at RT, the 
BAoSMCs were viewed with an inverted microscope (Olympus IX51, Olympus 
Optical, London, UK) and images captured using an Olympus digital camera 
and analySIS imaging software (Olympus soft imaging systems, Munster, 
Germany). 
 
To quantify mineralisation the dye was eluted.  This was performed by treating 
stained BAoSMCs with 800 µl of 10% acetic acid to each well for 30 min while 
shaking to extract the Ca2+.  Cells were detached from the plate using a 
plastic scraper and the resulting solution (yellow) was collected and vortexed.  
Mineral oil was added to prevent evaporation and the solution heated to 85 °C 
for 10 min.  The solution was cooled on ice before centrifuging at 20,000 x g 
for 15 min.  The supernatant was transferred to a clean 1.5 ml eppendorf tube 
and 200 µl 10% ammonium hydroxide added to neutralise the acid.  150 µl of 
the resulting solution (pH should be 4.1–4.2) was added to a 96 well plate 
(Corning Inc., New York, USA) in triplicate and absorbance measured at 405 
nm.  
 
2.3.4  Ca2+ deposition assay 
To verify results generated with alizarin red staining a second method of Ca2+ 
detection was also employed.  The Ca2+ assay described detects total calcium 
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using the o-Cresolphthalein-calcium reaction which produces a vivid purple 
product that is absorbed between 560 and 590nm.   
 
BAoSMCs (passage 5–7) were plated in 6-well plates (Corning Inc., New York, 
USA) at 1 x 104 cells/cm2 and Ca2+ deposition assays performed in parallel to 
mineralisation assays.  Upon mineralisation, medium was aspirated and 
BAoSMCs washed twice with PBS.  Then, 500 µl 0.6 N HCl was added to 
each well and the plates incubated on a rotating platform overnight at 4 °C.  
The following day the HCl was removed from the wells and transferred to 
fresh 1.5 ml eppendorf tubes and kept for Ca2+ quantification.  BAoSMCs 
were then washed with PBS before adding 500 µl 0.1 M NaOH and shaking 
for 30 min.  Cells were scraped from the culture dish using a cell scraper and 
assayed for protein content using a BCA assay (Thermo Scientific Inc, Illinois, 
US) (see section 2.5).  Protein concentration was used to normalise the Ca2+ 
detected through the cresolphthalein method.   
 
HCl samples were assayed for Ca2+ quantification.  Samples (5 µl) were 
incubated in a 96-well plate along with 100 µl colour reagent  containing HCl, 
O-cresolphthalein complexone powder, hydroxyquinoline (stored in the dark 
and at 4 °C) and 100 µl AMP buffer (AMP reagent (2-amino-2-methyl-1-
propanol) dissolved in water and pH adjusted to 10.7, stored at 4 °C in dark) 
for 15 min and absorbance read at 570 nm.  A Ca2+ gradient was also 
included to create a standard curve for comparison.  A stock Ca2+ standard 
(50 mg/dl) was created using dry CaCO3 dissolved in water and concentrated 
HCl and stored in brown bottle at RT.  Stock Ca2+ solution was diluted to 
create Ca2+ standards at 5, 7.5, 10, 12.5 and 25 mg/dl Ca2+ which were 
assayed along with the samples.  All reagents unless otherwise stated are 
from Acros Organics, Thermo Fisher Scientific, Geel, Belgium.   
 
 
2.4  Alkaline phosphatase (ALP) activity 
Alkaline phosphatase (ALP), a phenotypic marker of osteoblasts, has been 
shown to be present at sites of vascular calcification and its activity implicated 
in the process of SMC mineralisation72, 249, 250.  Therefore its activity was 
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evaluated as one factor suggestive of osteogeogenic differentiation within 
SMC cultures.   
 
BAoSMC (passage 7–9) were plated in a 6-well plate (Corning Inc., New York, 
USA) at 1 x 104 cells/cm2.  Upon confluence, BAoSMCs were incubated with 
5% FCS-DMEM and 5 mM BGP in the presence of 1.2 mM or 1.8 mM Ca2+.  
Protein was harvested from cultures on day 3 and day 5 by aspirating the 
medium and washing BAoSMCs twice in ice cold PBS.  Cells were lysed 
using 0.1% Triton X-100 in 0.9% NaCl and detached from the plate with a 
plastic scraper.  Alkaline phosphatase activity was measured colorimetrically 
by the conversion of p-nitrophenyl phosphate (pNPP; Sigma-Aldrich Co, 
Dorset, UK (colourless) to p-nitrophenol (pNP; yellow) and phosphate.  Cell 
lysate (10 µl) was added to 200 µl pNPP, incubated at 37 °C for 20 min and 
the absorbance read immediately at 405 nm.  A standard curve of pNP (10 
mM – 10 nM) (Sigma-Aldrich Co, Dorset, UK) was used to correlate 
absorbance readings to conversion to pNP, representing ALP activity.  Protein 
concentration was measured using a BCA assay (Thermo Scientific Inc, 
Illinois, US) (see section 2.5).   
 
 
2.5  Assessment of protein content 
Protein content was assessed using the Pierce BCA assay, according to the 
manufacturer’s instructions.  Protein standards ranging 25–2000 µg/µl were 
used (diluted in lysis buffer appropriate to sample).  Samples and standards, 
15 µl, were loaded onto a 96-well plate (Corning Inc., New York, USA).  BCA 
reagents A and B were prepared at a 1:50 ratio and 200 µl added to each well 
before incubation at 37 °C for 30 min.  Absorbance was read at 562 nm.   
 
 
2.6  Western blotting  
2.6.1  ERK activation assay 
BAoSMCs (passage 6–10) and CaSR-HEKs (HEK293 expressing human 
CaSR; passage 12–14) were seeded in 35 mm culture dishes (Corning Inc., 
New York, USA) in 10% FCS-DMEM (1.2 mM Ca2+).  Cells were washed with 
  39 
PBS heated to 37 °C before being exposed to a low Ca2+ solution (0.5 mM) 
for 20 min for equilibration (these and subsequent incubations were 
conducted at 37 °C).  0.5 mM Ca2+ solution consisted of 20 mM HEPES (pH 
7.4), 125 mM NaCl, 4 mM KCl, 0.5 mM CaCl2, 0.5 mM MgCl2 and 5.5 mM 
glucose.   After this time equilibration medium was removed the cells treated 
with a low (0.5 mM) or high (5 mM) Ca2+ solution for 5 min (BAoSMC) or 10 
min (CaSR-HEK).  When the concentration of CaCl2 was increased to 5 mM, 
the concentration of NaCl was reduced accordingly to keep the total 
osmolarity constant.  Timings for SMC incubation were selected in line with 
findings by Molostvov et al. (2007).  After incubation, treatments were 
removed and cells washed with ice cold PBS and stored on ice.  Cells were 
lysed with ice cold RIPA buffer; 12 mM HEPES (pH 7.6), 300 mM mannitol, 
1% (v/v) Triton X-100, 0.1% (w/v) SDS, 1 mM  EDTA and 1 mM EGTA with 
freshly added phosphatase inhibitors (100 μM sodium vanadate and 1 mM 
NaF) and protease inhibitors (250 μM  sodium pyrophosphate, 1.25 μM 
pepstatin, 4 μM leupeptin and 4.8 μM phenylmethylsulfonyl fluoride; Sigma-
Aldrich Co, Dorset, UK). 
 
Lysates were transferred to fresh 1.5 ml eppendorf tubes and centrifuged at 
2500 x g for 15 min to pellet the cell debris and nuclear fraction.  Lysates were 
mixed with 5x Laemmli buffer and heated to 95 °C for 3 min.  Proteins were 
separated on a 10% polyacrylamide gel and transferred to nitrocellulose 
membrane (Amersham, GE Healthcare, Buckinghamshire, UK).  The protein 
equivalency of the samples was confirmed by ponceau-staining the blot 
before immunoblotting.  Membranes were blocked with Tris-buffered saline 
Tween-20 (TBST; 150 mM Tris-HCl, 1.5 mM NaCl, 0.1% Tween 20) 
containing 2% BSA before incubation with a rabbit polyclonal antibody 
(1:5000) targeting the active forms of ERK1 and ERK2 (Promega UK Ltd., 
Hampshire, UK) at RT for 1 hr on a shaker.  The primary antibody 
preferentially targets the dually phosphorylated form of ERK1 and ERK2 
corresponding to residues Thr183 and Tyr185.  After serial washes immunoblots 
were developed with a horseradish peroxidase-conjugated anti-rabbit mouse 
secondary antibody from DakoCytomation (Ely, Cambridgeshire, UK) for 1 hr 
at RT and the antigen-antibody reaction analysed by enhanced 
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chemiluminescense using a commercially available kit (ECL plus; Amersham, 
GE Healthcare, Buckinghamshire, UK). 
 
2.6.2  CaSR western blotting 
BAoSMC (passage 6–8) and HAoSMC (passage 4-5) were grown in 75 cm2 
culture flasks in 10% FCS-DMEM (1.2 mM Ca2+) until confluence.  Upon 
confluence, SMCs were lysed on ice with RIPA buffer supplemented with 
protease and phosphatase inhibitors (as above; section 2.6.1) with the 
addition of 1 mM N-ethylmaleimide.  Lysates were spun at 2500 x g for 20 min, 
pelleting the cell debris and cell nuclei.  The post nuclear supernatant was 
then spun at 17,000 x g for 30 min at 4 °C.  After resuspension total protein 
concentration of the samples were determined as detailed in section 2.5. 
 
Membrane preparations were mixed with 5x Laemmli buffer and heated at 
65 °C for 3 min prior to immunoblotting.  Proteins were separated on a 5% 
polyacrylamide gel and transferred to nitrocellulose membrane.  Immunoblots 
were blocked with 2% BSA in TBST for 1 hr at 37 °C and probed with an anti-
CaSR moloclonal antibody (Affinity BioReagents MA1-934, Rockford, Illinois, 
USA), raised to amino acids 214–235 of the extracellular domain of the 
human parathyroid CaSR.  Primary antibody was diluted 1:5000 in 2% BSA in 
TBST and incubated for 1 hr at RT.  Immunoblots were washed for 20 min 
with periodic changes of TBST and incubated with the secondary antibody, a 
horseradish peroxidase-conjugated anti-rabbit antibody (DakoCytomation, 
Cambridgeshire, UK) for 1 hr at RT.  After washing, immunoblots were 
incubated with enhanced chemiluminescence (ECL plus; Amersham, GE 
Healthcare, Buckinghamshire, UK) to detect binding of the secondary 
antibody to the primary anti-CaSR antibody.  
 
 
2.7  Bio-Plex phosphoprotein detection array 
HAoSMC (passage 4–6) were plated at 2 x 105 cells/10cm2. All materials, 
including Bio-Plex kits, were from BioRad (BioRad Laboratories Inc, 
Hempstead, UK) unless otherwise stated.  The following day (day 1) medium 
was changed to DMEM/F:12 (1:1) (Invitrogen, Paisley UK) with sterilized 0.2% 
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BSA and cells incubated overnight.  On the day of the experiment (day 2) the 
medium was aspirated and HAoSMCs washed briefly with PBS heated to 
37 °C.  HAoSMCs were equilibrated in low Ca2+ buffer (0.5 mM, as described 
in section 2.6.1) for 20–30 min.  For Ca2+ experiments: after equilibration, low 
Ca2+ buffer was aspirated and cells incubated with 0.5 mM Ca2+ (control) and 
5 mM Ca2+ for 5 min, consistent with the time-dependent elevation in Ca2+-
induced signalling in HAoSMC demonstrated by Molostvov et al. (2007).  For 
calcimimetic experiments: after equilibration, low Ca2+ buffer was aspirated 
and cells incubated with 2.5 mM Ca2+ in the presence and absence (control) 
of R-568 (1 nM).  Following the 5 min incubation, HAoSMCs were washed 
with ice cold wash buffer and lysed using 250 µl lysis buffer supplemented 
with factor 1 (250x), factor 2 (500x) (Bio-Plex cell lysis kit) and 
phenylmethylsulfonyl flouride (Sigma-Aldrich Co, Dorset, UK) dissolved in 
DMSO (500 mM), in accordance with manufacturer’s instructions.  HAoSMCs 
were incubated with the lysis buffer on a rotating platform at 300 rpm for 20 
min at 4 °C after which they were removed using a plastic scraper. Lysates 
were collected in 1.5 ml eppendorf tubes and centrifuged at 4,500 x g for 20 
min at 4 °C.  The supernatant was collected and diluted 1:1 using assay buffer 
(Bio-Plex phosphoprotein detection reagent kit).     
 
The Bioplex assay was performed following the manufacturer's protocol 
(BioRad, BioRad Laboratories Inc, Hempstead, UK), and summarised in 
Figure 2.2.  The target phosphoproteins examined and the binding sites of the 
antibodies used are shown in Table 2.1.  Firstly, the 96-well filter plate (Bio-
Plex phosphoprotein detection reagent kit) was pre-wet with assay buffer.  
Then, 1 µl of each phosphoprotein bead solution (50x) was diluted in wash 
buffer (Bio-Plex phosphoprotein detection wash buffer) and added to each 
well.  Excess liquid was removed by aspiration.  After two washes, 50 µl of 
cell lysate (final concentration 200–900 µg/mL) was added to each well and 
incubated overnight at RT on a shaking platform at 300 rpm.  The following 
day, any unbound proteins were removed by washing with wash buffer. 
Biotinylated detection antibodies (25x), specific to each phosphoprotein bead, 
were prepared using the detection antibody diluent and 25 µl added to the 
reaction.  The plate was vortexed before a 30 min incubation.  After further 
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washes and vacuum filtration, Streptavidin-Phycoerythrin (Strept-PE) (100x; 
Bio-Plex phosphoprotein detection reagent kit) diluted to a 1x solution with 
wash buffer to a final volume of 50 µl was then added and incubated for a 
further 10 min in the dark.  Strept-PE was removed by vacuum filtration and a 
further series of washes .  The beads were resuspended in 125 µl of 
resuspension buffer, incubated for 30 seconds at 1,100 rpm on a shaking 
platform and analysed using the Luminex 100 system.  The Luminex system 
identifies beads for specific phosphoproteins by the bead region, the ratio of 
the internal red and green fluorescent dyes. Data are expressed as % change 
from control.   
 
 
 
 
 
 
 
 
 
Figure 2.2  The methodological processes and rationale underlying the Bioplex assay 
(adapted from Bioplex manual). 
This image has been 
removed by the author for 
copyright reasons. 
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Table 2.1  Phosphorylation sites targeted by Bioplex antibodies 
 
Phosphoprotein Amino acid site 
Akt Ser473 
BCR-Abl Tyr245 
c-Jun Ser63 
CREB Ser133 
ERK 1/2 
Thr202/Thr204 
Thr185/Thr187 
GSK-3/ß Ser21/Ser9 
HSP27 Ser78 
IGF-1R Tyr1131 
I-B Ser32/Ser36 
JNK Thr183/Tyr185 
MEK Ser217/Ser221 
PDGF Tyr751 
p38 Thr180/Thy182 
p53 Ser15 
p70 S6K Thr359/Ser363 
p90 RSK Thr421/Ser424 
Src Tyr416 
Stat3 Tyr705 
Tyk2 Tyr1054/Tyr1055 
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2.8  Adenoviral infection 
A recombinant adenovirus (RAd) encoding the full length human CaSR with 
an arginine to glutamine substitution at position 185 (pacAd5CMV/dnCaSR), 
resulting in a dominant negative form, was generated under the direction of Dr. 
Beverly Davidson at the University of Iowa Gene Transfer Vector Core and 
has been characterised previously84.   A multiplicity of infection (MOI) of 150 
pfu/cell and viral titre of 3 x 1010 plaque-forming units/µl was used and 
transfection efficiency confirmed using a CaSR Western blot.   
 
BAoSMCs (passage 9) were transfected at 80% confluence (typically day 4).  
48 hrs following infection (day 6), BAoSMCs were induced to calcify with 
medium containing 5% FCS-DMEM and 5 mM BGP with either 1.2 mM or 1.8 
mM Ca2+.  BAoSMCs were maintained in this media for the remainder of the 
experiment.  Overexpression of the transgene was maintained by re-infection 
of the cultures on day 8.  Alizarin red staining was performed on day 12.   
 
 
2.9  RT-PCR 
2.9.1  RNA isolation  
RNA from freshly isolated bovine parathyroid gland was kindly provided by 
Donald Ward (University of Manchester).  RNA was isolated from cultured 
BAoSMCs (passage 6–8), at 90% confluence, using Trizol reagent (Invitrogen, 
Paisley, UK).  Medium was removed, BAoSMCs washed with ice cold PBS 
and cells lysed directly in the culture flask.  1 ml Trizol/T75 flask was added 
and cells detached using a cell scraper.  The Trizol solution was removed and 
placed in a 1.5 ml eppendorf tube where 0.2 ml chloroform (0.2 ml to 1 ml 
Trizol) was added.  The lysates were vortexed vigorously for 15 sec and 
centrifuged at 12,000 x g for 10 min at 4 °C.  Following centrifugation, the 
mixture separates into a lower red, phenol-chloroform phase, an interphase, 
and a colourless upper aqueous phase. RNA remains exclusively in the 
aqueous phase.  
 
The clear aqueous solution (upper level) was transferred to a clean 1.5 ml 
eppendorf tube.  To precipitate the RNA, the aqueous phase was mixed with 
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0.5 ml isopropanol for 2 min before being centrifuged at 12,000 x g for 10 min 
at 4 °C.  The RNA precipitate forms a small pellet on the bottom/side of the 
tube.  The RNA pellet produced was washed with 75% ethanol and further 
centrifuged at 12,000 x g for 5 min.  All leftover ethanol was removed and the 
pellet left to air-dry.  RNA was dissolved in diethylpyrocarbonate (DEPC)-
treated water (Ambion, Warrington, UK) and stored at -80 °C until use.  
 
RNA was quantified using a Nanodrop (Nanodrop ND-100 v3.3 
Spectrophotometer, Thermo Scientific, Delaware, USA) and the quality of the 
RNA assessed by running 1 µl on a 2% agarose gel and ethidium bromide 
staining.  Contaminating genomic DNA appears as a weak band of high 
molecular weight.   If present, contaminating genomic DNA was removed 
using Turbo DNase (Ambion inc, Huntingdon, UK). The reaction was 
incubated at 37 °C for 30 min before adding the inactivation reagent. The 
inactivation reagent was removed from the sample by centrifugation.    
 
 
2.9.2  First strand cDNA synthesis 
Reverse transcription of total RNA was carried out using SuperScript first 
strand synthesis kit (Invitrogen, Paisley, UK), according to manufacturer’s 
instructions.  Total RNA was mixed with 50 ng/µl random hexamers, 10 mM 
dNTP mix, 10 µl DEPC-treated water and incubated at 65 °C for 5 min.  
Following incubation the RNA/primer mixture was placed on ice for 1 min.  
The cDNA synthesis mix was prepared by adding 10 X reverse transcriptase 
buffer, 25 mM MgCl2, 0.1 M dithiothreitol (DTT), 40 U/µl RNaseOUT and 200 
U/µl Superscript III RT.  To this, the RNA/primer mixture was added, mixed 
gently and incubated for 10 min at 25 °C followed by 50 min at 50 °C.  The 
reaction was terminated by heat inactivation of the enzyme at 85 °C for 5 min 
and samples chilled on ice.  Finally, 1 µl of RNase H was added to each tube 
and the samples were incubated at 20 min at 37 °C before storing at -20 °C.  
Control reactions were performed in which the reverse transcription step was 
omitted.   
 
 
  46 
2.9.3  PCR 
PCR amplification of CaSR complementary DNA (cDNA) was attempted using 
2 different primer sets; primer 1 designed to amplify 2198–2253 and primer 2 
4755–4951 of NM_174002. The binding sites of each primer set is shown in 
Figure 2.3.  Primer 1 was designed using Primer3251, and the reverse primer 
bridges the exon6-exon7 junction.  Primer 2 was kindly provided by Dr. Masih 
Alam (University of Manchester), and is positioned within the 3’ downstream 
sequence.  Amplification was performed using Immomix Red (Bioline, London, 
UK) using the Eppendorf MasterCycler Gradient (Eppendorf, Cambridge, UK).  
Each PCR amplification was performed under the following conditions: an 
initial denaturation step at 95 °C for 10 min, followed by a total of 35 cycles of 
95 °C (30 sec), 58 °C (30 sec ), and 72 °C (30 sec) and a final elongation step 
of 72 °C.  Control PCR was carried out using primers specific for bovine 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), amplifying 572–626 of 
NM_001034034, to produce a PCR product of 54 bp.  As a negative control 
and to prevent amplification of contaminating genomic DNA, control samples 
which were treated without reverse transcriptase were also included. RT-PCR 
products were separated on a 1% agarose gel. 
 
 
2.10 Statistical analysis 
For paired comparisons, paired t-tests were performed.  For multiple 
comparisons a one way anova with tukey’s post hoc test was used.  Signalling 
data were analysed comparing raw data from control vs. test samples.  In 
instances where multiple control samples were included in one experiment the 
average of the control samples was used.  
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cggaaaaaaaaaaaaagttccccactctagtacagagaaggttggcagagtcgtaagcccccaacctctt
aaacttctctgcatctccaaggagaaggagggaagaggggttctttccgacctgaggagctggatctgggg
tccgagaaccccaaggtagcaccggaaagaacagcacaggaggcgagagcgtggccggtggccggg
agaaccagacccgacgcgcggtcctcggcgccggggtcccggggactcagctcagcacgactgggaa
gccgaaagtactacacacggtctctgcatgatgtgacttctgaagactcaagagccacccacttcactagtc
tgcaatggagaaggcagaaatggaaagtcaaaccccacggttccattctattaattctgtagacatgtgccc
ccactgcagggagtgagtcgcaccaagggggaaagtcctcaggggcccccagaccaccagcgcttga
gtccctcttcctggagagaaagcagaactatggcactttatagctgctgttggatcctcttggctttttctacctg
gtgcacttccgcctatgggcctgaccagcgagcccaaaagaaaggggacattatcctcggggggctctttc
ctattcattttggggttgcagtgaaagatcaggatctaaagtcgaggccggagtccgtggagtgtatcaggta
taatttccgaggatttcgctggttacaagctatgatatttgccatagaggaaataaacagcagtccagcccttc
ttcccaacatgaccctgggatacaggatattcgacacttgtaacaccgtctctaaagccttggaggccaccct
gagttttgtggcccagaacaaaattgactctttgaaccttgatgagttctgcaactgctcagagcacatcccct
ctaccatcgcagtggtgggagctactggctcgggcatctccacagcagtggccaacctgctggggctcttct
acatcccccaggtcagctatgcctcctccagcagactcctcagcaacaagaatcaattcaagtccttcctcc
gcaccatacccaatgatgaacaccaggccacggccatggctgacatcatcgagtacttccgctggaactg
ggtgggcacaattgcagctgacgatgactatggccggccagggatcgagaagtttcgagaggaagctga
ggagagggacatctgcatcgacttcagcgagctcatctcccaatactctgatgaggaaaagatccagcag
gtggtggaggtgatccagaattccaccgccaaagtcattgtcgtcttctccagcggcccagacctggaaccc
ctcatcaaagagatcgtccggcgcaatatcacaggcaggatctggctggccagcgaggcctgggccagc
tcttccctgattgctatgcccgagtatttccatgtggtcggaggcaccattgggtttggtttgaaagctgggcag
atcccaggcttccgggaattcctgcagaaagtccaccccaggaagtctgtccacaatggttttgccaagga
gttttgggaagaaacatttaactgccacctgcaagagggtgctaaaggcccattaccggtggacaccttcct
gagaggtcacgaagaaggaggtgccaggttaagcaacagtcccactgccttccgacctctgtgcactggg
gaggagaacatcagcagtgtcgagactccttacatggattatacacatttacggatatcctacaacgtctact
tagccgtctactccattgctcatgccctacaagatatatacacctgcatacctgggagagggctcttcaccaa
cggttcctgcgcagatatcaagaaggttgaagcttggcaggtcctgaaacacctgcggcacctaaattttac
cagcaatatgggggagcaagtaactttcgatgaatgtggagacctggcagggaactattccatcatcaact
ggcacctctccccagaggacggctccatagtgtttaaggaagttggatattacaatgtctatgccaagaaag
gagagagactcttcatcaatgatgaaaaaattctgtggagtggattctcaagggaggtgcctttctccaactg
cagtcgagactgcctggcagggaccaggaaaggaatcattgagggggagcccacctgctgctttgagtgt
gtggaatgtcctgatggggagtacagcgacgagacag*atgcaagtgcctgtgataagtgccctgatgact
tctggtccaatgagaaccacacttcctgcatcgccaaggagatcgagtttctgtcgtggaccgagcccttcg
ggatcgcactcacgctctttgctgtgctgggcattttcctcacagccttcgtgctgggcgtcttcatcaagttccg
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caacacgcccatcgtcaaggccaccaaccgggagctctcctatctccttctcttctccctgctctgctgcttctc
cagctccctgttcttcatcggggagccccaggactggacgtgccgcctgcgccagccggcctttggcatca
gcttcgtgctctgcatctcgtgcatcctggtgaaaaccaatcgggtcctcctggtgtttgaggccaagattccc
accagcttccaccggaagtggtgggggctcaacctgcagttcctgctggtcttcctctgcaccttcatgcagat
tgtcatctgtgccatttggctcaatacagcgcccccctcggctaccgcaaccacgagctggaggacgagat
catcttcatcacctgccacgagggctcgctcatggcgctgggcttcctgatcggctacacctgcttgctggcc
gccatctgcttcttcttcgccttcaagtcccggaagctgccagagaacttcaatgaagccaagttcatcacctt
cagcatgctcatcttcttcatcgtctggatctctttcatccccgcctacgccagcacttacggcaagttcgtctctg
ccgtggaggtgatcgccatcctggcggccagctttggcttgctggcctgtatcttcttcaacaaggtctacatc
atcctcttcaagccttcccggaacaccatcgaggaggtgcgctgcagcaccgcggcacacgccttcaagg
tggccgcccgagccacgctgcgccgcagcaacgtctcccgccagcggtccagcagcctagggggctcc
acgggatccaccccctcctcctccatcagcagcaagagcaacagcgaggacccgttccctcagcagcag
ccgaagaggcagaagcagccgcagccgctggccctgagcccgcacaacgcgcagcagccacagcc
gcggccaccctcgaccccacagccgcagccacagtcgcagcagccgccccgatgcaagcagaaggtc
atcttcggcagcggcaccgtcaccttctcgctgagctttgacgagcctcagaagaccgccgtggctcacag
gaattccacgcaccagacctccctggaggcccagaaaaacaatgacgccctgaccaaacaccaggcgt
tgctcccgctgcagtgcggagagacggactcagaattgacctcccaggagacaggcctgcagggccctg
tgggtgaggaccaccagctagagatggaggaccccgaagagatgtccccggcacttgtagtgtctaattcc
cggagctttgtcatcagtggcggaggcagcactgttacggaaaacatgctgcgttcttaaaagggaaggag
aaagccagttcagggggaatccaggcagtttccccgggatgaccttctccaaagggatgaggaactgccc
ccccacccccacccccttcctccaggaaggagggataagacccaccaaatgcttggaacttagttgcact
gctataaacgacagtgaatgaaataatgtcccccttaaaattaaaaagaggggagcggtgtgcttctgtggt
taggtttatcagagtgctgagatccctatagtcaggttcgcctttcctatccctgcttccattctcctcttctgttctat
cccatccaacagtccagagataaaaccatggctttaagatacccacctattccccctagggtcttatttgttgtt
tttgttgctgttgttttggtttgatttttgtttttaatgttgaaacgtctgccctgaactttgcagacagcctggtccaaa
aacaaacctgtgcagagtgacaggacctcctatgggcaccactagagttgagtgcgaaagacagaatgt
cgccagcgctgcccaacaccttgacagtgggaagaacttgaaatgtccagagctgtaagatgaatgtgtcc
cctcctatttatgaaaaatgttaaatatgtggtttcctacttgctgctgctgtcacgtgacatggagaaggttagc
atccatcctccagcagtatgtctgatcttgtccagagtgtgatggtgatgccacgtttagattccaatatctcagg
aatcacctcagcctgcatgaatccaatgagctgtatctgtaattaatattgtcatatgtagctttatccttaagaa
aatgtgtttgttttaatagtccgtggaaaatataagctggaaaaaatgtcccagtctggttgatataaggcagta
ttattgagtcccgttttctttgcccgccccaccacccacaccccaatgagctaagccctaaatgagccctttca
gggcccagggatccagaagctccctctttctccaccccaaacgcttcctgaagtcagatccatgcctttccct
gtgaagaataagctcccagtctctgacctcctaccagtttctggggtaagaacacgtggttccaagagagct
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ctcatgggatattactcttggcaccccccaatgccatacttaggttccctccagcagtgggatctgcccatggg
tagttacaagattgaacgttgaatggcatactgctgaacagtcagttctggagctagagaggcctggggtca
agtgctgggtttgtcactcacaagttgggtgaccacaggcagggaaccttgacctcactcagccccagcttc
tttgtgtctaaaatggaggtaataatcatccttttcccgcagagctcttatgtgggttaaatgagataaatgtatgt
aaagtattttagcatggtgcctagcccatagtaagcacgcaataaatattagttaatatta 
 
 
Figure 2.3  Binding sites of primer sets on the Bos taurus CaSR sequence (NM_174002).  
Positioning of the two primer sets demonstrated in yellow (Primer 1) and pink (Primer 2).  The 
start and stop codons, highlighting the translated region, are bolded.  * represents positioning 
of intron 6–7. 
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3.0  Results  
 
3.1 Characterisation of explanted cells 
Three preparations of cells were explanted from bovine aorta (as described in 
section 2.1.1), named preparation A – C.  Immunofluorescent staining using a 
monoclonal -sma antibody, was used to characterise the explanted cells.  A 
mouse IgG2a replaced the primary antibody and served as a negative control.  
Cells explanted from the aorta showed appropriate morphology for smooth 
muscle cells and positive -sma staining of the actin filaments in each 
preparation (Figure 3.1, left panel) whilst no staining was observed when the 
primary antibody was replaced with mouse IgG (Figure 3.1, right panel).   
 
To further characterise each SMC preparation, the mineralisation potential 
was assessed.  SMCs can be induced to undergo mineralisation when 
cultured in the presence of β-glycerophosphate (BGP)72.  The mineralisation 
potential of prep A-C was evaluated in response to 5 mM BGP in the 
presence of 1.8 mM Ca2+ (Figure 3.2).  In the presence of 1.8 mM Ca2+ and 5 
mM BGP, all preparations showed an increase in mineralisation confirmed 
using alizarin red staining (Figure 3.2, right panel).  In preparations A and C, 
cells retracted into multicellular nodular structures which stained with alizarin 
red, whilst mineralisation in preparation B appeared more diffuse and 
widespread throughout the cell population.   
 
  51 
 
Figure 3.1   Immunostaining of bovine aortic explanted cells (prep A-C) with α-sma.  
BAoSMC (passage 3) were cultured in 10% FCS-DMEM in the presence of 1.2 mM Ca
2+
.  
Images show immunofluorescence staining with α-smooth muscle actin (1:400) and 
fluorescein isothiocyanate (FITC) secondary (1:100) in cultured explanted BAoSMCs (left 
panel).  As a control, the α-sma primary antibody was replaced with mouse IgG2a (right 
panel).  Nuclei were counterstained using the DNA specific dye DAPI (blue).  Bar = 25 µm. 
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Figure 3.2  Mineralisation potential of explanted BAoSMC (prep A-C).  Explanted 
BAoSMC (passage 3) were incubated from confluence (day 0) with calcifying medium (5% 
FCS-DMEM with 5 mM BGP) in the presence of 1.8 mM Ca
2+
.  Mineral deposition was 
detected with alizarin red staining at variable time points (right hand panel).  Bar = 500 µm.   
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The different preparations of BAoSMCs showed variability in their response to 
incubation with 2.5 mM Ca2+ in the presence of BGP (Figure 3.3).  At day 9, 
BAoSMCs incubated with 5 mM BGP and 2.5 mM Ca2+ from preparation A 
remain healthy, however by day 14 the cell monolayer had detached (image 
not shown).  With preparation B, detachment of the cell monolayer was 
detected earlier in the course of the experiment with complete detachment 
detected by day 9 (Figure 3.3).  Preparation C BAoSMCs did not show cell 
monolayer detachment but by day 9 rapid nodule formation was detected 
alongside cell loss.   
 
For consistency only one preparation of BAoSMCs were used in all future 
experiments.  On the basis of these initial results, any of the preparations 
shown would have been suitable for follow on experiments (all showing 
positive α-sma staining and the ability to undergo mineralisation), however 
preparation C was selected.  Additionally, a maximum Ca2+ concentration of 
2.2 mM was used for experiments requiring chronic incubation. 
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Figure 3.3  Effect of 2.5 mM Ca
2+
 and 5 mM BGP on BAoSMC morphology and 
distribution (prep A  - C).  Explanted BAoSMC (passage 3) were incubated from confluence 
(day 0) with 5% FCS-DMEM with 5 mM BGP in the presence of 2.5 mM Ca
2+
.  Images were 
captured at day 0 and day 9.  No image is presented for preparation B at day 9 as the cell 
monolayer had detached from the culture flask.  Cell morphology in the presence of 1.8 mM 
Ca
2+
 from the same experiment is shown in Figure 3.2.  Bar = 500 µm. 
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3.2  Assessment of CaSR immunoreactivity in BAoSMC  
To examine the expression of the CaSR in BAoSMC methods to investigate 
both protein and messenger RNA (mRNA) expression were used.  Alam et al. 
(2009) previously examined the protein expression of CaSR in BAoSMC, 
successfully demonstrating CaSR-like immunoreactivity84.  Therefore to 
confirm that preparation C BAoSMC also expressed CaSR, 
immunofluorescence and western blot analysis were employed.  
Immunostaining BAoSMC with an anti-CaSR antibody raised against residues 
214–235 of the human CaSR, produced positive staining (Figure 3.4Ai).  
Whilst positive staining was detected in the majority of BAoSMCs (additional 
images shown in Figure 6.2B), a few cells showed no expression (Figure 
3.4Ai, arrow). Replacing the primary antibody with mouse IgG2a (ii) or 
omitting the primary antibody (iii) resulted in the absence of immunoreactivity.  
 
CaSR-like immunoreactivity in BAoSMC was also demonstrated using SDS 
PAGE and Western blotting of BAoSMC membrane preparations (Figure 
3.4B).  Under reducing conditions 3 major bands were detected with apparent 
Mw’s of ~160, ~200 and ~250 kDa.  The ~160 kDa polypeptide corresponds 
to the expected position of the glycosylated form of the full length CaSR while 
the 250 kDa band is likely to represent the dimeric form.  In human embryonic 
kidney cells (HEK293) induced to stably express human CaSR (CaSR-HEK), 
4 major bands were detected; with bands at ~160 kDa and ~200 kDa 
corresponding to those seen in SMCs and a doublet at ~280 / 300 kDa 
(Figure 3.4C).  A comparison of the immunoreactivities produced by CaSR-
HEK and SMC samples is shown in Figure 6.2A.   
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Figure 3.4  CaSR immunoreactivity in BAoSMC.  A:  BAoSMC (prep C; passage 4) grown 
on chamber slides for 24 hrs in 10% FCS-DMEM (1.2 mM Ca
2+
) were fixed with 4% 
formaldehyde before incubation with a polyclonal antibody against human CaSR (1:200).  A 
fluorescein isothiocyanate (FITC)-conjugated secondary antibody (green; 1:40) and DAPI 
(blue) was used to visualise the CaSR and nuclear staining (i). Arrows used to highlight 
BAoSMCs with negative staining.  Control cells were stained with either mouse IgG2a (ii) or 
secondary antibody alone (iii).   (iv) shows BAoSMC stained with anti-CaSR (as above) at a 
higher magnification.  Bar = 25 µm.  B:  Membrane preparations from cultured BAoSMC 
(passage 6) were separated using 5% SDS-PAGE and CaSR immunoreactivity detected by 
Western blotting using a CaSR antibody (1:5000).  Exposure time 3 min.  Lysate from CaSR-
HEK cells (C) were used as a positive control. Exposure time 10 sec.  Size (in kDa) of 
molecular weight markers is indicated on the left.   
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3.3  Assessment of CaSR mRNA expression in BAoSMC  
To investigate whether CaSR mRNA is expressed in cultured BAoSMC, RT-
PCR was performed on complementary DNA (cDNA) synthesized from total 
RNA.  Amplification of CaSR from BAoSMC and parathyroid cDNA (from 
freshly isolated bovine parathyroid gland) was performed with two distinct 
primer sets (detailed in section 2.9.3 and illustrated in Figure 2.3).  PCR 
products of the expected size for each primer set were demonstrated with 
parathyroid cDNA, 55 bp and 196 bp respectively (Figure 3.5A).  No products 
were detected in the absence of reverse transcriptase.  However, RT-PCR of 
BAoSMC cDNA did not yield any CaSR amplicons, despite the acceptable 
quality of the cDNA demonstrated with successful amplification of GAPDH, a 
house keeping gene (Figure 3.5B).  Despite the negative result, the presence 
of CaSR cannot be confirmed or denied as amplification of CaSR was not 
attempted in other tissues with reported low expression of CaSR (e.g. lung).    
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Figure 3.5  Calcium-sensing receptor (CaSR) mRNA expression was not detected in 
BAoSMC  
RT-PCR was carried out using cDNA synthesized from total RNA from cultured BAoSMC 
(prep C; passage 6) and freshly isolated bovine parathyroid gland (provided by Donald T 
Ward).  A:  Two distinct primer sets for CaSR (described in section 2.9.3) were used (Ai-ii).  
Lane 1: Hyperladder IV, Lane 2: PTG (+ reverse transcriptase (RT)), Lane 3: PTG (-RT), 
Lane 4: SMC (+RT), Lane 5: PTG (-RT).  B:  A control PCR to demonstrate successful 
reverse transcription of BAoSMC RNA was conducted using bovine GAPDH primers.  Lane 1: 
Hyperladder V, Lane 2: SMC (+ RT), Lane 3: SMC (-RT).   
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3.4  Ca2+ increases mineralisation and osteogenic differentiation in 
BAoSMC in the presence of BGP 
The effect of Ca2+, a typical CaSR agonist, on BAoSMC mineralisation was 
investigated.  No mineralisation was detected in BAoSMC treated with 
different concentrations of Ca2+ (1.2 mM, 1.8 mM and 2.2 mM) in the absence 
of BGP, however retraction of cells into nodular formations was observed 
(Figure 3.6).   
 
 
 
 
Figure 3.6  Ca
2+
-induced mineralisation requires the presence of BGP.  BAoSMC (prep 
C; passage 5) were treated upon confluence with increasing concentrations of Ca
2+
 in the 
absence of BGP.  Images show cells stained with alizarin red at indicated time points 
(staining in the presence of BGP from the same experiment is shown in Figure 3.7A).  Images 
depict a single experiment, however similar results were obtained in two independent 
experiments performed on different BAoSMC isolates (see figure 6. 3).  Bar = 500 µm. 
 
 
However in the presence of 5 mM BGP, BAoSMC treated with different 
concentrations of Ca2+ (1.2 mM, 1.8 mM and 2.2 mM) showed a dose- and 
time-dependent increase in mineral deposition (Figure 3.7).  Ca2+ 
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accumulation was quantified using cresolphthalein method and alizarin red 
dye elution.  Increases in Ca2+ accumulation were detected using both 
methods, with each showing significant increases with each elevation of 
[Ca2+] (Figure 3.7B & C). 
 
The potential for Ca2+ to promote osteogenic differentiation alongside Ca2+ 
deposition was also investigated.  Alkaline phosphatase is an early indicator 
of SMC osteogenic conversion, and its activity was measured in BAoSMC 
incubated with 1.2 and 1.8 mM Ca2+ in the presence of BGP.  On day 3 no 
difference in alkaline phosphatase activity was detected, however on day 5, 
alkaline phsophatase activity was shown to be significantly elevated in cells 
incubated with 1.8 mM Ca2+ compared to cells incubated with 1.2 mM Ca2+ 
(Figure 3.8A).  No signs of mineralisation were observed on day 5 (Figure 
3.8B), however by day 14 alizarin red staining confirmed mineral deposition, 
with greater mineralisation detected in BAoSMCs incubated with 1.8 mM Ca2+ 
compared to 1.2 mM (Figure 3.8C).   
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Figure 3.7  Concentration-dependent effects of Ca
2+
o on SMC mineral deposition  A:  
BAoSMC (prep C; passage 5) were treated upon confluence with increasing concentrations of 
Ca
2+
 alongside 5 mM BGP.  Images show BAoSMCs stained with alizarin red at indicated 
time points (staining in the absence of BGP from the same experiment is shown in Figure 3.6).  
Images shown were captured from a single experiments, however Ca
2+
-induced increases in 
mineralisation were shown in 2 additional experiments (Figure 6.4).  Bar = 500 µm.  B:  
Mineralisation quantified by elution of alizarin red stain from stained mineral deposits on day 
14.  Results are expressed as moles of alizarin red stain per mg of total cellular protein. Data 
are from a single mineralisation experiment conducted in triplicate.  Data represent the mean 
± SEM. * P < 0.05 vs. 1.2 mM Ca
2+
; ♦ P < 0.05 vs. 1.8 mM Ca
2+
.  C:  Ca
2+
 accumulation was 
quantified on day 14 using the cresolphthalein method.  
Data are represented as mean ± SEM from a single experiment (n=3).  * P < 0.05 vs. 1.2 mM 
Ca
2+
; ♦ P < 0.05 vs. 1.8 mM Ca
2+
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Figure 3.8  Alkaline phosphatase activity in BAoSMC is Ca
2+
-dependent.  A: BAoSMC 
(prep C; passage 7-9) were incubated with 5% FCS-DMEM and 5 mM BGP in the presence 
of 1.2 mM or 1.8 mM Ca
2+
 for the indicated period of time.  BAoSMC lysates were extracted 
and ALP activity measured using the colorimetric conversion of p-nitrophenol phosphate to p-
nitrophenol and absorbance measured at 405 nm.  P-nitrophenol concentrations was 
normalised to protein content.  Data presented are expressed as % change versus control 
and combine results from n=3 independent experiments.  *P < 0.05 versus 1.2 mM Ca
2+
.  B:  
BAoSMCs (prep C; passage 9) were plated in parallel to those used in an alkaline 
phophatase experiment and treated with 1.2 and 1.8 mM Ca
2+
 in the presence of 5 mM BGP.  
Images were captured on day 5.  Bar = 500 µm.  C:  BAoSMCs (prep C; passage 9) were 
plated in parallel to those used in an alkaline phophatase experiment and treated with 1.2 and 
1.8 mM Ca
2+
 in the presence of 5 mM BGP.  Cells were stained with alizarin red dye on day 
14.   Bar = 500 µm. 
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3.5 Ca2+-induced mineralisation may, at least in part, be independent of 
the CaSR  
Alam et al. (2009) first implicated the SMC CaSR in the local calcification 
process, reporting enhanced mineralisation with overexpression of a dominant 
negative form of the CaSR84.  To expand on these findings, preliminary 
experiments using an adenovirus expressing a dominant negative (R185Q) 
variant of the CaSR were used to evaluate the role of the CaSR in Ca2+-
induced mineralisation.  BAoSMC transfected with the adenovirus in the 
presence of 1.2 mM Ca2+, showed markedly increased expression of the 
receptor at 48 and then 96 hrs compared to cells with no infection (Figure 
3.9A) in the absence of cell toxicity.   
 
Despite transfection with dnCaSR, BAoSMCs incubated in 1.8 mM Ca2+ and 5 
mM BGP produced an increase in BAoSMC mineralisation, compared to 
BAoSMCs incubated in 1.2 mM Ca2+ (Figure 3.9B).  Without the appropriate 
controls cautious interpretation is required however, if validated, these results 
suggest that Ca2+ may have an additional role in the calcification process, 
independent of the CaSR.     
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Figure 3.9  Effect of overexpressing a dominant negative adenoviral CaSR on Ca
2+
-
induced mineralisation in BAoSMC.  A:  Cell lysates (20 μg) from BAoSMC with no 
infection or infected with dnCaSR construct (MOI 150 pfu/cell) were taken at 48 and 96 hours 
examined for successful transfection using Western blotting with anti-CaSR antibody (1:5000).  
B: BAoSMC (prep C; passage 9) were cultured in 10 % FCS-DMEM containing 1.2 mM Ca
2+
.  
Upon reaching 80% confluence (day 4), cells were infected with dnCaSR recombinant 
adenovirus (pacAd5CMV/dnCaSR).  48 hr later (day 6) cells were treated with 5% FCS-
DMEM containing 5 mM BGP and 1.2 mM or 1.8 mM Ca
2+
.  Cells were subsequently re-
infected at day 8 to maintain high transgene expression and mineralisation assessed 
qualitatively at day 12 with alizarin red staining.  Images are representative of a single 
preliminary experiment performed in duplicate.  Bar = 500 µm. 
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3.6  The effect of calcimimetics on mineral deposition by BAoSMC 
To further investigate the possible protective effects of local CaSR activation 
the effect of three calcimimetic compounds on Ca2+-induced mineralisation 
was examined in the presence of BGP.  The effect of AMG641(10 pM – 1 nM), 
a potent calcimimetic, was evaluated in BAoSMC incubated with 5 mM BGP 
and 1.8 mM Ca2+.  AMG641 evoked a dose-dependent decrease in BAoSMC 
mineralisation, however when quantified statistical significance was achieved 
with the higher dose, 1 nM, only (Figure 3.10).   
 
A second calcimimetic, R-568 (1 nM), also reduced mineral deposition by 
BAoSMC in cells incubated with 1.8 and 2.2 mM Ca2+ (Figure 3.11A).  
Quantification of these effects showed a significant reduction in Ca2+ 
accumulation in the matrix with 1 nM R-568 at 1.8 mM Ca2+ (Figure 3.11B).  
However, at higher Ca2+ concentrations (i.e. 2.2 mM), despite a trend towards 
decreased Ca2+ accumulation being observed, R-568 failed to significantly 
reduce Ca2+ accumulation. 
 
To account for the possibility of non-CaSR mediated effects of the 
calcimimetics, S-568, an isomer of R-568 which has 10-100 times less 
potency to activate the CaSR252 was evaluated for its ability to delay 
mineralisation.  Little/no difference in mineralisation is seen between 
BAoSMCs treated with S-568 (1 nM) in the presence of 2.2 mM Ca2+ and 
those treated with 2.2 mM Ca2+ only (Figure 3.12).  Furthermore, when 
examined quantitatively no significant difference was detected. 
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Figure 3.10  Effect of AMG641 on Ca
2+
-induced mineralisation.  A:  BAoSMC (prep C; 
passage 7) were treated upon confluence with 1.8 mM Ca
2+
 and 5 mM BGP in the presence 
of vehicle (1:1000 DMSO) (i) or AMG641 at 10 pM (ii), 100 pM (iii) and 1 nM (iv).  On day 19 
alizarin red staining was performed to visualise mineralisation.  Images represent a single 
experiment performed in triplicate.  Similar results were obtained in 2 independent 
experiments (shown in Figure 6.5).  Bar = 500 µm.  B: Mineralisation was quantified on day 
19 using ARS elution.  Data are represented as mean ± SEM from one experiment (n=3). *P 
< 0.05 compared to vehicle control. 
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Figure 3.11  Protective actions of R-568 on Ca
2+
-induced mineralisation.  A:  BAoSMCs 
(prep C; passage 9) were cultured in 5% FCS-DMEM and 5 mM BGP with 1.8 or 2.2 mM Ca
2+
 
in the presence or absence of R-568 (1nM).  Cells were stained with alizarin red at day 9.  
Images shown were obtained from a singular experiment but indicative of 2 independent 
experiments although time of onset and progression of mineralisation varied (images are 
shown in Figure 6.6).  Bar = 500 µm.  B:  Mineralisation was quantified on day 9 using ARS 
elution from a single experiment with n=3.  
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Figure 3.12  S-568 does not delay Ca
2+
-induced mineralisation. A:  BAoSMCs (prep C; 
passage 6) were incubated with 2.2 mM Ca
2+
 in the presence or absence of S-568 (1nM).  
BAoSMCs were stained with alizarin red at day 10.  Images shown were obtained from a 
single experiment performed in triplicate but are indicative of 2 independent experiments 
although time of onset and progression of mineralisation varied (images from repeat 
experiments are shown in Figure 6.7).  Bar = 500 µm.  B:  Mineralisation was quantified on 
day 10 using ARS elution.  Data are represented as mean ± SEM from a single experiment 
(n=3). 
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3.7 Signalling profile(s) induced by acute Ca2+ and calcimimetic 
incubation  
 
To evaluate the activated signalling pathways in SMCs upon Ca2+ incubation, 
a multiplexable assay was used to assess the modulation of 19 
phosphoproteins (methodology explained in section 2.9).  Previous studies 
have reported ERK signalling in human, bovine and rat SMC stimulated with 
elevated Ca2+o 
84, 242-244.  In this study a broader range of signalling molecules 
were examined simultaneously (a list of the phosphoproteins targeted is 
shown in table 1). 
 
HAoSMC were used to ensure maximum cross-reactivity with human 
antibodies.  Firstly, CaSR expression was confirmed in these cells.  
Membrane preparations of HAoSMCs assessed by Western blotting exhibited 
three prominent bands at ~160, ~200 and ~250 kDa (Figure 3.13A).  The 
band at ~160 kDa is consistent with the fully glycosylated form of CaSR, also 
observed in BAoSMC (Figure 3.4B) and CaSR-HEKs (3.4C).   
 
Immunofluorescent staining was also used to verify the presence of a CaSR-
like protein in HAoSMC.  Initial experiments using a polyclonal CaSR antibody 
and anti-mouse FITC showed positive staining, however removal of the 
primary antibody did not abolish all staining and reveals non-specific staining 
produced by the secondary antibody (Figure 3.13B).  Therefore the 
experiment was repeated with alternative secondary antibodies; goat anti-
mouse Alexa Fluor 468 (Figure 3.13C) and Alexa Fluor 488 (Figure 3.13D).  
With both antibodies some non-specific staining was observed, however more 
prominent staining is detected in HAoSMCs treated with anti-CaSR.   
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Figure 3.13  CaSR like immunoreactivity in human aortic SMCs.  A:  Membrane 
preparations of primary HAoSMC (passage 5) were separated on a 5% acrylamide gel and 
Western blotted with anti-CaSR (1:5000). Sizes (in kDa) of molecular weight markers are 
indicated on the left.  B/C/D: Primary HAoSMC cells (passage 5) were cultured for 24 hr 
before fixing with 4% formaldehyde and incubation with a polyclonal antibody against human 
CaSR (1:100).  FITC (B), Alexa Flour 568 (red) (C) and Alexa Flour 488 (green) (D) were 
used as the secondary antibodies (1:40). Cell nuclei were stained using the DNA-specific dye 
DAPI (blue).  B:  (i) nuclear (DAPI) and CaSR immunostaining. Control cells were stained with 
either mouse IgG2a (ii)  or secondary antibody alone (iii). C&D:  Nuclear and CaSR 
immunostaining (i) and negative control for which the primary antibody was omitted (ii).  Bar = 
25 µm.   
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As a positive control, cell signalling in CaSR-HEKs exposed to 5 mM Ca2+ was 
evaluated (lysates provided by Donald T. Ward).  Compared to CaSR-HEKs 
incubated with 0.5 mM Ca2+, cells incubated with 5 mM Ca2+ showed 
elevations in the phosphorylation of signalling components of the MAPK 
signalling cascades (Table 3.1).  Typical of CaSR signalling, significant 
elevations in phosphorylated MEK, p90RSK and CREB were detected.  
Furthermore, activation of the phosphoinositide 3-kinase pathway, typically 
elicited by CaSR agonists, was suggested with increased phosphorylation of 
p70S6K kinase in cells incubated with 5 mM Ca2+ versus control (0.5 mM 
Ca2+). 
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Table 3.1.  Ca
2+
-induced signalling in CaSR-HEK cells.  CaSR-HEKs were seeded in 10% 
FCS-DMEM and allowed to reach 70% confluence.  CaSR-HEKs were incubated in the 
presence of 0.5 mM or 5 mM Ca
2+
o for 10 min before lysates were prepared as described in 
the methods section (section 2.7).  CaSR-HEK lysates were provided by Donald Ward, 
University of Manchester.  Lysates were ran on a multiplex phospho-protein bead array, 
which allow for detection of phosphorylation levels of 19 phosphoproteins (a technical error 
prevented calculation of ERK phosphorylation status). Values are the results of n=4 samples 
and expressed as % of control (0.5 mM Ca
2+
) ± SEM.  * P < 0.05 
 
Phosphoprotein % change in phosphorylation status with 
5mM Ca2+ compared to 0.5 mM Ca2+ 
Akt 224.3 ± 72 
BCR-Abl 148.6 ± 44 
c-Jun 191.5 ± 30 
CREB 792.7 ± 82 * 
ERK - 
GSK-3/ß 612.4 ± 288 * 
HSP27 155.8 ± 38 
IGF-1R 525.9 ± 203 
I-B 303.9 ± 72 * 
JNK 164.8 ± 40 
MEK 989.7 ± 233 * 
PDGF 203.7 ± 48 
p38 213.1 ± 53 
p53 153.3 ± 23 
p70 S6K 482.0 ± 89 * 
p90RSK 545.3 ± 173 * 
Src 160.5 ± 40 
Stat3 311.8 ± 91 
Tyk2 179.0 ± 36 
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3.7.1 Ca2+-induced signalling in HAoSMC 
 
Table 3.2  Ca
2+
-induced signalling in SMCs. HAoSMCs (passages 4-6) were seeded in 
10% FCS-DMEM and cultured overnight in serum free medium. To assess Ca
2+
-induced 
signalling, upon reaching 70% confluence HAoSMCs were incubated with either 0.5 mM 
(control) or 5 mM Ca
2+
 for 5 minutes.  Cell lysates were prepared as described in the methods 
section (section 2.7) and ran on a multiplex phospho-protein bead array, which allow for 
detection of phosphorylation levels of 19 phosphoproteins (indicated below). Values are the 
results of n=6 samples expressed as % of control (0.5 mM Ca
2+
) ± SEM.  * P < 0.05 
 
Phosphoprotein % change in phosphorylation status with 
5mM Ca2+ compared to 0.5 mM Ca2+ in SMC 
Akt 92.5 ± 14 
BCR-Abl 69.7 ± 8 * 
c-Jun 66.7 ± 14 
CREB 91.6 ± 16 
ERK 89.4 ± 13 
GSK-3/ß 96.5 ± 20 
HSP27 75.0 ± 9 
IGF-1R 54.4 ± 11 * 
I-B 75.5 ± 12 
JNK 75.2 ± 9 
MEK 82.7 ± 14 
PDGF 56.0 ± 11 * 
p38 76.5 ± 11 
p53 70.7 ± 7 * 
p70 S6K 74.9 ± 13 
p90RSK 80.9 ± 8 
Src 68.3 ± 8 * 
Stat3 87.5 ± 11 
Tyk2 65.1 ± 11 * 
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When examining signalling in HAoSMCs, cells were incubated for 5 minutes 
in line with the time-dependent elevation in Ca2+-induced signalling in 
HAoSMC demonstrated by Molostvov et al. (2007).  Compared to 0.5 mM 
Ca2+, incubation of HAoSMC with 5 mM Ca2+ for 5 minutes produced 
decreases in the phosphorylation status of all tested phosphoproteins, and 
these reductions reached statistical significance for BCR-Abl, IGF-1R, PDGF, 
p53, Src and Tyk2 (Table 3.2.) (P<0.05).  Surprisingly, no significant change 
was detected in ERK phosphorylation, or its upstream activator MEK 
inconsistent with previous studies in SMCs84, 242-244.   
 
To verify these findings, ERK phosphorylation was investigated using a 
second method, western blotting with a phospho-ERK antibody.   Consistent 
with the data from Table 3.2 no change in ERK phosphorylation was 
demonstrated in BAoSMC incubated with 5 mM Ca2+, compared to BAoSMCs 
incubated with 0.5 mM Ca2+, despite clear increases detected in CaSR-HEK 
cells (Figure 3.14). 
 
 
Figure 3.14.  ERK phosphorylation in the presence of 0.5 mM or 5.0 mM Ca
2+ 
in CaSR-
HEK and BAoSMC.   
CaSR-HEK cells (left; passage 12) and BAoSMC (right; prep C, passage 6) were exposed to 
5 mM Ca
2+
 for 5 minutes.  Cell lysates (20 μg) were separated on a 10% acrylamide gel and 
analysed by Western blotting with anti phospho-ERK 1/2.  MW markers of ERK 1 and 2 are 
demonstrated on the left.  Results are representative of n=4 experiments.   
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3.7.2  Calcimimetic-induced signalling in HAoSMC 
The signalling pathways involved in response to calcimimetic treatment were 
also assessed.   HAoSMC were treated with 2.5 mM Ca2+ in the presence and 
absence of R-568.  In the presence of R-568 (1 nM), increases in the 
phosphorylation status of all phosphoproteins were observed, and significant 
elevations in MEK (21.9 ± 4%) and p90RSK (8.0 ± 1%) detected, compared to 
those incubated with Ca2+ alone (Table 3.3).   
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Table 3.3  R-568-induced signalling in SMCs. HAoSMCs (passages 4-6) were seeded in 
10% FCS-DMEM and cultured overnight in serum free medium. To assess R-568 (1 nM) 
signalling cells were incubated with 2.5 mM Ca
2+
 in the presence and absence (control) of R-
568. Cell lysates were prepared as described in the methods section (section 2.7) and ran on 
a multiplex phospho-protein bead array, which allow for detection of phosphorylation levels of 
19 phosphoproteins. Values are the results of n=3 samples both expressed as % of control 
(2.5 mM Ca
2+
 alone) ± SEM.  * P < 0.05 
 
Phosphoprotein % change in phosphorylation status with 
R-568 compared to 2.5 mM Ca2+ alone 
Akt 100.6 ± 13 
BCR-Abl 124.8 ± 22 
c-Jun 103.2 ± 11 
CREB 105.8 ± 12 
ERK 122.6 ± 23 
GSK-3/ß 126.9 ± 37 
HSP27 107.1 ± 4 
IGF-1R 134.3 ± 27 
I-B 113.7 ± 13 
JNK 119.0 ± 19 
MEK 121.9 ± 4 * 
PDGF 126.5 ± 18 
p38 122.9 ± 8 
p53 121.8 ± 34 
p70 S6K 107.5 ± 6 
p90RSK 108.0 ± 1 * 
Src 117.9 ± 24 
Stat3 117.3 ± 10 
Tyk2 116.0 ± 10 
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4.0 Discussion 
 
The effects of hypercalcaemia and calcimimetics on vascular calcification 
have been studied in vivo 236-240 and in vitro 82-84, 240.  The parathyroid CaSR238, 
239, and the SMC CaSR84, 240  have been implicated in the actions of Ca2+ and 
calcimimetics on the mineralisation process.  This research supports previous 
findings suggesting calcimimetics can act directly on SMCs to protect against 
the mineralisation process84, 240 and identifies the downstream signalling 
pathways activated by calcimimetic treatment in SMCs.  Furthermore we 
provide additional insight into the respective role of the SMC CaSR in the 
promotion and protection of mineralisation produced by Ca2+ and 
calcimimetics respectively.    
 
4.1  Characterisation of explant cultures  
4.1.1. α-sma expression and mineralisation potential 
Firstly, primary cultures were assessed for α-sma expression.  α-sma  is 
predominantly expressed within SMC.  Whilst its expression is relatively 
restricted to SMCs, α-sma has also been shown to be present in fibroblasts.  
In most reports fibroblasts only express α-sma in response to tissue injury253, 
although α-sma expression has been detected in the absence of injury also254.  
As cells were characterised with α-sma only, the possibility of contaminating 
cells cannot be excluded, however the method used is a well-established 
method for isolating SMCs from aorta involving removal of the adventita and 
endothelial layer.   
 
It is a well accepted principle that SMC preparations can behave differently in 
regards to their mineralisation potential.  Early experiments showed that not 
all SMC cultures mineralise255 and the rate of mineralisation is variable across 
individual preparations and experiments70, 255-257.  Therefore, initially, each 
preparation of cells was assessed for their ability to calcify.  All preparations 
showed mineralisation following incubation with 1.8 mM Ca2+ and 5 mM BGP, 
albeit in different patterns.  Preparation A and C formed multicellular nodular 
structures, typical of the calcified vascular cells initially described by Prof. 
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Demer’s group255.  Although, with increasing passages the pattern of 
mineralisation observed with preparation C changed and in later experiments 
more diffuse and widespread calcification was detected.  This may reflect a 
change in SMC as they move from a more contractile phenotype to a 
synthetic phenotype.  The change in SMC phenotype can be characterised by 
differing morphology, with contractile SMCs possessing an elongated spindle 
shape vs. synthetic cells with a cobblestone morphology, differing proliferative 
and migratory characteristics, with synthetic SMCs showing a higher growth 
rates and higher migratory activity, and expression of protein markers 
including α-sma, smooth muscle-myosin heavy chain (SMMHC) and 
smoothelin- A/B 258, however expression of these protein markers was not 
monitored in this research.  While senescence of SMC, classified as passage 
11 onwards, has been shown to increase SMC calcification259, in the present 
study cells were not used at passage 10 or above. 
 
 
4.1.2  CaSR expression in BAoSMC 
The major objective of this work was to further understand the role of the 
CaSR in SMC mineralisation.  Expression of the CaSR in SMC is now well 
established84, 240, 242-244, although previously has been a controversial topic, 
with some groups failing to detect the CaSR245, 246 and others detecting a 
CaSR-like protein but that is molecularly distinct91.  However, the first step 
was to confirm CaSR expression in the cell population to be tested (i.e. 
preparation C BAoSMC and HAoSMC).  In this study we detected the 
presence of a CaSR-like protein in BAoSMC (prep C) via Western blotting and 
immunofluorescence using a CaSR-specifc antibody raised against a region 
within the extracellular domain of the protein.  Positive staining was observed 
throughout the cell reflecting the pattern of localisation of the CaSR reported 
in rat SMC244 and other cell types260, 261, although in contrast   to the punctate 
staining shown by Alam et al. (2009)84.  A few cells failed to show CaSR 
expression, although this represented the minority with majority showing 
positive expression.    
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Positive staining was also detected in HAoSMC, although some 
immunoreactivity was also observed in cells incubated with secondary 
antibody alone suggesting non-specific staining of the secondary antibody.  
Similar findings were reported by Molostvov et al (2007), who detected 
positive CaSR staining intracellularly and at the plasma membrane, however 
some immunoreactivity was shown with the secondary antibody alone or 
when the CaSR antibody was pre-absorbed with the immunising peptide243.  
However, in support of current findings, more prominent staining was detected 
in cells treated with anti-CaSR243.   
 
Western analysis of membrane preparations from both HAoSMC and 
BAoSMC revealed immunoreactivities at ~160 kDa, ~200 kDa and ~250kDa.  
The ~160 kDa band, was observed in SMCs and CaSR-HEKs (see Figure 
3.4B, 3.4C and 3.13A) and corresponds to the glycosylated form of the full 
length CaSR monomer.  These findings are consistent with findings from 
Molostvov et al. (2007), where SMC CaSR immunoreactivity was identified at 
160kDa, aligned with CaSR immunoreactivities observed in HKC-8 cells, a 
human renal proximal tubular cell line (positive control)243.  The lower 
molecular weight band (~140 kDa), representing the unglycosylated form of 
CaSR262 was absent from membrane preparations of SMCs.  Previous reports 
confirm the absence of the 140 kDa band in cultured SMCs243, however 
lysates from freshly dissected renal and epigastric arteries from transplant 
patients, reveals immunoreactive species including a 140 kDa band243.   
 
CaSR immunoreactivities were also observed at ~200 and 250 kDa with 
BAoSMC and HAoSMC.  Whilst not visible on lower exposure blots, these 
bands to appear to align with immunoreactivities detected with CaSR-HEK 
cells (see Figure 6.2A).  Previous reports have identified two bands major 
between 200 and 300 kDa in CaSR-HEK cells, which are believed to 
represent the dimeric forms of the receptor263.  Therefore, the 250 kDa band 
observed in SMCs may represent a dimeric form of the receptor, however this 
is not anticipated under reducing conditions.  Although, bands of 250 kDa and 
above, are also detected in CaSR-HEKs, suggesting some dimeric forms of 
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the receptors may remain.  Whilst not presented in Figure 3.4 or 3.13 SMCs 
also show the traditional dimer doublet at ~280 kDa (shown in Figure 6.2A).   
 
Despite confirmation of protein expression of the CaSR, no CaSR messenger 
RNA was detected in cultured BAoSMC contrary to previous reports243, 244, but 
supported by Farzaneh-Far et al. (2001) who failed to identify CaSR mRNA 
expression24.  This may, in part, reflect the sensitivities of our methods, as 
despite a clear CaSR signal detected from parathyroid gland tissue, the level 
of CaSR mRNA expression in smooth muscle cells is significantly lower than 
those observed in the parathyroid gland.  However, it may also, additionally, 
suggest that there is little generation of new CaSR in cultured cells, supported 
by the absence of the immature unglycosylated form in cultured cells243.    
 
 
4.2  The effect of CaSR activation on SMC mineralisation   
Strong in vitro data supports a role for the CaSR, independent of systemic 
changes in calciotropic hormones.  Alam et al. (2009) first proposed a 
relationship between SMC CaSR and SMC mineralisation, demonstrating 
increased mineralisation when cells were treated with a dominant negative 
CaSR construct84.  The reported effects of CaSR agonists on SMC 
mineralisation were variable with Ca2+ and Gd3+, promoting SMC 
mineralisation, whilst R-568, delayed the onset of mineralisation84.  The aim of 
this research was to expand our knowledge of how CaSR agonists modulate 
SMC mineralisation and the relative involvement of the CaSR in these actions.   
 
 
4.2.1 The effect of Ca2+ on SMC mineralisation   
Data presented as part of this study support the findings of Alam et al. (2009) 
showing increased mineralisation with increased [Ca2+]o in the presence of an 
external source of phosphate84.  Increasing [Ca2+]o alone was not sufficient to 
trigger mineralisation suggesting that the resulting mineralisation is a 
reflection of the final Ca x P rather than the Ca2+ concentration alone.  
Additional reports of Ca2+-induced mineralisation exist, however in these 
reports increased mineralisation is detected in the absence of an external 
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phosphate source82, 83, in contrast to results presented.  A species difference 
may underlie the differential response as Yang et al. (2004) and Reynolds et 
al. (2004) both used human SMCs, compared to the current report, and Alam 
et al. (2009), which used bovine SMCs.   
 
Increasing [Ca2+]o  also resulted in a significant elevation in alkaline 
phosphatase (ALP) activity, supporting previous findings of Ca2+-induced 
mRNA expression of ALP82.  ALP is among one of the first functional genes 
expressed in the process of calcification in osteogenesis264 and current 
findings suggest it may also be an early step in vascular calcification with 
significant elevations detected on day 5, in advance of mineralisation.   
 
The role of Ca2+ in the induction of ALP has more recently been questioned 
as interestingly it has been found that applying high Ca2+/PO4
3- medium (i.e. 
2.7 mM Ca2+ / 2 mM PO4
3-) to vessel rings from humans decreases ALP 
activity compared to both baseline medium (low Ca2+/PO4
3-) 86.   This is in 
contrast to applying high PO4
3- medium (1.8 mM Ca2+ / 2 mM PO4
3-) where 
significant elevations in ALP activity are observed in pre-dialysis and dialysis 
vessels86.  In opposition to current findings these findings suggest that Ca2+-
induced calcification in humans occurs in the absence of elevated ALP 
activity86.        
 
It is well accepted that increases in extracellular Ca2+ can contribute to 
increased SMC mineralisation82-84.  However, an intriguing question 
unanswered from the findings of Alam et al. (2009) was how Ca2+ and Gd3+, 
typical agonists of CaSR, enhance mineralisation whilst R-568, an allosteric 
modulator, inhibits mineralisation84.  The authors reported that increasing 
extracellular Ca2+ concentrations from 1.2 mM Ca2+ to 1.8 or 2.5 mM resulted 
in reduced CaSR expression84, although the effect of Gd3+ or calcimimetic 
treatment on the expression of the SMC CaSR was not reported.  Given the 
available data one could hypothesize that a possible mechanism for Ca2+-
induced mineralisation is by downregulation of the SMC CaSR, thus reducing 
the level of protection afforded by its presence.  Furthermore it was suggested 
that calcimimetics may oppose this action by increasing SMC CaSR 
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expression84, an action that has been observed in the parathyroid glands265, 
266 and HEK-293 cells228.  Whilst only a hypothesis at the time, recently 
Mendoza et al. (2011) has presented evidence to confirm this suggestion; 
showing that AMG641 can significantly increase CaSR mRNA in SMCs92.   
 
 
4.2.1.1  Understanding the process of Ca2+-induced mineralisation 
Whilst data support CaSR downregulation as one of the likely steps in Ca2+-
induced mineralisation84, this study also reports preliminary results suggesting 
additional mechanisms contributing to the promotion of mineralisation, 
independent of CaSR-mediated events.  Mechanisms for Ca2+-induced 
mineralisation, independent of the CaSR are well reported and have recently 
been reviewed78.  Whilst the experimental data presented require cautious 
interpretation and further validation, we showed that despite treatment with 
the dominant negative adenoviral construct of CaSR (R185Q), Ca2+ maintains 
the ability to dose-dependently induce SMC mineralisation.   
 
One of the major limitations of this experiment is that the extent of residual 
CaSR activity by the endogenous receptor was not investigated.  Residual 
activity of the endogenous CaSR may account for the modest increase in 
mineralisation detected with increased extracellular Ca2+ (1.8 mM vs. 1.2 mM 
Ca2+).  Additionally this experiment lacked the appropriate controls.  Without 
the inclusion of an empty virus control the relative importance of CaSR-
dependent and CaSR-independent actions on local Ca2+-induced 
mineralisation cannot be commented upon.   
Although very preliminary at the time, evidence supporting these findings 
have since emerged247.  Caudriller et al. reported that Ca2+-induced 
mineralisation occurs in the absence of CaSR and that cells treated with 
CaSR-SiRNA became more sensitive to the calcifying actions of Ca2+247.  This 
finding reinforces that CaSR has a protective role in SMCs and also proposes 
the question of whether Ca2+ acts in a protective capacity through the CaSR, 
but its effects are outweighed by other calcifying activities.   
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The signalling activities induced in SMC by Ca2+, appear to be distinct from 
previously reported CaSR-mediated actions.  Ca2+ evoked signalling in CaSR-
HEKs showed elevations in a number of protein kinases involved in MAPK 
signalling (i.e. MEK/p90RSK/p70 s6K), consistent with previous reports in 
CaSR-HEK198, 267, 268 and CaSR mediated signalling in other cell types269-273.  
Whereas, no elevation in components of MAPK signaling were detected when 
SMC were incubated with 5 mM Ca2+, compared to 0.5 mM Ca2+.  These data 
contradict a number of previous reports in SMC which have shown ERK 
activation in response to CaSR agonists92, 242-244, and have shown these 
changes to be CaSR-dependent242, 243.  No definitive conclusions can be 
drawn from the comparison between Ca2+-induced signalling in CaSR-HEKs 
and SMCs as CaSR interactions may be cell specific and different durations 
of incubation were used between experiments.  However, these results open 
up the possibility that the Ca2+-induced signalling events reported in SMCs 
are not CaSR mediated, although without further work using dominant 
negative CaSR this remains conjecture.   
 
Instead, Ca2+ incubation (5 mM) of SMC evoked significant depressions in a 
number of signalling pathways; BCR-Abl, IGF-1R, PDGF, p53, Src, Tyk2 
compared to 0.5 mM Ca2+.  Of interest within this group is IGF-1R, which has 
been suggested to be involved in SMC mineralisation274, 275.  Loss of IGF-1R 
signalling, or inhibition of its downstream signalling molecules, promotes 
mineralisation274, 275.  Therefore it may be possible that by attenuating IGF-1R 
signalling, Ca2+ reduces the protection afforded by the active IGF-1R receptor.   
 
Furthermore, incubation of SMCs with elevated levels of extracellular Ca2+ 
modulates components of apoptotic pathways.  Acute incubation with 5 mM 
Ca2+ suppresses levels of activated BCR-Abl, an apoptosis inhibitor, and p53, 
which has been reported to protect SMCs from apoptosis, both in vivo and in 
vitro276.  Supporting this hypothesis, extracellular Ca2+ (5.4 mM) has been 
shown to induce apoptosis83 compared to 1.8 mM Ca2+.  However these 
results need to be interpreted cautiously  with recent reports showing that 
extracellular Ca2+ at 1.36 – 3.3 mM can be protective of apoptosis275 
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suggesting that the actions of extracellular Ca2+ on apoptosis may be dose 
specific. 
 
 
4.2.2 The effect of calcimimetics on SMC mineralisation   
Previous studies have reported that R-56884, 240 can delay the onset of SMC 
mineralisation induced by Ca2+ in vitro.  In the present study we expanded on 
these findings demonstrating that, a second calcimimetic, AMG641 also 
delays mineral deposition by BAoSMC in vitro, in a dose dependent manner.   
Additionally, as a control for the effect of R-568, its isomer S-568 which shows 
little/no activity at the CaSR was investigated.  Unlike R-568, S-568 produced 
no protection against the onset of mineralisation, suggesting that the 
protective actions of calcimimetics are mediated through the CaSR.  
Consistent with previous reports, calcimimetics did not inhibit the process of 
calcification but slowed the development / progression of mineralisation84. 
 
To conclusively report that the actions of AMG641 and R-568 are mediated 
via the CaSR, knockout studies would be required.  The dominant negative 
adenoviral construct, used in this research, was not suitable for verification of 
this finding as recent data have shown that calcimimetics can act as 
pharmacochaperone and increase membrane expression and activity of 
mutant receptors, including the R185Q receptor used in this research228, 277.  
However, further evidence that the local protective actions of R-568 are 
mediated through the CaSR came from Ivanovski et al. (2009) who 
demonstrated that knockout of the CaSR, in vitro, by siRNA technology 
attenuates the protective role of calcimimetics240.   
 
 
4.2.2.1  Calcimimetic-induced signalling in SMC 
Acute treatment of SMCs with R-568 in the presence of 2.5 mM Ca2+ evoked 
increased phosphorylation of MEK and p90RSK compared to Ca2+ alone.  
Activation of the MEK/ERK pathway is consistent with existing reports that 
treatment with CaSR agonists increased ERK phosphorylation in SMCs84, 242, 
244.  Furthermore use of CaSR siRNA abolishes ERK phosphorylation induced 
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by neomycin234, confirming CaSR specific activation of MEK / ERK pathways.  
Lending additional support to these findings, Mendoza et al. (2011) recently 
reported increased ERK phosphorylation with AMG641 treatment in SMCs92.  
However, confirmation that the reported the observed elevations in MEK and 
p90RSK produced by R-568 are CaSR-dependent will require knockout 
studies.   
 
Strangely this study failed to show a significant activation of ERK despite 
activation of signalling components up- and down-stream of ERK.  In CaSR-
HEK cells, Ca2+-induced MEK / ERK pathway activation has been linked to 
Gαq/11, Gαi/o , P13K, as well as PKC and filamin
278.  Limited data exists to 
understand how these molecules interact with the SMC CaSR to elicit 
activation of MEK / ERK pathways.  Smajilovic et al. (2006) reported no or 
very little IP3 accumulation in the presence of neomycin and high 
concentration Ca2+ (20–30 mM), respectively, with no mobilisation of 
intracellular Ca2+244.  However, Molostvov et al. (2008) showed that the PLC 
inhibitor, U73122, could attenuate ERK phosphorylation and observed IP3 
production in response to neomycin and gentamicin, suggesting a mechanism 
dependent on the PLC pathway242.   This group also showed that ERK 
phosphorylation was independent of PI3K242.  Findings from this research 
support that observation showing that elevations in phosphorylated MEK and 
p90RSK were not accompanied by increased Akt phosphorylation. 
 
Activation of MEK / ERK can trigger a large number of signalling molecules.  
Downstream of MEK activation, phosphorylation of a number of the tested 
phosphoproteins may be expected (e.g. c-Jun, IκB,  p53, p70s6k, Stat3, 
CREB), however this research only showed significant elevations on p90RSK.  
Furthermore, no other MAPK pathways (i.e. p38 or JNK) were shown to be 
activated by calcimimetics in SMCs, as have been shown in CaSR-HEKs and 
other cell types198, 267, 279.   
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4.2.2.2 Implications for mineralisation 
The roles of MEK and p90RSK in the process of calcification were not 
examined as part of this research although do warrant further investigation.  
To understand the impact of each of these pathways and their potential as 
mediators of the protective actions of the calcimimetics we would need to 
examine signalling pathways following chronic calcimimetic treatment with 
and without their respective inhibitors (MEK; UO126, PD98059 / p90RSK; BI-
D1870, SL0101).   
 
Among the molecules identified that can induce/delay BAoSMC mineralisation, 
a number of authors have identified MEK / ERK signalling as playing a key 
role in this process29, 274, 280-282.  Speer et al. (2009) speculated a role for 
extracellular signal-regulated kinases (ERKs)29, as ERK signalling had been 
implicated in osteoblastic differentiation283-285, and they found levels of 
phosphorylated ERK1/2 increased prior to a decrease in the levels of SMC 
lineage markers29.  The role of ERK in osteoblastic differentiation in SMC was 
confirmed using the MEK inhibitor U0126 which prevented down regulation of 
SMC lineage markers and the SMC-specific transcription coactivator 
myocardin in calcifying SMCs29.  Interestingly, ERK has also been reported to 
be involved in the upregulation of smooth muscle myosin heavy chain286 and 
thus may help protect against SMC transdifferentiation.  However 
discrepancies in the current literature exist as to whether MEK / ERK 
signalling provides a protective role274, 280 or its activation is one of the steps 
promoting mineralisation29, 281, 282, 287.  A large degree of substrate 
dependence appears to exist as a result of the cross talk among the 
downstream signalling pathways and the different microenvironments created 
by each group.   
 
p90RSK (p90 ribosomal S6 kinase) lies immediately downstream from ERK 
and while a lot of research interest has surrounded ERK signalling, less is 
known about the role of p90RSK in the process of vascular calcification.  In its 
inactive form, p90RSK resides in the cytoplasm, however upon stimulation is 
transported to the nucleus complexed with ERK.  p90RSK has a number of 
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cytosolic substrates, including Iκ-B288 and also regulates a number of 
transcription factors including c-Fos289, CREB290 and Nur77291.   
 
Of interest to the process of SMC mineralisation, p90RSK has the potential to 
antagonise apoptosis through neutralizing BAD, a pro-apoptotic member of 
the Bcl family of proteins288, 292, 293.  This opposes the signalling activities 
observed in SMC upon acute incubation with 5 mM Ca2+, where reduced 
activation of apoptosis inhibitors were detected.  Therefore, calcimimetics may 
help delay mineralisation by increasing survival of SMC.  Molostvov et al. 
(2008) have already demonstrated that CaSR-mediated PLC activation is 
important for SMC survival and protection against apoptosis and reported on 
the importance of MEK / ERK signalling in this process242, however more 
direct association to the mineralisation process is required. 
 
 
4.5  Conclusions 
This work advances our understanding of the current role of the CaSR in SMC 
mineralisation.  I have shown that treatment with calcimimetics can delay 
SMC mineralisation and hypothesise that this protection is mediated via a 
CaSR-dependent mechanism.  Additionally I demonstrated that the role of 
Ca2+ as a promoter of SMC mineralisation is, in part, independent of its 
actions on the CaSR.  MAPK signalling pathways are reported to be activated 
after acute stimulation with calcimimetics in SMCs and the literature supports 
a hypothetical role for these signalling molecules in the mineralisation process.       
 
 
4.6  Limitations of current work 
1. The cell population used in these experiments were identified as 
smooth muscle cells on the basis of positive α-smooth muscle actin (α-
sma) staining uniformly across the cell culture, however α-sma is not 
exclusive to SMCs alone.  α-sma has also been identified in 
fibroblasts294, which are similar in morphology to SMCs; therefore the 
possibility of cross-contamination cannot be excluded. 
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2. Whilst the presence of the CaSR in SMC is now widely accepted, the 
current data do not provide definitive evidence.   
a. Methods used to asses CaSR mRNA expression were no 
optimised to detect low abundance mRNA transcripts, previously 
observed in bovine SMCs92.   
b. Immunfluorescence experiments could have been performed 
under more stringent conditions with stronger controls (i.e. pre-
incubation of the CaSR antibody with immunising peptide).  
Protocols for immunostaining of the CaSR in HAoSMC should 
have been further optimised using different blocking agents and 
dilutions of antibodies.  
c. Assessment of CaSR mRNA and protein expression from 
freshly isolated bovine SMCs may have yielded better results, 
but were not investigated in this research.     
3. This research reports preliminary findings that Ca2+-induced 
mineralisation can occur independently of CaSR.  However, no empty 
virus control was included in this preliminary research and therefore the 
relative role played by CaSR cannot be inferred.  As part of future work 
we would expect confirmation that cells treated with the dominant 
negative RAd produce a dose dependent increase in mineralisation 
with increasing concentrations of Ca2+ (vs. empty virus control).   
4. The bioplex allowed for an initial screen of 19 phosphoproteins in a 
time efficient manner, however, limitations to exist which may have led 
to the generation of false positives / negatives and thus results require 
validation 
a. Total phosphoprotein was not assessed in parallel to 
phosphorylation status and therefore effects could have been 
masked or amplified.  Positive results require confirmation with 
western blot for both the phosphorylated form and total 
phosphoprotein.   
b. Ca2+-treated CaSR-HEKs were used as a positive control, 
however, positive controls showing activation of each 
phosphoprotein were not included, and therefore results may 
contain false negatives 
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c. Methods used required that the average of control values for 
individual experiments were used in statistical analysis 
incorporating a false uniformity within the data set. 
5. Finally, the current research utilised pharmacological tools to suggest 
that calcimimetic effects are mediated through the CaSR.  Calcimimetic, 
however, have been shown to effect Ca2+ channels at high doses295, 
therefore for confirmation of these findings knockout studies are 
necessary, which have recently been published240.  Similarly the 
signalling pathways found to be activated by CaSR cannot be 
conclusively attributed to the CaSR activation without KO being used. 
 
 
4.7  Future research questions and directions 
We know, through this research and that of others, that calcimimetics can act 
on SMC to prevent mineralisation.  However it is still unknown how they 
produce their protective actions, whether their protective actions can reverse 
established mineralisation and the relative contribution of activation of SMC 
CaSR vs parathyroid CaSR.   
 
1. Reported data suggest that calcimimetics may enhance signalling 
through MAPK pathways, in particular MEK and p90RSK.  Firstly, to 
expand on current findings, confirmation that enhanced MAPK 
signalling results from CaSR activation is necessary, using CaSR 
siRNA.  Secondly, the potential contribution of the activation of these 
signalling molecules to the mineralisation process, and apoptosis, 
should be investigated, using pharmacological manipulation of each of 
these pathways independently.  Therefore, in vitro calcification 
experiments assessing the degree of protection afforded by 
calcimimetics in the presence and absence of MEK (UO126 / 
PD98059) and p90RSK (BI-D1870 and SL0101) inhibitors should be 
performed.  
 
2. (i) To further evaluate the current hypothesis that the loss of CaSR is 
associated with SMC mineralisation we need to better understand at 
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what stage in the mineralisation process CaSR is downregulated.  
Alam et al. (2009) reported CaSR downregulation in response to high 
levels of [Ca2+]o as early as 24 hours after a change in culture 
conditions.  However whether this occurs prior to changes in gene 
expression of osteoblast / smooth muscle markers is unknown.  Using 
qPCR, expression levels of osteoblastic (e.g. osterix, Runx2, 
osteonectin) and SM markers (α-sma, SM22α, myocardin) will be 
analysed alongside CaSR expression.   
(ii) In parallel, the ability of calcimimetics to promote CaSR expression 
and correct for CaSR down regulation in high Ca2+ environments 
should be examined.  Reports by Mendoza et al. (2011) reported the 
ability of AMG641 to increase CaSR expression in cells incubated in 
1.8 mM Ca2+, a concentration which has been reported to result in 
receptor down regulation84.  However the length of time cells were 
incubated in this environment and the extent of down regulation prior to 
treatment with AMG641 are unknown.  
 
3. As a potential therapeutic strategy for calcification, it is important to 
understand the extent of protection afforded by calcimimetics and 
whether calcimimetics are also capable of reversing / slowing the 
progression of established calcification.  This can be investigated in 
vitro, staggering the introduction of calcimimetic therapy to SMCs 
cultured with pro-calcifying stimulus (i.e. 5mM BGP + 1.8 mM Ca2+) ie 
day 0, day 3, day 6, day 9…  This should accompany ex vivo work in 
which cells isolated from calcifying arterial medias of matrix Gla-protein 
knockout (MGP -/-) mice are treated with calcimimetics and the 
progression of mineralisation monitored.   
 
4. Finally, despite the accumulating in vitro evidence, the physiological 
role of SMC CaSR remains largely unknown.  Severe 
hyperparathyroidism, premature death, and incomplete gene excision 
in CaSR–/– mice have precluded the assessment of CaSR function in 
SMCs, thus a tissue specific knockout is required.  Dr. Shoback and 
colleagues have recently generated mice with tissue specific deletions 
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in the parathyroid gland, bone and cartilage296.  As part of a 
collaborative effort with our group, the floxed animals with exon 7 of the 
CaSR ‘knocked out’ (equating to the 7TMD and 4 intracellular loops of 
the receptor protein) are being bred with a SM22α-Cre transgenic 
mouse to remove CaSR in a tissue specific manner.  This will allow us 
to assess the relative contribution of the SMC CaSR in calcification i.e. 
does loss of SMC CaSR in vivo predispose animals to the development 
of calcification and to what extent are the protective effects of 
calcimimetics dependent on the presence of CaSR SMC? 
  92 
Chapter 5:  References 
 
1. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang 
Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-
artery calcification in young adults with end-stage renal disease who 
are undergoing dialysis. The New England journal of medicine. 
2000;342:1478-1483 
2. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. 
Electron beam computed tomography in the evaluation of cardiac 
calcification in chronic dialysis patients. American journal of kidney 
diseases : the official journal of the National Kidney Foundation. 
1996;27:394-401 
3. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, 
Chertow GM. Cardiac calcification in adult hemodialysis patients. A link 
between end-stage renal disease and cardiovascular disease? Journal 
of the American College of Cardiology. 2002;39:695-701 
4. Gross ML, Meyer HP, Ziebart H, Rieger P, Wenzel U, Amann K, Berger 
I, Adamczak M, Schirmacher P, Ritz E. Calcification of coronary intima 
and media: Immunohistochemistry, backscatter imaging, and x-ray 
analysis in renal and nonrenal patients. Clinical journal of the American 
Society of Nephrology : CJASN. 2007;2:121-134 
5. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, 
Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, 
Rosendaal FR, Dekker FW. Cardiovascular and noncardiovascular 
mortality among patients starting dialysis. JAMA : the journal of the 
American Medical Association. 2009;302:1782-1789 
6. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, 
Kawano Y. Coronary calcification in patients with chronic kidney 
disease and coronary artery disease. Clinical journal of the American 
Society of Nephrology : CJASN. 2009;4:1892-1900 
7. Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, Shahapuni 
I, Presne C, Makdassi R, Andrejak M, Tribouilloy C, Galan P, Safar ME, 
Choukroun G, Massy Z. Pulse wave velocity and vascular calcification 
at different stages of chronic kidney disease. Journal of hypertension. 
2010;28:163-169 
8. McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of 
coronary vascular calcification in patients with chronic kidney disease 
and end-stage renal disease: A systematic review. Journal of 
nephrology. 2004;17:205-215 
9. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, 
Rees L, Shanahan CM. Chronic mineral dysregulation promotes 
vascular smooth muscle cell adaptation and extracellular matrix 
calcification. Journal of the American Society of Nephrology : JASN. 
2010;21:103-112 
10. Goodman WG. Vascular calcification in chronic renal failure. Lancet. 
2001;358:1115-1116 
11. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial 
calcifications, arterial stiffness, and cardiovascular risk in end-stage 
renal disease. Hypertension. 2001;38:938-942 
  93 
12. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, 
Chedid K, London AM. Aortic and large artery compliance in end-stage 
renal failure. Kidney international. 1990;37:137-142 
13. Jeziorska M, McCollum C, Wooley DE. Observations on bone 
formation and remodelling in advanced atherosclerotic lesions of 
human carotid arteries. Virchows Archiv : an international journal of 
pathology. 1998;433:559-565 
14. Shanahan CM. Inflammation ushers in calcification: A cycle of damage 
and protection? Circulation. 2007;116:2782-2785 
15. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, 
Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis 
associates with inflammation in early-stage atherosclerosis evaluated 
by molecular imaging in vivo. Circulation. 2007;116:2841-2850 
16. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. 
Arterial media calcification in end-stage renal disease: Impact on all-
cause and cardiovascular mortality. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2003;18:1731-
1740 
17. Amann K. Media calcification and intima calcification are distinct 
entities in chronic kidney disease. Clinical journal of the American 
Society of Nephrology : CJASN. 2008;3:1599-1605 
18. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of 
age-related medial elastocalcinosis: Impact on large artery stiffness 
and isolated systolic hypertension. Cardiovascular research. 
2005;66:307-317 
19. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary 
artery calcification and aortic pulse wave velocity in chronic kidney 
disease patients. Kidney international. 2004;65:1790-1794 
20. London GM. Cardiovascular disease in chronic renal failure: 
Pathophysiologic aspects. Seminars in dialysis. 2003;16:85-94 
21. Burke AP, Taylor A, Farb A, Malcom GT, Virmani R. Coronary 
calcification: Insights from sudden coronary death victims. Zeitschrift 
fur Kardiologie. 2000;89 Suppl 2:49-53 
22. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, 
Amann K. Morphology of coronary atherosclerotic lesions in patients 
with end-stage renal failure. Nephrology, dialysis, transplantation : 
official publication of the European Dialysis and Transplant Association 
- European Renal Association. 2000;15:218-223 
23. Giachelli CM. Ectopic calcification: Gathering hard facts about soft 
tissue mineralization. The American journal of pathology. 
1999;154:671-675 
24. Farzaneh-Far A, Proudfoot D, Shanahan C, Weissberg PL. Vascular 
and valvar calcification: Recent advances. Heart. 2001;85:13-17 
25. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces 
the osteoblast differentiation factor cbfa1 in human blood vessels. 
Kidney international. 2003;63:1003-1011 
26. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, 
Weissleder R. Multimodality molecular imaging identifies proteolytic 
  94 
and osteogenic activities in early aortic valve disease. Circulation. 
2007;115:377-386 
27. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan 
CM. Osteo/chondrocytic transcription factors and their target genes 
exhibit distinct patterns of expression in human arterial calcification. 
Arteriosclerosis, thrombosis, and vascular biology. 2003;23:489-494 
28. Bobryshev YV. Transdifferentiation of smooth muscle cells into 
chondrocytes in atherosclerotic arteries in situ: Implications for diffuse 
intimal calcification. The Journal of pathology. 2005;205:641-650 
29. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, 
Dichek D, Giachelli CM. Smooth muscle cells give rise to 
osteochondrogenic precursors and chondrocytes in calcifying arteries. 
Circulation research. 2009;104:733-741 
30. Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2/cbfa1, but not loss 
of myocardin, is required for smooth muscle cell lineage 
reprogramming toward osteochondrogenesis. Journal of cellular 
biochemistry. 2010;110:935-947 
31. Shen J, Yang M, Jiang H, Ju D, Zheng JP, Xu Z, Liao TD, Li L. Arterial 
injury promotes medial chondrogenesis in sm22 knockout mice. 
Cardiovascular research. 2011;90:28-37 
32. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA. 
Reversal of the adynamic bone disorder and decreased vascular 
calcification in chronic kidney disease by sevelamer carbonate therapy. 
Journal of the American Society of Nephrology : JASN. 2007;18:122-
130 
33. Pai A, Leaf EM, El-Abbadi M, Giachelli CM. Elastin degradation and 
vascular smooth muscle cell phenotype change precede cell loss and 
arterial medial calcification in a uremic mouse model of chronic kidney 
disease. The American journal of pathology. 2011;178:764-773 
34. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, 
Kestenbaum BR. Association of serum phosphate with vascular and 
valvular calcification in moderate ckd. Journal of the American Society 
of Nephrology : JASN. 2009;20:381-387 
35. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Current medicinal 
chemistry. 1999;6:1067-1093 
36. Bergwitz C, Juppner H. Regulation of phosphate homeostasis by pth, 
vitamin d, and fgf23. Annual review of medicine. 2010;61:91-104 
37. Renkema KY, Alexander RT, Bindels RJ, Hoenderop JG. Calcium and 
phosphate homeostasis: Concerted interplay of new regulators. Annals 
of medicine. 2008;40:82-91 
38. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. 
Circulating concentration of fgf-23 increases as renal function declines 
in patients with chronic kidney disease, but does not change in 
response to variation in phosphate intake in healthy volunteers. Kidney 
international. 2003;64:2272-2279 
39. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, 
Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, 
Nishizawa Y. Fgf-23 in patients with end-stage renal disease on 
hemodialysis. Kidney international. 2004;65:1943-1946 
  95 
40. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz 
E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, 
Kohler H, Riegler P. Fibroblast growth factor 23 (fgf23) predicts 
progression of chronic kidney disease: The mild to moderate kidney 
disease (mmkd) study. Journal of the American Society of Nephrology : 
JASN. 2007;18:2600-2608 
41. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby 
D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, 
Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. 
Fibroblast growth factor 23 is elevated before parathyroid hormone and 
phosphate in chronic kidney disease. Kidney international. 2011 
42. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, 
Yamashita T, Fukumoto S, Shimada T. Direct evidence for a causative 
role of fgf23 in the abnormal renal phosphate handling and vitamin d 
metabolism in rats with early-stage chronic kidney disease. Kidney 
international. 2010;78:975-980 
43. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. Pth 
increases fgf23 gene expression and mediates the high-fgf23 levels of 
experimental kidney failure: A bone parathyroid feedback loop. 
American journal of physiology. Renal physiology. 2010;299:F882-889 
44. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto 
K, Fukushima N. Human fibroblast growth factor-23 mutants suppress 
na+-dependent phosphate co-transport activity and 1alpha,25-
dihydroxyvitamin d3 production. The Journal of biological chemistry. 
2003;278:2206-2211 
45. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice 
overexpressing human fibroblast growth factor 23 (r176q) delineate a 
putative role for parathyroid hormone in renal phosphate wasting 
disorders. Endocrinology. 2004;145:5269-5279 
46. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita 
T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of fgf23 
demonstrates an essential physiological role of fgf23 in phosphate and 
vitamin d metabolism. The Journal of clinical investigation. 
2004;113:561-568 
47. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, 
Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Fgf-23 transgenic 
mice demonstrate hypophosphatemic rickets with reduced expression 
of sodium phosphate cotransporter type iia. Biochemical and 
biophysical research communications. 2004;314:409-414 
48. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, 
Andress DL. Prevalence of abnormal serum vitamin d, pth, calcium, 
and phosphorus in patients with chronic kidney disease: Results of the 
study to evaluate early kidney disease. Kidney international. 
2007;71:31-38 
49. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The 
severity of secondary hyperparathyroidism in chronic renal insufficiency 
is gfr-dependent, race-dependent, and associated with cardiovascular 
disease. Journal of the American Society of Nephrology : JASN. 
2002;13:2762-2769 
  96 
50. Korkor AB. Reduced binding of [3h]1,25-dihydroxyvitamin d3 in the 
parathyroid glands of patients with renal failure. The New England 
journal of medicine. 1987;316:1573-1577 
51. Kifor O, Moore FD, Jr., Wang P, Goldstein M, Vassilev P, Kifor I, 
Hebert SC, Brown EM. Reduced immunostaining for the extracellular 
ca2+-sensing receptor in primary and uremic secondary 
hyperparathyroidism. The Journal of clinical endocrinology and 
metabolism. 1996;81:1598-1606 
52. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, 
Drueke TB. Depressed expression of calcium receptor in parathyroid 
gland tissue of patients with hyperparathyroidism. Kidney international. 
1997;51:328-336 
53. Drueke TB. Klotho, fgf23, and fgf receptors in chronic kidney disease: 
A yin-yang situation? Kidney international. 2010;78:1057-1060 
54. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, 
Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, 
Kitazawa R, Fukagawa M, Kita T. Depressed expression of klotho and 
fgf receptor 1 in hyperplastic parathyroid glands from uremic patients. 
Kidney international. 2010;77:232-238 
55. Goodman WG. Medical management of secondary 
hyperparathyroidism in chronic renal failure. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2003;18 Suppl 
3:iii2-8 
56. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, 
Young B, Sherrard DJ, Andress DL. Serum phosphate levels and 
mortality risk among people with chronic kidney disease. Journal of the 
American Society of Nephrology : JASN. 2005;16:520-528 
57. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. 
Association of elevated serum po(4), ca x po(4) product, and 
parathyroid hormone with cardiac mortality risk in chronic hemodialysis 
patients. Journal of the American Society of Nephrology : JASN. 
2001;12:2131-2138 
58. Block GA. Prevalence and clinical consequences of elevated ca x p 
product in hemodialysis patients. Clinical nephrology. 2000;54:318-324 
59. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of 
serum phosphorus and calcium x phosphate product with mortality risk 
in chronic hemodialysis patients: A national study. American journal of 
kidney diseases : the official journal of the National Kidney Foundation. 
1998;31:607-617 
60. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive 
value of commonly measured variables and an evaluation of death rate 
differences between facilities. American journal of kidney diseases : the 
official journal of the National Kidney Foundation. 1990;15:458-482 
61. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, 
Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and 
consequences of altered mineral metabolism: The dialysis outcomes 
and practice patterns study. Kidney international. 2005;67:1179-1187 
62. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Sr., 
Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium 
  97 
levels to the incidence of cardiovascular disease in the community. 
Archives of internal medicine. 2007;167:879-885 
63. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between 
serum phosphate level and cardiovascular event rate in people with 
coronary disease. Circulation. 2005;112:2627-2633 
64. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in 
phosphate homeostasis and pathogenesis of disordered mineral 
metabolism in chronic kidney disease. Seminars in dialysis. 
2007;20:302-308 
65. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD. Role 
of hyperphosphatemia and 1,25-dihydroxyvitamin d in vascular 
calcification and mortality in fibroblastic growth factor 23 null mice. 
Journal of the American Society of Nephrology : JASN. 2007;18:2116-
2124 
66. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, 
Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, 
Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the 
mouse klotho gene leads to a syndrome resembling ageing. Nature. 
1997;390:45-51 
67. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, 
Maemura K, Nakano T, Akishita M, Ouchi Y. Statins protect human 
aortic smooth muscle cells from inorganic phosphate-induced 
calcification by restoring gas6-axl survival pathway. Circulation 
research. 2006;98:1024-1031 
68. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, 
Weissberg PL. Apoptosis regulates human vascular calcification in 
vitro: Evidence for initiation of vascular calcification by apoptotic bodies. 
Circulation research. 2000;87:1055-1062 
69. Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG, Haendeler J, Berk 
BC. Gas6 inhibits apoptosis in vascular smooth muscle: Role of axl 
kinase and akt. Journal of molecular and cellular cardiology. 
2004;37:881-887 
70. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, 
Giachelli CM. Phosphate regulation of vascular smooth muscle cell 
calcification. Circulation research. 2000;87:E10-17 
71. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, 
Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic 
transition associated with calcification: Upregulation of cbfa1 and 
downregulation of smooth muscle lineage markers. Circulation 
research. 2001;89:1147-1154 
72. Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, Morii H. Beta-
glycerophosphate accelerates calcification in cultured bovine vascular 
smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology. 
1995;15:2003-2009 
73. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum 
up-regulate osteopontin expression in vascular smooth muscle cells. 
Kidney international. 2002;62:1724-1731 
74. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, 
Ingalls CM, Liao HW, Giachelli CM. Phosphate feeding induces arterial 
medial calcification in uremic mice: Role of serum phosphorus, 
  98 
fibroblast growth factor-23, and osteopontin. Kidney international. 
2009;75:1297-1307 
75. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate 
cotransporter, pit-1, in vascular smooth muscle cell calcification. 
Circulation research. 2006;98:905-912 
76. Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, Tang C, Wang X. 
Mitochondrial reactive oxygen species promote p65 nuclear 
translocation mediating high-phosphate-induced vascular calcification 
in vitro and in vivo. Kidney international. 2011;79:1071-1079 
77. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska 
KA. The mechanism of phosphorus as a cardiovascular risk factor in 
ckd. Journal of the American Society of Nephrology : JASN. 
2008;19:1092-1105 
78. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial 
calcification in chronic kidney disease: Key roles for calcium and 
phosphate. Circulation research. 2011;109:697-711 
79. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, 
Raggi P. Effects of sevelamer and calcium on coronary artery 
calcification in patients new to hemodialysis. Kidney international. 
2005;68:1815-1824 
80. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the 
progression of coronary and aortic calcification in hemodialysis patients. 
Kidney international. 2002;62:245-252 
81. West SL, Swan VJ, Jamal SA. Effects of calcium on cardiovascular 
events in patients with kidney disease and in a healthy population. 
Clinical journal of the American Society of Nephrology : CJASN. 2010;5 
Suppl 1:S41-47 
82. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels 
induce smooth muscle cell matrix mineralization in vitro. Kidney 
international. 2004;66:2293-2299 
83. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, 
Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. 
Human vascular smooth muscle cells undergo vesicle-mediated 
calcification in response to changes in extracellular calcium and 
phosphate concentrations: A potential mechanism for accelerated 
vascular calcification in esrd. Journal of the American Society of 
Nephrology : JASN. 2004;15:2857-2867 
84. Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard 
TN, Sage AP, Martin D, Ward DT, Alexander MY, Riccardi D, Canfield 
AE. Calcification is associated with loss of functional calcium-sensing 
receptor in vascular smooth muscle cells. Cardiovascular research. 
2009;81:260-268 
85. Lomashvili K, Garg P, O'Neill WC. Chemical and hormonal 
determinants of vascular calcification in vitro. Kidney international. 
2006;69:1464-1470 
86. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, 
Rees L, Shanahan CM. Chronic mineral dysregulation promotes 
vascular smooth muscle cell adaptation and extracellular matrix 
calcification. Journal of the American Society of Nephrology : JASN. 
2010;21:103-112 
  99 
87. Anderson HC, Garimella R, Tague SE. The role of matrix vesicles in 
growth plate development and biomineralization. Frontiers in 
bioscience : a journal and virtual library. 2005;10:822-837 
88. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, 
Westenfeld R, Jahnen-Dechent W, Chen NX. Role of calcification 
inhibitors in the pathogenesis of vascular calcification in chronic kidney 
disease (ckd). Kidney international. 2005;67:2295-2304 
89. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg 
PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum 
protein fetuin-a in inhibition of human vascular smooth muscle cell 
calcification. Journal of the American Society of Nephrology : JASN. 
2005;16:2920-2930 
90. Chen NX, O'Neill KD, Chen X, Moe SM. Annexin-mediated matrix 
vesicle calcification in vascular smooth muscle cells. Journal of bone 
and mineral research : the official journal of the American Society for 
Bone and Mineral Research. 2008;23:1798-1805 
91. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. Matrix gla 
protein is regulated by a mechanism functionally related to the calcium-
sensing receptor. Biochemical and biophysical research 
communications. 2000;277:736-740 
92. Mendoza FJ, Martinez-Moreno J, Almaden Y, Rodriguez-Ortiz ME, 
Lopez I, Estepa JC, Henley C, Rodriguez M, Aguilera-Tejero E. Effect 
of calcium and the calcimimetic amg 641 on matrix-gla protein in 
vascular smooth muscle cells. Calcified tissue international. 
2011;88:169-178 
93. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, 
Schurgers LJ, Skepper JN, Proudfoot D, Mayr M, Shanahan CM. 
Calcium regulates key components of vascular smooth muscle cell-
derived matrix vesicles to enhance mineralization. Circulation research. 
2011;109:e1-12 
94. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-
Dechent W. The serum protein alpha2-hs glycoprotein/fetuin inhibits 
apatite formation in vitro and in mineralizing calvaria cells. A possible 
role in mineralization and calcium homeostasis. The Journal of 
biological chemistry. 1996;271:20789-20796 
95. Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne 
T, Jahnen-Dechent W. Structural basis of calcification inhibition by 
alpha 2-hs glycoprotein/fetuin-a. Formation of colloidal calciprotein 
particles. The Journal of biological chemistry. 2003;278:13333-13341 
96. Heiss A, Eckert T, Aretz A, Richtering W, van Dorp W, Schafer C, 
Jahnen-Dechent W. Hierarchical role of fetuin-a and acidic serum 
proteins in the formation and stabilization of calcium phosphate 
particles. The Journal of biological chemistry. 2008;283:14815-14825 
97. Chen NX, O'Neill KD, Chen X, Duan D, Wang E, Sturek MS, Edwards 
JM, Moe SM. Fetuin-a uptake in bovine vascular smooth muscle cells 
is calcium dependent and mediated by annexins. American journal of 
physiology. Renal physiology. 2007;292:F599-606 
98. Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, 
Kaiser S, Blessing M. Cloning and targeted deletion of the mouse 
  100 
fetuin gene. The Journal of biological chemistry. 1997;272:31496-
31503 
99. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, 
Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein 
alpha 2-heremans-schmid glycoprotein/fetuin-a is a systemically acting 
inhibitor of ectopic calcification. The Journal of clinical investigation. 
2003;112:357-366 
100. Westenfeld R, Schafer C, Kruger T, Haarmann C, Schurgers LJ, 
Reutelingsperger C, Ivanovski O, Drueke T, Massy ZA, Ketteler M, 
Floege J, Jahnen-Dechent W. Fetuin-a protects against atherosclerotic 
calcification in ckd. Journal of the American Society of Nephrology : 
JASN. 2009;20:1264-1274 
101. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, 
Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. 
Association of low fetuin-a (ahsg) concentrations in serum with 
cardiovascular mortality in patients on dialysis: A cross-sectional study. 
Lancet. 2003;361:827-833 
102. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande 
FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW. 
Association of serum fetuin-a levels with mortality in dialysis patients. 
Kidney international. 2007;72:202-207 
103. Verduijn M, Prein RA, Stenvinkel P, Carrero JJ, le Cessie S, Witasp A, 
Nordfors L, Krediet RT, Boeschoten EW, Dekker FW. Is fetuin-a a 
mortality risk factor in dialysis patients or a mere risk marker? A 
mendelian randomization approach. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2011;26:239-
245 
104. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, 
Barany P, Lindholm B, Jogestrand T, Heimburger O, Holmes C, 
Schalling M, Nordfors L. Low fetuin-a levels are associated with 
cardiovascular death: Impact of variations in the gene encoding fetuin. 
Kidney international. 2005;67:2383-2392 
105. Lehtinen AB, Burdon KP, Lewis JP, Langefeld CD, Ziegler JT, Rich SS, 
Register TC, Carr JJ, Freedman BI, Bowden DW. Association of 
alpha2-heremans-schmid glycoprotein polymorphisms with subclinical 
atherosclerosis. The Journal of clinical endocrinology and metabolism. 
2007;92:345-352 
106. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, 
Whooley MA. Association of fetuin-a with mitral annular calcification 
and aortic stenosis among persons with coronary heart disease: Data 
from the heart and soul study. Circulation. 2007;115:2533-2539 
107. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, 
Karsenty G. Spontaneous calcification of arteries and cartilage in mice 
lacking matrix gla protein. Nature. 1997;386:78-81 
108. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix 
mineralization is regulated locally; different roles of two gla-containing 
proteins. The Journal of cell biology. 2004;165:625-630 
109. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, 
Vermeer C, Weissberg PL, Proudfoot D. Post-translational 
  101 
modifications regulate matrix gla protein function: Importance for 
inhibition of vascular smooth muscle cell calcification. Journal of 
thrombosis and haemostasis : JTH. 2007;5:2503-2511 
110. Price PA, Urist MR, Otawara Y. Matrix gla protein, a new gamma-
carboxyglutamic acid-containing protein which is associated with the 
organic matrix of bone. Biochemical and biophysical research 
communications. 1983;117:765-771 
111. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification 
of human vascular cells in vitro is correlated with high levels of matrix 
gla protein and low levels of osteopontin expression. Arteriosclerosis, 
thrombosis, and vascular biology. 1998;18:379-388 
112. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens 
JP, Vermeer C. Role of vitamin k and vitamin k-dependent proteins in 
vascular calcification. Zeitschrift fur Kardiologie. 2001;90 Suppl 3:57-63 
113. Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De 
Mey JG, Vermeer C. Matrix gla protein accumulates at the border of 
regions of calcification and normal tissue in the media of the arterial 
vessel wall. Biochemical and biophysical research communications. 
2001;289:485-490 
114. Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, 
Appels A, Reutelingsperger CP, Cleutjens JP, Vermeer C. Novel 
conformation-specific antibodies against matrix gamma-
carboxyglutamic acid (gla) protein: Undercarboxylated matrix gla 
protein as marker for vascular calcification. Arteriosclerosis, thrombosis, 
and vascular biology. 2005;25:1629-1633 
115. Hackeng TM, Rosing J, Spronk HM, Vermeer C. Total chemical 
synthesis of human matrix gla protein. Protein science : a publication of 
the Protein Society. 2001;10:864-870 
116. Zebboudj AF, Imura M, Bostrom K. Matrix gla protein, a regulatory 
protein for bone morphogenetic protein-2. The Journal of biological 
chemistry. 2002;277:4388-4394 
117. Sweatt A, Sane DC, Hutson SM, Wallin R. Matrix gla protein (mgp) and 
bone morphogenetic protein-2 in aortic calcified lesions of aging rats. 
Journal of thrombosis and haemostasis : JTH. 2003;1:178-185 
118. Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of the 
binding of matrix gla protein (mgp) to bone morphogenetic protein-2 
(bmp-2). Thrombosis and haemostasis. 2000;84:1039-1044 
119. Yao Y, Zebboudj AF, Shao E, Perez M, Bostrom K. Regulation of bone 
morphogenetic protein-4 by matrix gla protein in vascular endothelial 
cells involves activin-like kinase receptor 1. The Journal of biological 
chemistry. 2006;281:33921-33930 
120. Zebboudj AF, Shin V, Bostrom K. Matrix gla protein and bmp-2 
regulate osteoinduction in calcifying vascular cells. Journal of cellular 
biochemistry. 2003;90:756-765 
121. Koos R, Krueger T, Westenfeld R, Kuhl HP, Brandenburg V, Mahnken 
AH, Stanzel S, Vermeer C, Cranenburg EC, Floege J, Kelm M, 
Schurgers LJ. Relation of circulating matrix gla-protein and 
anticoagulation status in patients with aortic valve calcification. 
Thrombosis and haemostasis. 2009;101:706-713 
  102 
122. Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, 
Kizu A, Nishizawa Y, Saito S. Matrix gla protein is associated with 
coronary artery calcification as assessed by electron-beam computed 
tomography. Thrombosis and haemostasis. 2004;91:790-794 
123. Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, 
Yuksel B, Gardiner RM, Chung E. Mutations in the gene encoding the 
human matrix gla protein cause keutel syndrome. Nature genetics. 
1999;21:142-144 
124. Hur DJ, Raymond GV, Kahler SG, Riegert-Johnson DL, Cohen BA, 
Boyadjiev SA. A novel mgp mutation in a consanguineous family: 
Review of the clinical and molecular characteristics of keutel syndrome. 
American journal of medical genetics. Part A. 2005;135:36-40 
125. Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, 
Gladziwa U, Rensma PL, Leunissen KM, Schurgers LJ. 
Undercarboxylated matrix gla protein levels are decreased in dialysis 
patients and related to parameters of calcium-phosphate metabolism 
and aortic augmentation index. Blood purification. 2007;25:395-401 
126. Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, 
Bouwman FG, Kwaijtaal M, Brandenburg VM, Ketteler M, Schurgers LJ. 
The circulating inactive form of matrix gla protein (ucmgp) as a 
biomarker for cardiovascular calcification. Journal of vascular research. 
2008;45:427-436 
127. Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, 
Muhlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ. 
Uncarboxylated matrix gla protein (ucmgp) is associated with coronary 
artery calcification in haemodialysis patients. Thrombosis and 
haemostasis. 2009;101:359-366 
128. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, 
Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA. The circulating 
inactive form of matrix gla protein is a surrogate marker for vascular 
calcification in chronic kidney disease: A preliminary report. Clinical 
journal of the American Society of Nephrology : CJASN. 2010;5:568-
575 
129. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson 
MC, Mintz KA, Robey PG, Teitelbaum SL, Cheresh DA. Interactions 
between the bone matrix proteins osteopontin and bone sialoprotein 
and the osteoclast integrin alpha v beta 3 potentiate bone resorption. 
The Journal of biological chemistry. 1993;268:9901-9907 
130. Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW. 
Osteopontin-hydroxyapatite interactions in vitro: Inhibition of 
hydroxyapatite formation and growth in a gelatin-gel. Bone and mineral. 
1993;22:147-159 
131. Okamoto H. Osteopontin and cardiovascular system. Molecular and 
cellular biochemistry. 2007;300:1-7 
132. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, 
Karsenty G, Giachelli CM. Inactivation of the osteopontin gene 
enhances vascular calcification of matrix gla protein-deficient mice: 
Evidence for osteopontin as an inducible inhibitor of vascular 
calcification in vivo. The Journal of experimental medicine. 
2002;196:1047-1055 
  103 
133. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is 
required for inhibition of vascular smooth muscle cell calcification. The 
Journal of biological chemistry. 2000;275:20197-20203 
134. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz 
SM. Osteopontin is elevated during neointima formation in rat arteries 
and is a novel component of human atherosclerotic plaques. The 
Journal of clinical investigation. 1993;92:1686-1696 
135. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin 
expression in cardiovascular diseases. Annals of the New York 
Academy of Sciences. 1995;760:109-126 
136. O'Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, 
Schwartz SM, Giachelli CM. Osteopontin is synthesized by 
macrophage, smooth muscle, and endothelial cells in primary and 
restenotic human coronary atherosclerotic plaques. Arteriosclerosis 
and thrombosis : a journal of vascular biology / American Heart 
Association. 1994;14:1648-1656 
137. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin 
mrna is expressed by smooth muscle-derived foam cells in human 
atherosclerotic lesions of the aorta. The Journal of clinical investigation. 
1993;92:2814-2820 
138. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim HM, 
Kitamura Y, Yutani C, Nomura S. Expression of osteopontin 
messenger rna by macrophages in atherosclerotic plaques. A possible 
association with calcification. The American journal of pathology. 
1993;143:1003-1008 
139. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse 
calcification in human coronary arteries. Association of osteopontin 
with atherosclerosis. The Journal of clinical investigation. 
1994;94:1597-1604 
140. Mohler ER, 3rd, Adam LP, McClelland P, Graham L, Hathaway DR. 
Detection of osteopontin in calcified human aortic valves. 
Arteriosclerosis, thrombosis, and vascular biology. 1997;17:547-552 
141. Aryan M, Kepez A, Atalar E, Hazirolan T, Haznedaroglu I, Akata D, 
Ozer N, Aksoyek S, Ovunc K, Ozmen F. Association of plasma 
osteopontin levels with coronary calcification evaluated by tomographic 
coronary calcium scoring. Journal of bone and mineral metabolism. 
2009;27:591-597 
142. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression 
of genes for calcification-regulating proteins in human atherosclerotic 
plaques. The Journal of clinical investigation. 1994;93:2393-2402 
143. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, 
Nakamura H, Ohsuzu F. Plasma osteopontin levels are associated with 
the presence and extent of coronary artery disease. Atherosclerosis. 
2003;170:333-337 
144. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M, Matsui 
Y, Sugawara T, Shimizu T, Uede T, Kitabatake A. Development of 
atherosclerosis in osteopontin transgenic mice. Heart and vessels. 
2002;16:111-117 
  104 
145. Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and 
polyphosphate of aortic calcification induced by vitamin d3 in rats. 
Clinical science. 1968;35:363-372 
146. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC. 
Phosphate-induced vascular calcification: Role of pyrophosphate and 
osteopontin. Journal of the American Society of Nephrology : JASN. 
2004;15:1392-1401 
147. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on 
hydroxyapatite and its implications in calcium homeostasis. Nature. 
1966;212:901-903 
148. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis 
mediated by ppi depletion promotes spontaneous aortic calcification in 
npp1-/- mice. Arteriosclerosis, thrombosis, and vascular biology. 
2005;25:686-691 
149. Villa-Bellosta R, Wang X, Millan JL, Dubyak GR, O'Neill WC. 
Extracellular pyrophosphate metabolism and calcification in vascular 
smooth muscle. American journal of physiology. Heart and circulatory 
physiology. 2011 
150. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in 
control of tissue calcification and arthritis. Science. 2000;289:265-270 
151. Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte 
P, Kalhoff H, Sano K, Boisvert WA, Superti-Furga A, Terkeltaub R. Pc-
1 nucleoside triphosphate pyrophosphohydrolase deficiency in 
idiopathic infantile arterial calcification. The American journal of 
pathology. 2001;158:543-554 
152. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. 
Loss-of-function enpp1 mutations cause both generalized arterial 
calcification of infancy and autosomal-recessive hypophosphatemic 
rickets. American journal of human genetics. 2010;86:267-272 
153. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. 
Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: 
Potential mechanism for uremic vascular calcification. Kidney 
international. 2008;73:1024-1030 
154. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma 
pyrophosphate levels in hemodialysis patients. Journal of the American 
Society of Nephrology : JASN. 2005;16:2495-2500 
155. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and 
vascular calcification in chronic kidney disease. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2010;25:187-
191 
156. O'Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL. 
Treatment with pyrophosphate inhibits uremic vascular calcification. 
Kidney international. 2011;79:512-517 
157. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, 
Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. 
Osteoprotegerin-deficient mice develop early onset osteoporosis and 
arterial calcification. Genes & development. 1998;12:1260-1268 
158. Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, Kawamata S, 
Mito S, Soe NN, Yoshizumi M. Role of osteoprotegerin in arterial 
  105 
calcification: Development of new animal model. Arteriosclerosis, 
thrombosis, and vascular biology. 2007;27:2058-2064 
159. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, 
Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin 
inactivation accelerates advanced atherosclerotic lesion progression 
and calcification in older apoe-/- mice. Arteriosclerosis, thrombosis, and 
vascular biology. 2006;26:2117-2124 
160. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, 
Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification 
without affecting atherosclerosis in ldlr(-/-) mice. Circulation. 
2008;117:411-420 
161. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin 
inhibits artery calcification induced by warfarin and by vitamin d. 
Arteriosclerosis, thrombosis, and vascular biology. 2001;21:1610-1616 
162. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W, Kabaya T, 
Nihei H. Serum osteoprotegerin levels and the extent of vascular 
calcification in haemodialysis patients. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2004;19:1886-
1889 
163. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, 
Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, 
Deanfield J, Rees L. The circulating calcification inhibitors, fetuin-a and 
osteoprotegerin, but not matrix gla protein, are associated with 
vascular stiffness and calcification in children on dialysis. Nephrology, 
dialysis, transplantation : official publication of the European Dialysis 
and Transplant Association - European Renal Association. 
2008;23:3263-3271 
164. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, 
Draibe SA, Moyses RM, Neves KR, Jorgetti V, Blair A, Guiberteau R, 
Fernandes Canziani ME. Coronary calcification in hemodialysis 
patients: The contribution of traditional and uremia-related risk factors. 
Kidney international. 2005;67:1576-1582 
165. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The 
osteoprotegerin/rank/rankl system: A bone key to vascular disease. 
Expert review of cardiovascular therapy. 2006;4:801-811 
166. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification 
and atherosclerosis. Atherosclerosis. 2009;204:321-329 
167. Brown EM, Vassilev PM, Quinn S, Hebert SC. G-protein-coupled, 
extracellular ca(2+)-sensing receptor: A versatile regulator of diverse 
cellular functions. Vitamins and hormones. 1999;55:1-71 
168. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene 
expression by hypocalcemia, hypercalcemia, and vitamin d in the rat. 
The Journal of clinical investigation. 1990;86:1313-1319 
169. Riccardi D, Hall AE, Chattopadhyay N, Xu JZ, Brown EM, Hebert SC. 
Localization of the extracellular ca2+/polyvalent cation-sensing protein 
in rat kidney. The American journal of physiology. 1998;274:F611-622 
170. Garrett JE, Tamir H, Kifor O, Simin RT, Rogers KV, Mithal A, Gagel RF, 
Brown EM. Calcitonin-secreting cells of the thyroid express an 
  106 
extracellular calcium receptor gene. Endocrinology. 1995;136:5202-
5211 
171. Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-
sensing receptor in the kidney. American journal of physiology. Renal 
physiology. 2010;298:F485-499 
172. Brown EM. Anti-parathyroid and anti-calcium sensing receptor 
antibodies in autoimmune hypoparathyroidism. Endocrinology and 
metabolism clinics of North America. 2009;38:437-445, x 
173. Kifor O, Moore FD, Jr., Delaney M, Garber J, Hendy GN, Butters R, 
Gao P, Cantor TL, Kifor I, Brown EM, Wysolmerski J. A syndrome of 
hypocalciuric hypercalcemia caused by autoantibodies directed at the 
calcium-sensing receptor. The Journal of clinical endocrinology and 
metabolism. 2003;88:60-72 
174. Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM. Acquired 
hypocalciuric hypercalcemia due to autoantibodies against the calcium-
sensing receptor. The New England journal of medicine. 2004;351:362-
369 
175. Oda Y, Tu CL, Pillai S, Bikle DD. The calcium sensing receptor and its 
alternatively spliced form in keratinocyte differentiation. The Journal of 
biological chemistry. 1998;273:23344-23352 
176. Cheng I, Klingensmith ME, Chattopadhyay N, Kifor O, Butters RR, 
Soybel DI, Brown EM. Identification and localization of the extracellular 
calcium-sensing receptor in human breast. The Journal of clinical 
endocrinology and metabolism. 1998;83:703-707 
177. Bradbury RA, Sunn KL, Crossley M, Bai M, Brown EM, Delbridge L, 
Conigrave AD. Expression of the parathyroid ca(2+)-sensing receptor 
in cytotrophoblasts from human term placenta. The Journal of 
endocrinology. 1998;156:425-430 
178. Brauner-Osborne H, Wellendorph P, Jensen AA. Structure, 
pharmacology and therapeutic prospects of family c g-protein coupled 
receptors. Current drug targets. 2007;8:169-184 
179. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, 
Nakanishi S, Jingami H, Morikawa K. Structural basis of glutamate 
recognition by a dimeric metabotropic glutamate receptor. Nature. 
2000;407:971-977 
180. Tsuchiya D, Kunishima N, Kamiya N, Jingami H, Morikawa K. 
Structural views of the ligand-binding cores of a metabotropic 
glutamate receptor complexed with an antagonist and both glutamate 
and gd3+. Proceedings of the National Academy of Sciences of the 
United States of America. 2002;99:2660-2665 
181. Hu J, Hauache O, Spiegel AM. Human ca2+ receptor cysteine-rich 
domain. Analysis of function of mutant and chimeric receptors. The 
Journal of biological chemistry. 2000;275:16382-16389 
182. Ray K, Clapp P, Goldsmith PK, Spiegel AM. Identification of the sites of 
n-linked glycosylation on the human calcium receptor and assessment 
of their role in cell surface expression and signal transduction. The 
Journal of biological chemistry. 1998;273:34558-34567 
183. Saidak Z, Brazier M, Kamel S, Mentaverri R. Agonists and allosteric 
modulators of the calcium-sensing receptor and their therapeutic 
applications. Molecular pharmacology. 2009;76:1131-1144 
  107 
184. Huang Y, Zhou Y, Castiblanco A, Yang W, Brown EM, Yang JJ. 
Multiple ca(2+)-binding sites in the extracellular domain of the ca(2+)-
sensing receptor corresponding to cooperative ca(2+) response. 
Biochemistry. 2009;48:388-398 
185. Petrel C, Kessler A, Maslah F, Dauban P, Dodd RH, Rognan D, Ruat 
M. Modeling and mutagenesis of the binding site of calhex 231, a novel 
negative allosteric modulator of the extracellular ca(2+)-sensing 
receptor. The Journal of biological chemistry. 2003;278:49487-49494 
186. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology 
modeling of the transmembrane domain of the human calcium sensing 
receptor and localization of an allosteric binding site. The Journal of 
biological chemistry. 2004;279:7254-7263 
187. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M. Positive 
and negative allosteric modulators of the ca2+-sensing receptor 
interact within overlapping but not identical binding sites in the 
transmembrane domain. The Journal of biological chemistry. 
2004;279:18990-18997 
188. Fan GF, Ray K, Zhao XM, Goldsmith PK, Spiegel AM. Mutational 
analysis of the cysteines in the extracellular domain of the human ca2+ 
receptor: Effects on cell surface expression, dimerization and signal 
transduction. FEBS letters. 1998;436:353-356 
189. Pidasheva S, Grant M, Canaff L, Ercan O, Kumar U, Hendy GN. 
Calcium-sensing receptor dimerizes in the endoplasmic reticulum: 
Biochemical and biophysical characterization of casr mutants retained 
intracellularly. Human molecular genetics. 2006;15:2200-2209 
190. Zhang Z, Sun S, Quinn SJ, Brown EM, Bai M. The extracellular 
calcium-sensing receptor dimerizes through multiple types of 
intermolecular interactions. The Journal of biological chemistry. 
2001;276:5316-5322 
191. Ray K, Hauschild BC, Steinbach PJ, Goldsmith PK, Hauache O, 
Spiegel AM. Identification of the cysteine residues in the amino-
terminal extracellular domain of the human ca(2+) receptor critical for 
dimerization. Implications for function of monomeric ca(2+) receptor. 
The Journal of biological chemistry. 1999;274:27642-27650 
192. Gama L, Wilt SG, Breitwieser GE. Heterodimerization of calcium 
sensing receptors with metabotropic glutamate receptors in neurons. 
The Journal of biological chemistry. 2001;276:39053-39059 
193. Chang W, Tu C, Cheng Z, Rodriguez L, Chen TH, Gassmann M, 
Bettler B, Margeta M, Jan LY, Shoback D. Complex formation with the 
type b gamma-aminobutyric acid receptor affects the expression and 
signal transduction of the extracellular calcium-sensing receptor. 
Studies with hek-293 cells and neurons. The Journal of biological 
chemistry. 2007;282:25030-25040 
194. Wellendorph P, Johansen LD, Brauner-Osborne H. The emerging role 
of promiscuous 7tm receptors as chemosensors for food intake. 
Vitamins and hormones. 2010;84:151-184 
195. Ward DT. Calcium receptor-mediated intracellular signalling. Cell 
calcium. 2004;35:217-228 
196. Kifor O, Diaz R, Butters R, Brown EM. The ca2+-sensing receptor (car) 
activates phospholipases c, a2, and d in bovine parathyroid and car-
  108 
transfected, human embryonic kidney (hek293) cells. Journal of bone 
and mineral research : the official journal of the American Society for 
Bone and Mineral Research. 1997;12:715-725 
197. Mamillapalli R, Wysolmerski J. The calcium-sensing receptor couples 
to galpha(s) and regulates pthrp and acth secretion in pituitary cells. 
The Journal of endocrinology. 2010;204:287-297 
198. Kifor O, MacLeod RJ, Diaz R, Bai M, Yamaguchi T, Yao T, Kifor I, 
Brown EM. Regulation of map kinase by calcium-sensing receptor in 
bovine parathyroid and car-transfected hek293 cells. American journal 
of physiology. Renal physiology. 2001;280:F291-302 
199. Kimoto K, Nakatsuka K, Matsuo N, Yoshioka H. P38 mapk mediates 
the expression of type i collagen induced by tgf-beta 2 in human retinal 
pigment epithelial cells arpe-19. Investigative ophthalmology & visual 
science. 2004;45:2431-2437 
200. Varela-Rey M, Montiel-Duarte C, Oses-Prieto JA, Lopez-Zabalza MJ, 
Jaffrezou JP, Rojkind M, Iraburu MJ. P38 mapk mediates the 
regulation of alpha1(i) procollagen mrna levels by tnf-alpha and tgf-
beta in a cell line of rat hepatic stellate cells(1). FEBS letters. 
2002;528:133-138 
201. Keeton AB, Bortoff KD, Bennett WL, Franklin JL, Venable DY, Messina 
JL. Insulin-regulated expression of egr-1 and krox20: Dependence on 
erk1/2 and interaction with p38 and pi3-kinase pathways. 
Endocrinology. 2003;144:5402-5410 
202. Hao F, Tan M, Xu X, Cui MZ. Histamine induces egr-1 expression in 
human aortic endothelial cells via the h1 receptor-mediated protein 
kinase cdelta-dependent erk activation pathway. The Journal of 
biological chemistry. 2008;283:26928-26936 
203. Oldenhof AD, Shynlova OP, Liu M, Langille BL, Lye SJ. Mitogen-
activated protein kinases mediate stretch-induced c-fos mrna 
expression in myometrial smooth muscle cells. American journal of 
physiology. Cell physiology. 2002;283:C1530-1539 
204. Luo S, Lee AS. Requirement of the p38 mitogen-activated protein 
kinase signalling pathway for the induction of the 78 kda glucose-
regulated protein/immunoglobulin heavy-chain binding protein by 
azetidine stress: Activating transcription factor 6 as a target for stress-
induced phosphorylation. The Biochemical journal. 2002;366:787-795 
205. Hirade K, Kozawa O, Tanabe K, Niwa M, Matsuno H, Oiso Y, 
Akamatsu S, Ito H, Kato K, Katagiri Y, Uematsu T. Thrombin stimulates 
dissociation and induction of hsp27 via p38 mapk in vascular smooth 
muscle cells. American journal of physiology. Heart and circulatory 
physiology. 2002;283:H941-948 
206. Weiss C, Faust D, Durk H, Kolluri SK, Pelzer A, Schneider S, Dietrich 
C, Oesch F, Gottlicher M. Tcdd induces c-jun expression via a novel ah 
(dioxin) receptor-mediated p38-mapk-dependent pathway. Oncogene. 
2005;24:4975-4983 
207. Chanprasert S, Geddis AE, Barroga C, Fox NE, Kaushansky K. 
Thrombopoietin (tpo) induces c-myc expression through a pi3k- and 
mapk-dependent pathway that is not mediated by akt, pkczeta or mtor 
in tpo-dependent cell lines and primary megakaryocytes. Cellular 
signalling. 2006;18:1212-1218 
  109 
208. Garrett JE, Capuano IV, Hammerland LG, Hung BC, Brown EM, 
Hebert SC, Nemeth EF, Fuller F. Molecular cloning and functional 
expression of human parathyroid calcium receptor cdnas. The Journal 
of biological chemistry. 1995;270:12919-12925 
209. Bosel J, John M, Freichel M, Blind E. Signaling of the human calcium-
sensing receptor expressed in hek293-cells is modulated by protein 
kinases a and c. Experimental and clinical endocrinology & diabetes : 
official journal, German Society of Endocrinology [and] German 
Diabetes Association. 2003;111:21-26 
210. Racke FK, Nemeth EF. Protein kinase c modulates hormone secretion 
regulated by extracellular polycations in bovine parathyroid cells. The 
Journal of physiology. 1993;468:163-176 
211. Racke FK, Nemeth EF. Cytosolic calcium homeostasis in bovine 
parathyroid cells and its modulation by protein kinase c. The Journal of 
physiology. 1993;468:141-162 
212. Bai M, Trivedi S, Lane CR, Yang Y, Quinn SJ, Brown EM. Protein 
kinase c phosphorylation of threonine at position 888 in ca2+o-sensing 
receptor (car) inhibits coupling to ca2+ store release. The Journal of 
biological chemistry. 1998;273:21267-21275 
213. Davies SL, Ozawa A, McCormick WD, Dvorak MM, Ward DT. Protein 
kinase c-mediated phosphorylation of the calcium-sensing receptor is 
stimulated by receptor activation and attenuated by calyculin-sensitive 
phosphatase activity. The Journal of biological chemistry. 
2007;282:15048-15056 
214. Awata H, Huang C, Handlogten ME, Miller RT. Interaction of the 
calcium-sensing receptor and filamin, a potential scaffolding protein. 
The Journal of biological chemistry. 2001;276:34871-34879 
215. Huang C, Wu Z, Hujer KM, Miller RT. Silencing of filamin a gene 
expression inhibits ca2+ -sensing receptor signaling. FEBS letters. 
2006;580:1795-1800 
216. Hjalm G, MacLeod RJ, Kifor O, Chattopadhyay N, Brown EM. Filamin-a 
binds to the carboxyl-terminal tail of the calcium-sensing receptor, an 
interaction that participates in car-mediated activation of mitogen-
activated protein kinase. The Journal of biological chemistry. 
2001;276:34880-34887 
217. Pi M, Spurney RF, Tu Q, Hinson T, Quarles LD. Calcium-sensing 
receptor activation of rho involves filamin and rho-guanine nucleotide 
exchange factor. Endocrinology. 2002;143:3830-3838 
218. Rey O, Young SH, Yuan J, Slice L, Rozengurt E. Amino acid-
stimulated ca2+ oscillations produced by the ca2+-sensing receptor are 
mediated by a phospholipase c/inositol 1,4,5-trisphosphate-
independent pathway that requires g12, rho, filamin-a, and the actin 
cytoskeleton. The Journal of biological chemistry. 2005;280:22875-
22882 
219. Zhang M, Breitwieser GE. High affinity interaction with filamin a 
protects against calcium-sensing receptor degradation. The Journal of 
biological chemistry. 2005;280:11140-11146 
220. Huang C, Miller RT. The calcium-sensing receptor and its interacting 
proteins. Journal of cellular and molecular medicine. 2007;11:923-934 
  110 
221. Quinn SJ, Kifor O, Trivedi S, Diaz R, Vassilev P, Brown E. Sodium and 
ionic strength sensing by the calcium receptor. The Journal of 
biological chemistry. 1998;273:19579-19586 
222. Quinn SJ, Bai M, Brown EM. Ph sensing by the calcium-sensing 
receptor. The Journal of biological chemistry. 2004;279:37241-37249 
223. Brown EM. The calcium-sensing receptor: Physiology, pathophysiology 
and car-based therapeutics. Sub-cellular biochemistry. 2007;45:139-
167 
224. Bai M. Structure-function relationship of the extracellular calcium-
sensing receptor. Cell calcium. 2004;35:197-207 
225. Huang Y, Zhou Y, Yang W, Butters R, Lee HW, Li S, Castiblanco A, 
Brown EM, Yang JJ. Identification and dissection of ca(2+)-binding 
sites in the extracellular domain of ca(2+)-sensing receptor. The 
Journal of biological chemistry. 2007;282:19000-19010 
226. Ray K, Northup J. Evidence for distinct cation and calcimimetic 
compound (nps 568) recognition domains in the transmembrane 
regions of the human ca2+ receptor. The Journal of biological 
chemistry. 2002;277:18908-18913 
227. Conigrave AD, Quinn SJ, Brown EM. L-amino acid sensing by the 
extracellular ca2+-sensing receptor. Proceedings of the National 
Academy of Sciences of the United States of America. 2000;97:4814-
4819 
228. Huang Y, Breitwieser GE. Rescue of calcium-sensing receptor mutants 
by allosteric modulators reveals a conformational checkpoint in 
receptor biogenesis. The Journal of biological chemistry. 
2007;282:9517-9525 
229. Zhang Z, Jiang Y, Quinn SJ, Krapcho K, Nemeth EF, Bai M. L-
phenylalanine and nps r-467 synergistically potentiate the function of 
the extracellular calcium-sensing receptor through distinct sites. The 
Journal of biological chemistry. 2002;277:33736-33741 
230. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi 
MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, 
Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, 
McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet 
for secondary hyperparathyroidism in patients receiving hemodialysis. 
The New England journal of medicine. 2004;350:1516-1525 
231. Cunningham J. Management of secondary hyperparathyroidism. 
Therapeutic apheresis and dialysis : official peer-reviewed journal of 
the International Society for Apheresis, the Japanese Society for 
Apheresis, the Japanese Society for Dialysis Therapy. 2005;9 Suppl 
1:S35-40 
232. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects 
of the calcimimetic cinacalcet hcl on cardiovascular disease, fracture, 
and health-related quality of life in secondary hyperparathyroidism. 
Kidney international. 2005;68:1793-1800 
233. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, 
Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, 
Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P. Evaluation of 
cinacalcet therapy to lower cardiovascular events (evolve): Rationale 
  111 
and design overview. Clinical journal of the American Society of 
Nephrology : CJASN. 2007;2:898-905 
234. Bonet J, Bayes B, Fernandez-Crespo P, Casals M, Lopez-Ayerbe J, 
Romero R. Cinacalcet may reduce arterial stiffness in patients with 
chronic renal disease and secondary hyperparathyroidism - results of a 
small-scale, prospective, observational study. Clinical nephrology. 
2011;75:181-187 
235. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, 
Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. 
The advance study: A randomized study to evaluate the effects of 
cinacalcet plus low-dose vitamin d on vascular calcification in patients 
on hemodialysis. Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - 
European Renal Association. 2011;26:1327-1339 
236. Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X, Martin D, Yao 
W, Lane N, Shalhoub V. The calcimimetic amg 641 abrogates 
parathyroid hyperplasia, bone and vascular calcification abnormalities 
in uremic rats. European journal of pharmacology. 2009;616:306-313 
237. Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, 
Wakita S, Wada M. Cinacalcet suppresses calcification of the aorta 
and heart in uremic rats. Kidney international. 2008;74:1270-1277 
238. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, 
Rodriguez M. Calcimimetic r-568 decreases extraosseous calcifications 
in uremic rats treated with calcitriol. Journal of the American Society of 
Nephrology : JASN. 2006;17:795-804 
239. Lopez I, Mendoza FJ, Guerrero F, Almaden Y, Henley C, Aguilera-
Tejero E, Rodriguez M. The calcimimetic amg 641 accelerates 
regression of extraosseous calcification in uremic rats. American 
journal of physiology. Renal physiology. 2009;296:F1376-1385 
240. Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, 
Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour 
B, Drueke TB, Massy ZA. The calcimimetic r-568 retards uremia-
enhanced vascular calcification and atherosclerosis in apolipoprotein e 
deficient (apoe-/-) mice. Atherosclerosis. 2009;205:55-62 
241. Weston AH, Absi M, Ward DT, Ohanian J, Dodd RH, Dauban P, Petrel 
C, Ruat M, Edwards G. Evidence in favor of a calcium-sensing receptor 
in arterial endothelial cells: Studies with calindol and calhex 231. 
Circulation research. 2005;97:391-398 
242. Molostvov G, Fletcher S, Bland R, Zehnder D. Extracellular calcium-
sensing receptor mediated signalling is involved in human vascular 
smooth muscle cell proliferation and apoptosis. Cellular physiology and 
biochemistry : international journal of experimental cellular physiology, 
biochemistry, and pharmacology. 2008;22:413-422 
243. Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, 
Zehnder D. Extracellular calcium-sensing receptor is functionally 
expressed in human artery. American journal of physiology. Renal 
physiology. 2007;293:F946-955 
244. Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, 
Terwilliger EF, Brown EM, Haunso S, Tfelt-Hansen J. Extracellular 
  112 
calcium sensing in rat aortic vascular smooth muscle cells. Biochemical 
and biophysical research communications. 2006;348:1215-1223 
245. Klein GL, Enkhbaatar P, Traber DL, Buja LM, Jonkam CC, Poindexter 
BJ, Bick RJ. Cardiovascular distribution of the calcium sensing receptor 
before and after burns. Burns : journal of the International Society for 
Burn Injuries. 2008;34:370-375 
246. Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, 
Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, 
Ward S, Lacey DL, Martin D. Calcification inhibitors and wnt signaling 
proteins are implicated in bovine artery smooth muscle cell calcification 
in the presence of phosphate and vitamin d sterols. Calcified tissue 
international. 2006;79:431-442 
247. Caudrillier A, Petit L, Boudot Z, Massy Z, Brazier M, Mentaverri R, 
Kamel S. Involvement of the car in smooth muscle cell mineralisation 
during atherosclerosis. Bone. 2009;44:S294 
248. Ashley AE, Niebauer J. Cardiology explained. 2004 
249. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, 
Edmonds ME. Medial localization of mineralization-regulating proteins 
in association with monckeberg's sclerosis: Evidence for smooth 
muscle cell-mediated vascular calcification. Circulation. 
1999;100:2168-2176 
250. Tanimura A, McGregor DH, Anderson HC. Calcification in 
atherosclerosis. I. Human studies. Journal of experimental pathology. 
1986;2:261-273 
251. Rozen S, Skaletsky H. Primer3 on the www for general users and for 
biologist programmers. Methods in molecular biology. 2000;132:365-
386 
252. Nemeth EF. Summary--calcium receptors: Potential targets for novel 
treatments for skeletal disease. Journal of musculoskeletal & neuronal 
interactions. 2004;4:416-417 
253. Shi Y, Pieniek M, Fard A, O'Brien J, Mannion JD, Zalewski A. 
Adventitial remodeling after coronary arterial injury. Circulation. 
1996;93:340-348 
254. Storch KN, Taatjes DJ, Bouffard NA, Locknar S, Bishop NM, Langevin 
HM. Alpha smooth muscle actin distribution in cytoplasm and nuclear 
invaginations of connective tissue fibroblasts. Histochemistry and cell 
biology. 2007;127:523-530 
255. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. 
Tgf-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular 
cells to calcify. The Journal of clinical investigation. 1994;93:2106-2113 
256. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha 
promotes in vitro calcification of vascular cells via the camp pathway. 
Circulation. 2000;102:2636-2642 
257. Tintut Y, Parhami F, Bostrom K, Jackson SM, Demer LL. Camp 
stimulates osteoblast-like differentiation of calcifying vascular cells. 
Potential signaling pathway for vascular calcification. The Journal of 
biological chemistry. 1998;273:7547-7553 
258. Rensen SS, Doevendans PA, van Eys GJ. Regulation and 
characteristics of vascular smooth muscle cell phenotypic diversity. 
  113 
Netherlands heart journal : monthly journal of the Netherlands Society 
of Cardiology and the Netherlands Heart Foundation. 2007;15:100-108 
259. Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide 
M, Takahashi T, Matoba S, Yamada H, Okigaki M, Matsubara H. 
Replicative senescence of vascular smooth muscle cells enhances the 
calcification through initiating the osteoblastic transition. American 
journal of physiology. Heart and circulatory physiology. 
2009;297:H1673-1684 
260. Chattopadhyay N, Yano S, Tfelt-Hansen J, Rooney P, Kanuparthi D, 
Bandyopadhyay S, Ren X, Terwilliger E, Brown EM. Mitogenic action of 
calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology. 
2004;145:3451-3462 
261. Yamauchi M, Yamaguchi T, Kaji H, Sugimoto T, Chihara K. 
Involvement of calcium-sensing receptor in osteoblastic differentiation 
of mouse mc3t3-e1 cells. American journal of physiology. 
Endocrinology and metabolism. 2005;288:E608-616 
262. Bai M, Quinn S, Trivedi S, Kifor O, Pearce SH, Pollak MR, Krapcho K, 
Hebert SC, Brown EM. Expression and characterization of inactivating 
and activating mutations in the human ca2+o-sensing receptor. The 
Journal of biological chemistry. 1996;271:19537-19545 
263. Bai M, Trivedi S, Kifor O, Quinn SJ, Brown EM. Intermolecular 
interactions between dimeric calcium-sensing receptor monomers are 
important for its normal function. Proceedings of the National Academy 
of Sciences of the United States of America. 1999;96:2834-2839 
264. Golub EE, Harrison G, Taylor AG, Camper S, Shapiro IM. The role of 
alkaline phosphatase in cartilage mineralization. Bone and mineral. 
1992;17:273-278 
265. Mendoza FJ, Lopez I, Canalejo R, Almaden Y, Martin D, Aguilera-
Tejero E, Rodriguez M. Direct upregulation of parathyroid calcium-
sensing receptor and vitamin d receptor by calcimimetics in uremic rats. 
American journal of physiology. Renal physiology. 2009;296:F605-613 
266. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, 
Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T. 
Calcimimetic compound upregulates decreased calcium-sensing 
receptor expression level in parathyroid glands of rats with chronic 
renal insufficiency. Journal of the American Society of Nephrology : 
JASN. 2004;15:2579-2587 
267. MacLeod RJ, Chattopadhyay N, Brown EM. Pthrp stimulated by the 
calcium-sensing receptor requires map kinase activation. American 
journal of physiology. Endocrinology and metabolism. 2003;284:E435-
442 
268. Hobson SA, Wright J, Lee F, McNeil SE, Bilderback T, Rodland KD. 
Activation of the map kinase cascade by exogenous calcium-sensing 
receptor. Molecular and cellular endocrinology. 2003;200:189-198 
269. McNeil SE, Hobson SA, Nipper V, Rodland KD. Functional calcium-
sensing receptors in rat fibroblasts are required for activation of src 
kinase and mitogen-activated protein kinase in response to 
extracellular calcium. The Journal of biological chemistry. 
1998;273:1114-1120 
  114 
270. Huang Z, Cheng SL, Slatopolsky E. Sustained activation of the 
extracellular signal-regulated kinase pathway is required for 
extracellular calcium stimulation of human osteoblast proliferation. The 
Journal of biological chemistry. 2001;276:21351-21358 
271. Yamaguchi T, Chattopadhyay N, Kifor O, Sanders JL, Brown EM. 
Activation of p42/44 and p38 mitogen-activated protein kinases by 
extracellular calcium-sensing receptor agonists induces mitogenic 
responses in the mouse osteoblastic mc3t3-e1 cell line. Biochemical 
and biophysical research communications. 2000;279:363-368 
272. Ward DT, McLarnon SJ, Riccardi D. Aminoglycosides increase 
intracellular calcium levels and erk activity in proximal tubular ok cells 
expressing the extracellular calcium-sensing receptor. Journal of the 
American Society of Nephrology : JASN. 2002;13:1481-1489 
273. Hobson SA, McNeil SE, Lee F, Rodland KD. Signal transduction 
mechanisms linking increased extracellular calcium to proliferation in 
ovarian surface epithelial cells. Experimental cell research. 2000;258:1-
11 
274. Radcliff K, Tang TB, Lim J, Zhang Z, Abedin M, Demer LL, Tintut Y. 
Insulin-like growth factor-i regulates proliferation and osteoblastic 
differentiation of calcifying vascular cells via extracellular signal-
regulated protein kinase and phosphatidylinositol 3-kinase pathways. 
Circulation research. 2005;96:398-400 
275. Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, 
Kavurma MM. Calcium and osteoprotegerin regulate igf1r expression 
to inhibit vascular calcification. Cardiovascular research. 2011;91:537-
545 
276. Mercer J, Figg N, Stoneman V, Braganza D, Bennett MR. Endogenous 
p53 protects vascular smooth muscle cells from apoptosis and reduces 
atherosclerosis in apoe knockout mice. Circulation research. 
2005;96:667-674 
277. White E, McKenna J, Cavanaugh A, Breitwieser GE. 
Pharmacochaperone-mediated rescue of calcium-sensing receptor 
loss-of-function mutants. Molecular endocrinology. 2009;23:1115-1123 
278. Ward DT, Riccardi D. New concepts in calcium-sensing receptor 
pharmacology and signalling. British journal of pharmacology. 2011 
279. Tfelt-Hansen J, MacLeod RJ, Chattopadhyay N, Yano S, Quinn S, Ren 
X, Terwilliger EF, Schwarz P, Brown EM. Calcium-sensing receptor 
stimulates pthrp release by pathways dependent on pkc, p38 mapk, jnk, 
and erk1/2 in h-500 cells. American journal of physiology. 
Endocrinology and metabolism. 2003;285:E329-337 
280. Liao XB, Zhou XM, Li JM, Yang JF, Tan ZP, Hu ZW, Liu W, Lu Y, Yuan 
LQ. Taurine inhibits osteoblastic differentiation of vascular smooth 
muscle cells via the erk pathway. Amino acids. 2008;34:525-530 
281. You H, Yang H, Zhu Q, Li M, Xue J, Gu Y, Lin S, Ding F. Advanced 
oxidation protein products induce vascular calcification by promoting 
osteoblastic trans-differentiation of smooth muscle cells via oxidative 
stress and erk pathway. Renal failure. 2009;31:313-319 
282. Gu X, Masters KS. Role of the mapk/erk pathway in valvular interstitial 
cell calcification. American journal of physiology. Heart and circulatory 
physiology. 2009;296:H1748-1757 
  115 
283. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, 
Franceschi RT. Mapk pathways activate and phosphorylate the 
osteoblast-specific transcription factor, cbfa1. The Journal of biological 
chemistry. 2000;275:4453-4459 
284. Wang X, Harimoto K, Liu J, Guo J, Hinshaw S, Chang Z, Wang Z. 
Spata4 promotes osteoblast differentiation through erk-activated runx2 
pathway. Journal of bone and mineral research : the official journal of 
the American Society for Bone and Mineral Research. 2011 
285. Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, 
Kawai S, Faucheu C, Huet L, Baron R, Roman-Roman S. Activation of 
mitogen-activated protein kinase cascades is involved in regulation of 
bone morphogenetic protein-2-induced osteoblast differentiation in 
pluripotent c2c12 cells. Bone. 2001;28:491-498 
286. Schauwienold D, Plum C, Helbing T, Voigt P, Bobbert T, Hoffmann D, 
Paul M, Reusch HP. Erk1/2-dependent contractile protein expression in 
vascular smooth muscle cells. Hypertension. 2003;41:546-552 
287. Simmons CA, Nikolovski J, Thornton AJ, Matlis S, Mooney DJ. 
Mechanical stimulation and mitogen-activated protein kinase signaling 
independently regulate osteogenic differentiation and mineralization by 
calcifying vascular cells. Journal of biomechanics. 2004;37:1531-1541 
288. Ghoda L, Lin X, Greene WC. The 90-kda ribosomal s6 kinase 
(pp90rsk) phosphorylates the n-terminal regulatory domain of 
ikappabalpha and stimulates its degradation in vitro. The Journal of 
biological chemistry. 1997;272:21281-21288 
289. Chen RH, Abate C, Blenis J. Phosphorylation of the c-fos 
transrepression domain by mitogen-activated protein kinase and 90-
kda ribosomal s6 kinase. Proceedings of the National Academy of 
Sciences of the United States of America. 1993;90:10952-10956 
290. Xing J, Ginty DD, Greenberg ME. Coupling of the ras-mapk pathway to 
gene activation by rsk2, a growth factor-regulated creb kinase. Science. 
1996;273:959-963 
291. Fisher TL, Blenis J. Evidence for two catalytically active kinase 
domains in pp90rsk. Molecular and cellular biology. 1996;16:1212-
1219 
292. Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, 
Gleave ME. Hsp27 promotes insulin-like growth factor-i survival 
signaling in prostate cancer via p90rsk-dependent phosphorylation and 
inactivation of bad. Cancer research. 2010;70:2307-2317 
293. Tan Y, Ruan H, Demeter MR, Comb MJ. P90(rsk) blocks bad-mediated 
cell death via a protein kinase c-dependent pathway. The Journal of 
biological chemistry. 1999;274:34859-34867 
294. Desmouliere A, Rubbia-Brandt L, Abdiu A, Walz T, Macieira-Coelho A, 
Gabbiani G. Alpha-smooth muscle actin is expressed in a 
subpopulation of cultured and cloned fibroblasts and is modulated by 
gamma-interferon. Experimental cell research. 1992;201:64-73 
295. Nakagawa K, Parekh N, Koleganova N, Ritz E, Schaefer F, Schmitt CP. 
Acute cardiovascular effects of the calcimimetic r-568 and its 
enantiomer s-568 in rats. Pediatr Nephrol. 2009;24:1385-1389 
  116 
296. Chang W, Tu C, Chen TH, Bikle D, Shoback D. The extracellular 
calcium-sensing receptor (casr) is a critical modulator of skeletal 
development. Science signaling. 2008;1:ra1 
 
 
  117 
Chapter 6:  Appendix 
 
6.1  Serum batch testing 
In vitro, mineralisation of BAoSMC is dependent on the batch of serum used 
(Prof.  Ann Canfield, University of Manchester, personal communication).  
Therefore prior to experimentation serum is assessed for its ability to induce 
mineralisation.  The figure below (Figure 6.1) illustrates one such experiment. 
 
 
 
Figure 6.1  Serum batch testing.  BAoSMC were grown to confluence in 10% FCS–DMEM 
containing 1.2 mM Ca
2+
.  Upon confluence cells were incubated with 1.8 mM Ca
2+
 with (i) 
established calcifying serum but no BGP (negative control), (ii) test serum in the presence of 
BGP or (iii) established calcifying serum in the presence of 5 mM BGP (positive control).  A 
lots of serum were tested 7SB0015HA and 7SB0015H5.  Cells were treated for 10 days 
before fixing and staining with ARS, illustrating mineral deposition. 
 
6.2. Supplementary figures   
The following figures show additional data / repeat experiments from findings 
presented with the results section (Chapter 3).   
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Figure 6.2  CaSR immunoreactivity in BAoSMC (supplement to Figure 3.4)  A:  
Membrane preparations from cultured BAoSMC (prep C; passage 4) were separated using 
5% SDS-PAGE and CaSR immunoreactivity detected by Western blotting using a CaSR 
antibody (1:5000).  Exposure time 2 min.  Original figure (Figure 3.4) shows 
immunoreactivities at two different exposure times, optimised for visualisation of SMC CaSR 
and CaSR-HEK CaSR.  Size (in kDa) of molecular weight markers is indicated on the left.  B:  
BAosMC (prep C; passage 4) grown on chamber slides for 24 hrs in 10% FCS-DMEM (1.2 
mM Ca
2+
) were fixed with 4% formaldehyde before incubation with a polyclonal antibody 
against human CaSR (1:200).  A fluorescein isothiocyanate (FITC)-conjugated secondary 
antibody (green; 1:40) and DAPI (blue) was used to visualise the CaSR and nuclear staining 
(i). Arrow used to highlight cells with negative staining.  Bar = 25 µm.   
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Figure 6.3  Ca
2+
-induced mineralisation requires the presence of BGP (supplement to 
Figure 3.6).  A and B represent independent experiments.  BAoSMC (prep C; passage 6 and 
7) were treated upon confluence with increasing concentrations of Ca
2+
 in the absence of 
BGP.  Images show cells stained with alizarin red at days 17 (experiment A) and 13 
(experiment B).  Bar = 500 µm. 
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Figure 6.4  Concentration-dependent effects of Ca
2+
o on SMC mineral deposition 
(supplement to Figure 3.7).  A and B represent independent experiments.  BAoSMC (prep 
C; passage 6 and 7) were treated upon confluence with increasing concentrations of Ca
2+
 
alongside 5 mM BGP.  Images show cells stained with alizarin red at day 17 (experiment A) 
and day 13 (experiment B).  Bar = 500 µm.  
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Figure 6.5  Effect of AMG641 on Ca
2+
-induced mineralisation (supplement to Figure 
3.10).  
A and B represent independent experiments.  BAoSMC (prep C; passage 8 and 9) were 
treated upon confluence with 1.8 mM Ca
2+
 and 5 mM BGP in the presence of vehicle (1:1000 
DMSO) (i) or AMG641 at 10 pM (ii), 100 pM (iii) and 1 nM (iv).  Images show cells stained 
with alizarin red at day 19 (experiment A) and day 11 (experiment B).  Bar = 500 µm. 
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Figure 6.6  Protective actions of R-568 on Ca
2+
-induced mineralisation (supplement to 
Figure 3.11).  A & B represent independent experiments.  BAoSMCs (prep C; passage 6 and 
8) were cultured in 5% FCS-DMEM and 5 mM BGP with 1.8 or 2.2 mM Ca
2+
 in the presence 
or absence of R-568.  Cells were stained with alizarin red at day 15 (experiment A) and day 
18 (experiment B).  Bar = 500 µm.   
 
 
 
  123 
 
 
Figure 6.7  S-568 does not delay Ca2+-induced mineralisation (supplement to 3.12). 
BAoSMCs (prep C; passage 9) were incubated with 1.8 mM or 2.2 mM Ca
2+
 in the presence 
or absence of S-568.  Cells were stained with alizarin red at day 10.  Bar = 500 µm.  
 
 
